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ABSTRACT
Epilepsy is a brain disease defined by having recurrent and spontaneous
seizures. The susceptibility to seizure is determined by seizure threshold, which
describes the balance between excitatory and inhibitory neurotransmission in the brain.
Epileptogenesis, the transition from normal brain to epileptic brain, is accompanied by a
progressive reduction of seizure threshold and has been shown to have genetic
influences. Expression of neuronal cyclooxygenase-2 (COX-2) gene, PTGS2, a primary
gene that regulates prostaglandin synthesis in the normal brain, is enhanced by
excitatory neurotransmission and is under tight regulation of N-Methyl-D-Aspartate type
glutamate receptor (NMDAR) activity in cortical neurons. The 3’ untranslated region
(3’UTR) of PTGS2 gene was found to be a key site of post-transcriptional regulation by
NMDAR activity. However, deletion of T-cell intracellular antigen-1 (TIA-1), an RNA
binding protein of COX-2 mRNA 3’UTR, did not affect COX-2 protein expression in
mouse brain. Although TIA-1 deletion did not alter innate seizure threshold, it facilitated
the acquisition of epilepsy and enhanced epileptogenesis-associated mortality. Further
investigation revealed that TIA-1 knockout mice have an altered transcriptome in their
hippocampi. Together, my findings illustrate an NMDAR-dependent regulatory
mechanism of a known modulator of seizure threshold (COX-2) in neurons, and provide
insight into the regulation of epileptogenesis by a novel genetic modifier (TIA-1).
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CHAPTER 1 Background
1.1 Epilepsy
Epilepsy is a chronic debilitating neurological disease that the World Health
Organization estimates affects 40-50 million people worldwide1,2. It is defined by a state
of having recurrent and spontaneous seizures3, which are periods of abnormal,
synchronous excitation of a population of neurons. Epilepsy is often associated with
cognitive and learning deficits, psychosocial problems, and sudden unexplained death48

. In United States, it is estimated that epilepsy affects 1 in 26 Americans in their

lifetime. Although seizures can be effectively suppressed with antiepileptic drugs
(AEDs) in many cases, a significant percentage of patients exhibit pharmacoresistance
during the course of their frequently lifelong condition9.
1.1.1 Classifications of seizure and epilepsy
According to the most recent announcement from International League Against
Epilepsy (ILAE)10, seizures and epilepsies are classified on three levels. On the first
level, seizures are defined by their clinical mechanisms. Focal onset seizures are
seizures that affect only one hemisphere of the brain, and generalized onset seizures
are seizures that involve both sides of the brain. Seizures can be further classified into
motor or non-motor. Motor seizures occur when electrical activity involves the motor
area of the cerebral cortex and induces behaviors such as spasms, myoclonic jerks or
tonic contraction of muscles, whereas non-motor seizure occur when electrical activity
involves the sensory area of the cerebral cortex and induces non-motor outcomes such
as emotional or cognitive alteration. When such seizures are associated with loss of
consciousness, they are described as “absence” seizures. In a recent modification of
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seizure and epilepsy classification announced by ILAE11, the terms “simple”, “complex”
and “secondarily generalized seizure”, which have been used to describe the conscious
level of a focal seizure or the propagation from focal seizure to a generalized seizure,
have been replaced by “without” or “with impaired consciousness or awareness” and
“evolving to a bilateral, convulsive seizure” respectively. On the second level, epilepsies
are categorized by the type of seizures. For example, focal epilepsy is epilepsy with
focal onset seizures. Finally, on the third level, epilepsy syndromes are defined by a
combination of specific features other than seizure types. These features include onset
age and the course of the disease in a patient (acute/chronic/recurrent), neuroimaging
or their EEG characteristics. For example, Dravet syndrome is diagnosed typically in the
first year of life in a normal child with various types of seizures. During the course of
Dravet syndrome, children may demonstrate cognitive and behavior impairments. It is
worth mentioning that genetic generalized epilepsy (GGE, adapted from “idiopathic
generalized epilepsy” to reflect the knowledge that clinical genetic studies demonstrate
a genetic basis for these epilepsies), which used to be categorized under epilepsy
syndrome, now only refers to four specific types of epilepsy syndromes including
childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy and
generalized tonic–clonic seizures10.
1.1.2 The hippocampal formation and epileptogenesis of temporal lobe epilepsy
The concept of epileptogenesis refers to the process occurs in brain that results
in the development of epilepsy. It is known that certain brain pathologies as well as
genetic factors all may contribute to epileptogenesis. A good example is temporal lobe
epilepsy (TLE), the most common type of intractable (drug resistant) epilepsy. Onset of
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recurrent seizures occurs after a latent period that can be as long as 5–10 years 12.
Evidence suggests that the initial insults such as stroke, brain tumor or trauma facilitate,
if not begin, the epileptogenesis process, which ultimately leads to recurrent seizures.
The fact that a delay exists between the initial insult and the first seizure suggests that a
progression of changes may occur in the brain during epileptogenesis. Specifically, TLE
associates with limbic system dysfunction, and neurons located within limbic structures
such as the hippocampus and amygdala have been shown to be more vulnerable to
epileptogenic insults13.
The hippocampus is one of the most intensely studied structures of the brain.
This is due to its role in learning and memory, its ability to form new neurons
(neurogenesis), and its unique layered organization of neurons. The hippocampal
formation consists of three sub-regions: dentate gyrus (DG), CA3 and CA1. The signal
relay in the hippocampal formation, also known as the trisynaptic circuit14, is made up of
three major cell groups collectively: granule cells in the DG, pyramidal neurons in CA3,
and pyramidal neurons in CA1. In its simplest view, the entorhinal cortex transmits its
signals to the DG via granule cell fibers known collectively as the perforant path. The
DG then synapses on pyramidal cells in CA3 via mossy fibers. CA3 then fires to CA1
via Schaffer collaterals. The DG has long been a focal point for studies on the
molecular, cellular, and network mechanisms responsible for epileptogenesis in TLE15.
Animal models of epileptogenesis reveal several major plasticity changes in the
hippocampal formation. These changes include severe neuronal death 16, rewiring of
axons of excitatory neurons17, abnormal neurogenesis18 and gliosis19, and altered
channel properties of inhibitory neurotransmitter receptors20. These neurobiological
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changes may alter the ion concentration in the brain, disrupting the balance between
excitatory versus inhibitory synaptic transmission and facilitating synchronized firing of
populations of excitatory neurons, which eventually support recurrent seizures21.
Understanding how cellular alterations (e.g. selective loss of inhibitory neurons in the
hilar region of the DG and sprouting of mossy fibers) influence functional properties is of
vital importance for understanding fundamental aspects of epileptogenesis, such as the
consequences of primary initial injuries, mechanisms underlying network
synchronization, and progression of intractability.
1.1.3 Genetic basis of epilepsy
Epilepsy has long been recognized to have a genetic basis. Epidemiologic
studies have clearly shown an increased risk of being diagnosed with epilepsy in firstdegree relatives of people with idiopathic or non-lesional focal epilepsy, whereas twin
studies have revealed higher concordance in monozygotic than dizygotic pairs 22. The
genetic contribution to epilepsy has been emphasized as our knowledge in epilepsy
etiology has increased. Many epilepsies that were considered “idiopathic” (a seemingly
affirmative diagnosis with the underlying cause being unknown) in the past, have now
been recognized as autoimmune-related (epilepsy caused by auto-antibodies against
ion channels, receptors and accessory proteins important in governing the electrical
activity of the brain23) and epilepsies with lesions that are only detectable by MRI 24.
Importantly, many epilepsies idiopathic in nature have been reclassified as possessing
a genetic basis. Even epilepsies resulting from trauma, stroke, neoplasm, infection or
congenital malformations, which have long been categorized as acquired epilepsies, are
now known to have genetic contributions25.
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Genetic contributions to epilepsy have also been demonstrated in mice. As an
example, mice from different strains presented different levels of sensitivity to seizure
induction. Specifically, studies have demonstrated that DBA/2J mice displayed a much
lower seizure threshold than C57BL/6J mice in response to electroconvulsive stimuli26
and chemoconvulsant27. Further analysis through quantitative trait locus revealed a
significant contributing locus on the distal arm of chromosome 1 27, and a loss-offunction study using a transgenic mouse line suggested the gene Kcnj10 is responsible
for the distinction in seizure susceptibility between strains28. This gene encodes a
subunit of inward rectifying potassium channel Kir4.1 which is found predominantly in
brain astrocytes. Indeed, potassium and glutamate buffering are significantly impaired in
astrocytes from DBA/2J mice compared to those from C57BL/6J mice29. In fact,
conditional knockout of Kir4.1 led to glial membrane depolarization and inhibition of
potassium and glutamate uptake, as well as premature death resulting from stressinduced seizures30.
However, certain forms of epilepsies are not associated with hereditary traits. For
instance, idiopathic generalized epilepsies did not show 100% concordance in
monozygotic twin studies31, implicating other influences, such as gene/environmental
interactions in their etiologies. Indeed, genome-wide epigenetic alterations including
DNA methylation, histone modifications, and microRNAs may account for functional and
structural changes within the brain circuits, thus determining the onset or progression of
epilepsies. For example, in human TLE, alteration in DNA promoter methylation and
increased expression of DNA methyltransferase have been identified32. In addition,
epigenetic profiling in rodent models of acquired epilepsies identified genome-wide
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changes in DNA methylation as well 33. Posttranscriptional modification of histones,
including transient and sustained changes in phosphorylation or acetylation of core
histone proteins have also been reported in rodent models of acquired epilepsies34,35.
Finally, it has been shown that noncoding RNAs, including microRNA and long
noncoding RNA, played important roles in regulating brain excitability and seizure
thresholds36. Together, these studies provide evidence of epigenetic influence on gene
expression in epilepsy and hint on novel therapeutic approaches in treating or
preventing epilepsy.
1.1.4 Hypotheses of genetic architecture of epilepsies
Hypotheses made on genetic architecture of epilepsies include the “common
disease, common variant hypothesis” or “common disease, rare variant hypothesis” 22.
The “common variant” hypothesis believes that common mutations such as recurrent
mutations in channel proteins are responsible for prevalence of epilepsies in the
population, whereas “rare variant” hypothesis believes that epilepsies are phenotypes
shared by distinct rare genetic mutations. Despite the discovery of some common
genetic mutations, numerous evidence support the “rare variant” hypothesis as well.
Accumulating evidence of association between genetically “complex” epilepsies with
rare micro deletions emphasizes this contribution of rare variants. With this respect,
de novo mutation has increasingly been revealed as an important mechanism in
epileptic encephalopathies 25. However, unsuccessful early attempts to identify common
variants through linkage and association studies argue against that common variants
play an important role in genetically “complex” epilepsies 37. In addition, a combination
of the two models is also possible. Not only common mutations (observed frequently
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and exhibiting polymorphisms among the population) in channel protein genes can lead
to significant phenotypic effects, rare mutations 37 can also induce functional deficiency
in electrophysiological properties of these channels.
Current genetic and genomic technologies for mutation identification are
changing the landscape of genetics research and generating an enormous amount of
information regarding the contributions of genetics to common complex epilepsies. To
date (March 2018), 9 meta-analysis studies, 7 large scale genome-wide association
studies, and numerous family-based linkage/association studies have been conducted
according to the online Epilepsy Genetic Association Database (epiGAD,
http://www.epigad.org/), providing evidence for both the “common variant” and “rare
variant” hypotheses.
1.1.4.1 Common genetic variants of epilepsies
Many common genetic variants of epilepsies have been identified in monogenic
epilepsies. In humans, a small proportion (~1%) of epilepsies exhibit a clear familial
pattern of Mendelian inheritance and can be classified into Mendelian/monogenic
epilepsies. These monogenic epilepsies, often heritable, share similar phenotypes in a
pedigree and have been shown to be associated with mutation(s) in a single gene.
Linkage analysis, a strategy to detect cosegregation between a phenotype and the
underlying causative gene locus, on these rare monogenic forms of epilepsy have
identified more than 20 genes with a major effect on susceptibility 22. The majority are
genes directly coding for ion channel subunit proteins 38 (e.g. voltage-gated
calcium/sodium/potassium channels, GABAA receptor, nicotinic acetylcholine receptor,
etc.), with the remainder being genes that encode protein that interact with channel

7

proteins. For instance, the leucine-rich glioma-inactivated 1 gene (LGI1), which is a
susceptible gene in familial temporal lobe epilepsy39, encodes a protein with a role in
the synapse as a regulator of potassium channels and of glutamate α-amino-3-hydroxy5-methyl-4-isoxazolepropionic acid receptor (AMPAR). The EF-Hand Domain
Containing 1 (EFHC1) gene, commonly mutated in Juvenile Myoclonic Epilepsy (an
epilepsy syndrome characterized by myoclonic seizures and generalized convulsions
that have onset between eight to 25 years of age) 40, encodes a protein that interacts
with the R-type voltage-dependent calcium channel (Cav2.3) and is involved in
neurotransmitter release. Other genes have more or less been associated with brain
development and/or receptor signaling. Many of these genes have now been applied as
clinical tools in genetic testing of epilepsies 25,37,38.
Other common genetic variants have been identified as copy number variance
(CNV). CNVs are chromosomal rearrangements including deletions, duplications or
insertions that range in size from approximately one kilobase to several megabases.
CNVs can be defined into two groups: private and recurrent 25. Compared to private
CNVs, which are rare and randomly located across the genome, recurrent CNVs occur
at genomic hot spots and are thought to arise de novo repeatedly in a population. While
many CNVs have unknown functional ramification and are dispersed throughout the
genomes of healthy individuals at high frequency, others could result in significant
alteration of gene expression and/or function 37. CNVs can be detected by gene
targeted studies using probes directed to specific genetic regions of known epilepsy
genes 37. Meanwhile, array comparative genomic hybridization (Array CGH) and Single
Nucleotide Polymorphism (SNP) genotyping arrays are genome-wide methods to detect

8

CNVs. These technologies can also be targeted to specific chromosomal regions 37.
Array CGH as a type of whole genome analysis is capable of detecting genomic
rearrangements of kilobases in size. Compared to conventional karyotyping, which has
a resolution of megabase level, Array CGH significantly increases the yield of the
screening. It is powerful in cases when CNVs have boundaries extending beyond the
target gene 37. In the clinic, Array CGH has largely replaced karyotyping as a key
genetic diagnosis tool, although karyotyping is still widely used as a validation strategy
in research41. Using Array CGH, a micro deletion at 15q13.3 has been recurrently
detected in cohorts of subjects who are resistant to antiepileptic medication 42,43. This
micro deletion was first characterized in a number of patients with intellectual disability,
most of whom suffered from seizures 37. It is one of the most prevalent genetic risk
factors identified for the genetic generalized epilepsy syndromes and has an unusually
high frequency in epilepsy cohorts. Seven genes are located within this lesion region,
with the nicotinic acetylcholine receptor α7 (CHRNA7) gene being the most likely
pathogenic factor.
1.1.4.2 Rare genetic variants of epilepsies
Although recurrent CNVs have been identified as common mutations in
epilepsies, other studies suggest that rare non-recurrent CNVs are also likely to play a
role in the genetic etiology of epilepsy. In one study, array CGH identified 24 nonpolymorphic mutations including 2 rare deletions in a cohort of 102 patients with various
types of epilepsy with or without additional neurodevelopmental abnormalities 44. Two
recent genome-wide studies also discovered rare CNVs in epilepsies: Enrichment of
large (>1 Mb) deletions were found in a diverse spectrum of sporadic epilepsy
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syndromes 45, the majority of which were seen in one individual each. Ten percent of
subjects tested in another study carried one or more rare CNV(s) that have not been
previously found to be enriched in controls46.
De novo mutations defines novel mutations that often occur in a parental
germline or during embryogenesis. With the rapid advances in sequencing technology,
next-generation sequencing (NGS) techniques including whole exome and whole
genome sequencing have been used to identify genetic contribution to epilepsies. Due
to their high sequencing resolution, these techniques are frequently used to identify de
novo mutation in epilepsy etiology. Dravet syndrome, an epileptic encephalopathy
(sclerosis accompanied by epileptiform activity), has been shown to be primarily caused
by de novo mutations occurring during the early stages of embryonic development.
Most Dravet syndrome cases are caused by mutations in the SCN1A gene, which
encodes the α-subunit of the type 1 voltage-gated sodium channel 25. Using SNP array,
the PCDH19 gene, which encodes proto-cadherin 19 on chromosome X, has also been
associated with Dravet-like syndrome or familial epilepsy and mental retardation that
was limited to females. Fifteen novel point mutations were identified after screening 150
unrelated patients with febrile and afebrile seizures, suggesting de novo mutations in
PCDH19 gene should be carefully examined in this Dravet-like syndrome, even in the
absence of family history and/or mental retardation 47. Although epileptic
encephalopathies are typically monogenic epilepsies and are rare at the population
level, correct explanation of the cause of epileptic encephalopathies is critical in
expanding our knowledge in epilepsy genetics and susceptible gene pools. New genes
in which de novo mutations can produce an epileptic encephalopathy are consistently
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being identified25, including Syntaxin binding protein 1 (STXBP1), PCDH19, Sodium
voltage-gated channel alpha subunit 2 (SCN2A) and Cyclin dependent kinase-like 5
(CDKL5). Sequencing technologies have identified new epilepsy genes in other forms of
epilepsies 48. A 3.2 Mb segment was found within 16p13.3 through linkage analysis in a
large family that has focal epilepsy and intellectual disability with autosomal recessive
inheritance 49. Targeted capture and sequencing of the mapped interval identified a de
novo mutation in TBC1 domain family member 24 (TBC1D24) gene, a gene of unknown
function. Acknowledging the risk of potential false positive findings, whole-genome
sequencing has demonstrated strong power in detecting de novo mutation from limited
sample sizes. In one case of severe epileptic encephalopathy with early-onset seizures,
whole-genome sequencing of the affected patient and her unaffected parents and
sibling50 successfully identified a single novel de novo missense mutation in SCN8A
gene, which encodes the voltage-gated sodium channel Nav1.6.
1.1.4.3 Insufficient finding of common genetic variants of epilepsies from
genome-wide association studies
In many common diseases, including several with heritability estimates lower
than those of epilepsies, robust evidence from genome-wide association studies
(GWAS) has demonstrated that common polymorphisms increase the risk of disease,
although the individual attributable risk is relatively small 25. To date, however, results
obtained from GWAS in epilepsy have been relatively limited and a clear picture of the
role of common polymorphisms has not yet emerged.
Although linkage analysis has been successful in some monogenic epilepsies,
early linkage/association studies in genetic “complex” epilepsy, whose genetic
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architecture is no doubt far more complicated than initially thought, has been notoriously
unsuccessful. Unlike monogenic epilepsies, most epilepsies present without a
significant family history. Thus, the majority of familial epilepsies do not exhibit
Mendelian inheritance. Rather, the inheritance pattern is complex, suggesting that the
phenotype is multifactorial in origin, and is caused by the interaction of a few (i.e.
oligogenic) or multiple (i.e. polygenic) genetic variants, possibly with a further influence
from environmental factors. Characterization of epilepsies with a polygenic basis is thus
a genetically “complex” major challenge. Initial efforts in association mapping of
epilepsy genetic loci have been underpowered and have focused on several candidate
genes 51, thus yielding few findings. Initial attempts of genome-wide association studies
also failed to identify valuable candidates, even with considerable sample size 52.
To date, seven epilepsy GWAS could be found in PubMed. The initial two studies
focused on focal epilepsy which has long been proposed to have a strong genetic
component. The first GWAS study in 2010 included more than 6,000 controls and more
than 3,000 individuals with focal epilepsies 52 whose phenotypes distributed across a
broad spectrum. Although the study was sufficiently powered for detecting associations
of variants with modest effects, none reached the significance required by genome-wide
analyses. The author concluded that it is unlikely that common SNPs account for risk in
broadly defined focal epilepsies, at least in the European population examined.
A second GWAS, published in 2012, also focused on focal epilepsy in subjects
from the Han Chinese population 53. This study examined 1,087 focal epilepsy patients
with acquired or unknown etiology and 3,444 controls. These patients were further
divided into a discovery cohort and a replication cohort to achieve a two-stage
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approach. Through combined meta-analysis of the two stages, a single SNP was
identified. The SNP is located on chromosome 1q32.1 within the CAMSAP1L1 gene,
which encodes a calmodulin-regulated spectrin-associated cytoskeletal protein.
Other groups using GWAS focused on the analysis of genetic generalized
epilepsy (GGE). Previous family-based genome-wide linkage studies of GGE had
limited impact given that most studies had relatively small sample sizes. Thus, a recent
genome-wide linkage meta-analysis conducted by the EPICURE Consortium attempted
to overcome the power issue by using a much larger sample size 54. The study
consisted of 379 GGE multiplex families including 982 relatives with GGEs. They still
failed to detect any significant linkages, but the broad phenotype definition was rather
broad. However, when phenotypes were further specified into GGE subtypes, a
significant linkage was found for myoclonic and absence seizures at 2q34 and 13q31.3,
emphasizing the importance of phenotype stratification on the ability to detect potential
genetic contributions in GWAS.
It is somewhat disappointing that even with a greatly expanded sample size,
genome-wide studies in complex epilepsy have only identified a handful of susceptibility
loci. A recent study conducted by the International League Against Epilepsy Consortium
on Complex Epilepsies combined genome-wide association data from 12 cohorts of
individual datasets with ethnically matched controls and cases. Epilepsies were grouped
into GGE, focal epilepsy, or unclassified epilepsy. Although the sample sizes of the
combined meta-analysis were 8,696 cases and 26,157 controls, the study identified only
2 loci, SCN1A and PCDH7 genes (2q24.3 and 4p15.1, respectively) that reached
genome-wide significance in epilepsy cohort (regardless of the epilepsy subtype). Both
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genes had been identified in previous association studies of epilepsy or epileptic
encephalopathy. For the cohort of GGE patients, a single signal at 2p16.1 was also
detected whereas no SNP achieved genome-wide significance for focal epilepsy.
Nonetheless, the data suggest that specific loci (SCN1A) can increase risk for epilepsy
broadly, or can have effects limited to a specific epilepsy subtype (e.g. Dravet
Syndrome).
Another group focused on identifying single nucleotide variants (mutation of
single nucleotide that is not shared among a population) in epilepsy using exome
sequencing, instead of looking at SNPs 55. In this study, the authors compared the
exome sequences from subjects of European ancestry consisting of 242 controls and
118 individuals with GGE, including Juvenile Myoclonic Epilepsy and Absence Epilepsy.
However, no significant association was obtained when searching for shared genetic
mechanisms between GGE subtypes. The authors argued that the impact of any
individual single-nucleotide variant in epilepsy is possibly small. They then suggested a
gene-based approach (such as SNP-based method, in which each genotyped SNP is
tested for association) in future sequencing studies of epilepsy predisposition. However,
in a previous study using exome sequencing of large cohorts of people with GGE, even
when the researchers focused specifically on finding mutations in genes encoding ion
channel proteins, they were unable to find any mutation in a single major unidentified
gene which accounts for epilepsy phenotypes 56.
In summary, results from GWAS and genome-wide linkage in the most common
forms of epilepsies suggest an extremely complex genetic architecture in these
genetically “complex” epilepsies. These may involve both rare and common variants
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that could be either disease predisposing or protective. These variants would most likely
contribute to small effects. A complicated multi-genetic or gene-environment interaction
may further elevate the complexity. This is possible considering the known variability of
penetrance (i.e. the proportion of individuals with a mutation who exhibit clinical
symptoms) observed in monogenic epilepsies 48.
1.1.5 Future of genetic studies of epilepsy
The genetic architecture of genetic “complex” epilepsies, like other disorders, are
believed to be highly polygenic with heritability distributed across many hundreds of loci.
Even where rare variants have been confirmed, as in the case of rare CNVs, they
present with only partial penetrance, thus suggesting the co-existence of genetic
variants that each may contribute to only a small fraction of the overall heritability.
Hence, enormous sample sizes have been required before individual genes begin to
stand out from the background. The importance of study scale can be seen from the
success in genome-wide studies of certain psychiatric disorders. Recent analysis of
schizophrenia risk by the Psychiatric Genomics Consortium encompassed data from 52
study cohorts totaling 82,000 individual human genomes 57. The size of such studies
enabled identification of 100 more loci that reach a genome-wide significance,
regardless of potential genotyping error and variant population substructure. Largescale meta-analyses have identified 20 risk loci of late-onset Alzheimer’s disease
(sample size of 72,000 genomes) and 10 more loci affecting bipolar disorder (sample
size of 15,000 genomes).
On the other hand, the depth of genome wide studies can be enhanced by
application of exome and whole-genome sequencing methods to large cohorts of
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affected and unaffected individuals. Early rational biological candidate-gene studies in
psychiatric disorders, which attempted to nominate candidate genetic variants for
association studies by known disease biology, have been largely unsuccessful 57. A
similar idea was to use targeted panels of genes consisting of those previously found to
be associated with disease 58. However, excessive focus on limited known candidates
hinders the progression toward revealing the underlying genetic mechanisms. An
extreme example would be schizophrenia, in which more than 1,400 candidate-gene
studies have been published, with half of them focused on the same 18 genes 57. While
exome sequencing may still not be comprehensive enough because it overlooks
regulatory sequences, innovations in NGS technology have started to allow such
studies to be pursued on a large scale. In schizophrenia and autism, large scale studies
based on exome or whole genome sequencing in large numbers of cases and their
relatives have taken place. In epilepsy, a large-scale international collaborative effort
(Epi4k project) has also been launched to sequence epilepsy genomes 59.
Besides expanding the scale and depth of genome wide studies to identify new
genes that are associated with epilepsy, effort should also be spent on studying known
modulators of epileptogenesis. Since numerous genes including channel protein genes
and neuromodulator genes have already been identified as potential regulators of
epileptogenesis, understanding the mechanisms through which these commonly
discovered genes regulate disease progression is equally important. A well-studied
pathway that has been associated with epilepsy is the arachidonic acid pathway of
prostaglandin synthesis.
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1.2 The role of cyclooxygenase-2 gene in seizure generation and epileptogenesis
Prostaglandins (PGs) are potent paracrine and autocrine lipid mediators that
contribute to a broad spectrum of physiological and pathophysiological activities that
range from gastric acid secretion60 and blood flow61 to inflammation62 and tumor
growth63. Cyclooxygenase-2 (COX-2) is one of two isoforms of COX that catalyze the
first committed step in the metabolism of arachidonic acid (AA) to PGs 64. COXdependent PG production increases rapidly and transiently in the brain following acute
convulsive seizures65,66 and pharmacological inhibitors of COX-2 activity reduce the
seizure threshold 67-69, an effect that is likely due to the loss of anti-convulsive PGs 67.
This section will introduce the COX-dependent production of PGs, as well as the
regulation of COX-2 gene expression and activity, and finally, how COX-2 may
contribute to seizure generation and epileptogenesis.
1.2.1 The arachidonic acid pathway of prostaglandin synthesis
Synthesis of PGs is mediated via the AA pathway (Fig.1.1) 64. Excitatory synaptic
activity triggers release of AA from membrane phospholipid stores via activation of
phospholipase A2 (PLA2). Of the many members of this large family of enzymes 70,
basal and activity-dependent release of AA from neurons is specifically catalyzed by the
group IV cytosolic phospholipase A2α isozyme (cPLA2α) 71. Free AA can then be rapidly
metabolized by the cyclooxygenase enzymes to produce prostaglandin G2 (PGG2), an
intermediate product that is subsequently reduced to prostaglandin H2 (PGH2). PGH2 is
the substrate for various prostaglandin synthases (PGSs) each producing specific
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bioactive PG. The nature of the biological responses elicited by these PGs is dictated by
specific membrane G protein-coupled receptors (GPCRs)72.

Fig. 1.1 Synthesis of PGs

COX enzymes are homodimers, with each monomer comprising three domains:
a N-terminal EGF-like domain (serves as a dimerization domain holding the monomers
together), a membrane-binding domain and a C-terminus catalytic domain that
comprises approximately 80% of the protein and contains the two distinct but
structurally and functionally interconnected catalytic sites64. Thus, COX enzymes
catalyze two reactions: 1) a cyclooxygenase reaction in which AA plus two molecules of
dioxygen are converted to PGG2 and 2) a peroxidase reaction in which PGG2 is reduced
to PGH2 by two electrons. COX enzymes are integrated via their membrane binding
domains into a single leaflet of the lipid bilayer on the luminal side of the endoplasmic
reticulum and the nuclear envelope. Four alpha helices of the membrane-binding
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structure create the entrance to a hydrophobic channel that provides the access route
for AA released from the hydrophobic core of the lipid bilayer, where the
cyclooxygenase reaction occurs. The peroxidase reaction occurs at the hemecontaining active site located near the protein surface64.
1.2.2 Regulation of COX-2 gene expression
In general, whereas the isozyme cyclooxygenase-1 (COX-1) is constitutively
expressed throughout the body, constitutive COX-2 expression is only detected
primarily in kidney, gastrointestinal tract, and thymus, with the most prominent
expression found within the brain 73. In the central nervous system (CNS), COX-2 is
expressed constitutively in discrete subpopulations of glutamatergic neurons, where it is
localized to somata and dendritic arborizations, particularly in the primary neurons of the
CA3 region of the hippocampus, cortical layers 2/3, and lateral amygdala 74. While the
regulation of COX-2 expression has been studied extensively in non-neuronal cell
types, much less is known about its regulation in neurons.
1.2.2.1 COX (PTGS) genes and protein structure
COX1 and COX-2 are homologous ER-resident N-glycoprotein isozymes that are
produced from different genes (PTGS1 and PTGS2, respectively, in the human
genome) located on different chromosomes64. COX-1 is present in many cell types in a
constitutive manner whereas COX-2 expression is typically transient. Although both
genes can be induced by phorbol esters or growth factors, COX-2 mRNA can be
induced by a variety of other stimuli. This is likely due to the sequence difference
between PTGS genes. The promoter region of PTGS1 gene contains three Sp1 sites
and lacks a TATA or CAAT box 75. In contrast, the PTGS2 gene promoter contains a
19

TATA box motif and a number of cis-acting elements that are recognized by various
transcription factors. The 3’ untranslated region (3’UTR) of COX-2 mRNA is a second
regulatory region that has the capacity to bind numerous RNA binding proteins (RBPs)
that can affect stability and/or translation of the transcript 76. In contrast, COX-1 mRNA
is very stable and its 3’UTR lacks the sequence elements that bind to these RBPs77.
The properties of COX-2 regulation are characteristics of “immediate early genes”.
Moreover, COX-2 but not COX-1 protein, contains a unique segment near its Cterminus78, which renders additional control over COX-2 protein stability (discussed
later).
Subtle interspecies differences exist in the sequences of PTGS genes between
humans and other mammals, whereas COX isoforms from invertebrates have
enormous cross-species differences79, suggesting that duplication events of COX
isoforms occurred independently in lower organisms. The fact that COX evolved
multiple isoforms in all organisms known to express it suggests distinct regulatory
mechanisms and biological roles for PTGS genes. In support of this, when the coding
sequence of the mouse Ptgs2 gene was replaced by that of Ptgs1 in a transgenic
mouse line, although the latter could be induced in a manner analogous to COX-2, it
only partially compensated for the renal and female reproductive phenotypes associated
with loss of COX-2, indicating distinct roles of COX enzymes80.
1.2.2.2 Multi-dimensional regulation of COX-2 expression and activity
COX-2 gene expression is regulated through transcriptional, post-transcriptional,
and posttranslational mechanisms 75,81. On top of that, COX-2 enzymatic activity is also
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tightly regulated (discussed below), resulting in a multi-dimensional and complex set of
mechanisms to control PGs level.
Numerous transcriptional regulatory proteins are known to bind to cis-acting
elements in the 5’ regulatory region of the PTGS2 gene. These proteins regulate both
the induced and constitutive expression of COX-2. As an example, Cyclic AMP
response element binding (CREB) protein mediated both transient COX-2 transcription
in neurons and long-lasting COX-2 transcription in astrocytes and microglia induced by
pilocarpine82. Genetic inhibition of CREB markedly attenuated status epilepticusinduced COX-2 up-regulation in hippocampal neurons82. Moreover, recent evidence
from cultures of cortical neurons indicated that basal COX-2 expression is modulated
transcriptionally by both CREB and Sp1 83.
The COX-2 mRNA 3’UTR, which in the mouse is >2kb in length, was initially
proposed and subsequently shown to possess cis-acting elements that regulated RNA
stability and translation efficiency 76,84,85. These and other studies identified an
Adenylate/Uridylate (AU)-rich element (ARE) located within 80 bases of the coding
sequence stop codon that is a key RBP recognition site. This ARE is 89% AU-rich and
contains seven AUUUA pentanucleotide motifs, which can be divided into two separate
AU domains: 1) a 5’ domain consisting of three overlapping AUUUA pentameric
nucleotide motifs, and 2) an adjacent 3’ domain containing four sequential AUUUA
pentamers. The nanomeric consensus sequence, UUAUUUA(A/U)(A/U), which has
been suggested to be the key determinant of mRNA stability 86, is embedded within
each of these domains. Lastly, a sequence of eight U nucleotides is positioned just 3’ of
the second AUUUA domain. Numerous RNA binding proteins (RBPs) have the capacity
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to bind this regulatory element, which then affect stability and/or translation of the
transcript 76. Table 1.1 describes a list of RBPs that have been shown to bind to COX-2
mRNA. All of these RBPs show evidence of brain expression, implying that they may
also regulate COX-2 expression in neurons, a hypothesis that needs to be further
explored. CUG binding protein 2 (CUGBP2) is one such RBP that is known to bind to
COX-2 3’UTR and suppress its translation. CUGBP2 was induced by radiation in
epithelial cells and, upon binding to the first 60nt of COX-2 3’UTR stabilized COX-2
mRNA yet decreased COX-2 protein translation via disrupting polysome distribution,
leading to increased cell apoptosis 87. T cell intracellular antigen-1 (TIA-1, described in
detail in section 1.3) is another RBP that has been shown to suppress COX-2 mRNA
translation by binding to this ARE 88.
Table 1.1. Expression and function of potential RBPs for COX-2

RBPs
HuR
TIA-1
TIAR
AUF1
AUF2
RBM3
TTP
CUGBP2
hnRNP A3

Able to bind
COX-2 ARE
89 90
Yes ,
89 90
Yes ,
89 90
Yes ,
89 98
Yes ,
89 98
Yes ,

Known regulatory functions for
COX-2 in non-neuronal cells
mRNA stabilization
Translational suppression
ND
ND
ND

89

ND

Yes

106 107

Yes

87 108

mRNA destabilization
mRNA stabilization,
Translational suppression
ND

Yes

,

Yes

,

89

Expressed in
brain
91 92 93
Yes , ,
93 94 95
Yes , ,
96 97
Yes ,
91 92 99
Yes , ,
100
Yes
101 102 103
Yes , , ,
104 105
,
91 93
Yes ,
Yes

109

Yes

110

Abbreviation: TIAR, TIA-1 related protein; AUF1/2, ARE/poly(U)-binding/degradation factor 1/2; RBM3,
RNA binding motif protein 3; TTP, tristetraprolin; CUGBP2, CUG binding protein 2; hnRNP A3,
heterogeneous nuclear ribonucleoprotein A3; ND, not determined for COX-2;

Besides RNA binding proteins, COX-2 mRNA can also be targeted by
microRNAs (miRNAs), which are short (19 22 nucleotides) non-coding RNAs that bind
partially complementary sequences within the 3’UTR of mRNA. Binding to miRNAs
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normally leads to functional repression of target transcripts. In non-neuronal cells, COX2 3’UTR is recognized by a host of miRNAs including miR-289 111, miR-101a112,113, miR199a113, miR-143114, miR-137115 and miR-144116. Importantly, miRNAs could also
compete with RBPs for 3’UTR binding such as in the case of miR-16. RNA binding
protein hnRNP-K binds COX-2 3’UTR in S-100 calcium-binding protein-stimulated
monocytes 117, which competes with miR-16 binding to ARE and stabilizes COX-2
mRNA.
COX-2 mRNA translation is also regulated by alternative usage of its
polyadenylation site 118. COX-2 3’UTR has a proximal and a distal polyadenylation site.
The proximal site is weaker (less used) than the distal site due to its non-canonical
polyadenylation signal. Upstream efficiency elements (USEs) are sequence elements
located upstream of the polyadenylation sites. Synergistic binding of trans-acting
factors119 to USE is required for proximal site adenylation. The significance of this
alternative mRNA processing event has been implicated in cancer. Colorectal cancer
cells, for example, selectively stabilize the polyadenylation variant of COX-2 mRNA
which lacks the distal segment of the 3’UTR during confluence 106, suggesting that
cancer cells may exploit this mechanism to escape rapid COX-2 mRNA decay.
Upon translation into protein, COX-2 is under further regulation through
mechanisms that affect protein half-life and enzymatic activity. COX-2 protein has a
unique C-terminus 19-amino acid (19-aa) segment that is crucial for its entry into the
ER-associated degradation (ERAD) system, where COX-2 protein is transported into
cytoplasm for degradation by the 26S proteasome 78. COX-2 protein degradation has
also been found to be initiated by suicide inactivation of the enzyme120, leading to COX23

2 enzymatic inactivation in the presence of substrate 64. This is supported by the fact
that COX-2 protein degradation is significantly blocked by non-steroidal antiinflammatory drugs (NSAIDs) 121. PTGS genes are the best known cellular target for
NSAIDs. Most of the NSAIDs inhibit both the PTGS genes, although they vary in their
efficacies against inhibiting catalysis of the two COX isozymes 122. However, evidence
suggests that NSAIDs can also regulate COX-2 expression. They do so by potentially
altering upstream signaling pathways of COX-2 transcription, including peroxisome
proliferator-activated receptor gamma (PPARγ)123, NF-kB 124 and anti-apoptotic kinase
(Akt)125. Endogenously, COX-2 enzymatic activity can be regulated by nitric oxide (NO),
a free radical but also a signaling molecule. NO has a dual effect on COX-2 activity126.
On the one hand, a low amount of NO potentiates COX-2 activity. As a result, nitric
oxide synthase (NOS) inhibitors block PG synthesis by inhibiting the generation of
peroxynitrite, which is required to initiate PTGS genes cyclooxgenase activity. On the
other hand, a large amount of NO blocks COX-2 activity, possibly through reducing the
heme group of PTGS genes. In macrophages, exogenous NO was sufficient to block
COX-2 protein induction and activity, whereas inhibition of NO signaling increased
COX-2 protein induction and activity after LPS stimulation 127. Furthermore, NOS has
been shown to bind to COX-2 protein directly and mediate its enzyme activity 128,129.
Because COX-2 gene and protein expression and enzymatic activity can be
regulated on numerous levels, it is not surprising that upstream signaling pathways
could have different impacts on COX-2 expression and activity via distinct mechanisms.
As an example, COX-2 transcription has been shown to be up-regulated by β-catenin
130

. β-catenin can also stabilize COX-2 mRNA through direct binding to the β-catenin-
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responsive element located on COX-2 3’UTR 131. Glucocorticoids, through activating
glucocorticoid receptors (GRs), can interact with transcription factors such as NF-κB
and AP-1 to suppress COX-2 transcription. However, GRs have also been shown to
block p38 phosphorylation, which in turn bocks its interaction with a p38-responsive
ARE on COX-2 3’UTR and destabilize COX-2 mRNA 132. Interleukin-1β (IL-1β) signaling
is also known to induce COX-2 transcription, possibly through the canonical NF-κB
signaling 133. However, IL-1β has also been shown to enhance COX-2 mRNA stability
via a p38/MAPK-dependent mechanism 134, possibly through further activation of
downstream RNA binding proteins such as hnRNP A0 135 or HuR 90.
1.2.2.3 COX-2 gene expression and N-Methyl-D-Aspartate type glutamate receptor
activity
COX-2 is constitutively expressed in glutamatergic neurons of the CNS 74 and
neuronal COX-2 expression is coupled to endogenous post-synaptic N-Methyl-DAspartate type glutamate receptor (NMDAR) activity and as such, can be modified by
changes in excitatory neuronal activity. Thus, COX-2 mRNA and protein expression
were markedly induced after high frequency stimulation of the perforant pathway in vivo
and antagonism of the NMDAR suppressed basal COX-2 mRNA levels by cortical
neurons in culture 83,136. Activation of the NMDAR is known to induce neurotoxicity in
various in vivo and in vitro models which results from COX-2-mediated excessive
production of prostaglandins. Brain damage induced by cortical microinjection of NMDA
was attenuated by COX-2 inhibitors 137-139, suggesting the detrimental role of COX-2
proteins in these conditions. It is not entirely clear which PG(s) and downstream PG
receptor(s) are responsible for neuronal excitotoxicity. The PGE2 receptor EP1 has
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been shown to mediate the neurotoxic effects of NMDA by increasing intracellular Ca2+
through impairing Na+/Ca2+ exchange 140. Pharmacologic or genetic inhibition of EP1
attenuated lesions induced by microinjection of NMDA or PGE2. In addition, COX-2
inhibition protected from NMDA induced neurotoxicity in mixed cortical neuron
culture141. This protective effect was overcome by PGE2 administration and EP1/3
agonist, but not by PGF2a administration 142, further suggesting the contribution of PGE2
and EP1 signaling. The type of PGE2 receptor activation is crucial in determining the
downstream effects. Evidence suggests that PGE2 is indeed protective in cerebral
ischemia via acting on EP2 143. Similarly, injection of selective EP4 agonist reduced
lesion volume induced by intrastriatal injection of NMDA 144. Interestingly, it has been
shown that the concentration and subcellular targeting of NMDA make important
differences in mechanisms through which COX-2 and PGs mediate excitotoxicity. A low
dose of NMDA can stimulate both synaptic and extrasynaptic NMDAR (referred to as
bath NMDAR stimulation hereafter) and lead to excitotoxicity. However, synaptic
NMDAR stimulation before bath NMDAR stimulation made a neuron resistant to
excitotoxicity 145. This sequential induction of synaptic then extrasynaptic NMDAR is
crucial in NMDAR-mediated maximal PG production, as synaptic NMDAR stimulation
increased COX-2 expression in neurons, whereas bath NMDAR stimulation increased
polyunsaturated fatty acids, the substrate for COX-2 in neurons. Lastly, COX-1 also
contributes to NMDAR-mediated excitotoxicity. On the one hand, COX-1 inhibition
blocked NMDA induced PGE2 production and free radical damage in hippocampus 146,
suggesting that NMDA induced PG production via COX-1 can be detrimental. On the
other hand, microglia produced COX-1 was protective in the model of cortical NMDA
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microinjection147, suggesting that COX-1 protein may be protective in excitotoxicity
depending on its cellular source. In support of this, COX-1 knockout mice exhibited
increased susceptibility to ischemic brain injury 148.
1.2.3 Functions of COX-2 enzyme
The complex and multi-dimensional regulation of COX-2 level is a reflection of
the importance of this enzyme. Indeed, COX-2 has been shown to participate in
numerous physiological activities, and has been implicated in various pathological
conditions. Other than the well-studied physiological roles of COX-2 in inflammation,
fever and pain, COX-2-mediated PG production has been implicated in bone formation
149

and renal function 150. COX-2 is also required in angiogenesis, the development of

blood vessels, through facilitating the production of vascular endothelial growth factor
(VEGF) 151. COX-2 derived PGI2 is critical in different aspects of female reproduction,
including facilitating oviduct dilation and embryo transfer, as well as embryonic
development 152. Moreover, estradiol induced COX-2 expression and PGE2 production
in preoptic neurons, which is critical in masculinization 153.
In the normal brain, the activity of COX-2 contributes to physiological functions,
including regulation of neuronal excitability and plasticity 154. COX-2 inhibition
suppressed LTP and LTD in mossy-fiber pathway via a mechanism that is independent
of NMDAR activation 155. Under pathophysiological conditions in the CNS, COX-2
function has been identified in ischemia, neurodegeneration, schizophrenia,
hyperalgesia and, epilepsy and epileptogenesis. COX-2 expression was induced by
various models of ischemia and COX-2 inhibition before and soon after ischemic insult
reduced the extent of cerebral damage 148. COX-2 protein was induced after retinal
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ischemia whereas COX-2 inhibitors prevented neuronal death and hematogenous cell
infiltration 156. In animal models, neuronal COX-2 overexpression led to an agedependent increase of neuronal apoptosis and gliosis, as well as an age-dependent
deficit in spatial memory 157. In humans, COX-2 has been implicated in progression of
Alzheimer’s disease (AD). AD brains had increased COX-2 expression whereas
NSAIDs retarded the course of dementia in AD patients 158, although in another study159
NSAID was found to have no effect on memory in healthy young adults. COX-2 has also
been shown to be responsible for increased PGE2 production and in turn, increased
Kynurenic acid (KYNA) production, which mediates NMDAR antagonism in
schizophrenia 160. In spinal cord, NMDARs were involved in mediating acute mechanical
nociceptive processing through activation of NOS and COX-2 enzymes 161. COX-2 was
found to constitutively express in spinal dorsal and ventral horns and in the dorsal root
ganglia whereas it played an important role in injury induced thermal and mechanical
hyperalgesia 162. COX-2 can also be induced in spinal cord after mechanical stimulation
and intrathecal injection of NMDA and by spinal cord injury 163.
In epileptogenesis and acute seizure generation, COX-2 may be detrimental or
beneficial depending on the cellular source and environmental context. In the former
case, COX-2 promotes neurodegeneration caused by excitotoxicity 141,164. In the latter
case, the COX-2 pathway of AA metabolism contributes to the maintenance of an
elevated seizure threshold in the normal brain. As mentioned above, COX-dependent
PG production increases rapidly and transiently in the brain following acute convulsive
seizures65,66. The earliest and highest wave of PG production is found in hippocampus
165,166

, the brain region associated with seizure onset 167. Several PGs may have
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anticonvulsive properties 168-172. Specifically, results from several studies employing
various animal models showed that inhibitors of COX-2 activity enhanced the
susceptibility for convulsions 67-69,173-176. This is consistent with observations in human
cases as well175. In addition, seizure threshold is elevated in mice overexpressing COX2 in neurons177. Together, these results provide compelling support for the notion that
this pathway of PG synthesis functions as a homeostatic control mechanism to maintain
the innate seizure threshold in the normal brain. On the other hand, results from other
pharmacological studies argue against this conclusion and even suggest a
proconvulsant action of the COX-2 pathway 178-183. The observations that some COX
inhibitors potentiated the action of certain antiepileptic drugs are consistent with this
possibility 184. The reason for these disparate results remains to be resolved. However,
several factors may influence the outcome with COX inhibitors 185. For example, unique
properties of individual inhibitors or differences in their treatment paradigms may have
contributed to the inconsistencies in some cases. In this regard, only a subset of COX
inhibitors affected seizure threshold in some studies 186, perhaps owing
to pharmacokinetic differences or off-target effects 123. Additionally, whereas the COX-2
selective inhibitor, rofecoxib, lowered the seizure threshold of PTZ when administered
orally in a bolus dose of 30 mg/kg 3 h prior to PTZ 68, subacute delivery of 30 mg/kg/day
rofecoxib in the diet for 5 days had no effect 181. It is possible that persistent inhibition in
the latter study elicited compensatory gene expression changes that masked the role of
COX-2 123,181. It is more difficult to reconcile results from another study showing that
acute rofecoxib treatment raised PTZ seizure threshold 180. However, the PTZ treatment
paradigms (bolus i.p. vs. i.v. infusion, respectively) and mouse strains used (C57BL/6
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vs. “Laka”, respectively) were key differences between the Akula et al.
(2008) and Claycomb et al. (2012) studies.
Studies using gene deletion approaches to assess the role of COX-2 in seizure
threshold similarly yield conflicting results. Thus, whereas global deletion of the Ptgs2
gene in all cell populations of the mouse brain lowered the seizure threshold relative to
wild-type littermates 187, no effect was observed using a conditional cre-lox approach to
target Ptgs2 deletion in forebrain neurons exclusively183. This difference might suggest
that neurons other than those in the forebrain account for the function of COX-2 in
maintenance of seizure threshold. However, both studies assess the role of COX-2 in
models of temporal lobe seizures, and as such, both genetic approaches deleted COX2 expression in key populations of glutamatergic neurons relevant to this model
(e.g., hippocampus, cerebral cortex, and thalamus). Alternatively, the results from the
global deletion approach might be related to loss of COX-2 function in non-neuronal cell
types, which would not be targeted in the conditional approach. Notably, COX-2 is
expressed constitutively under normal conditions in endothelial cells of the brain
microvascular endothelium, where it may modulate blood flow to the brain in response
to neuronal activity188. Alternatively, the different outcomes could be related to genetic
background differences between the global and forebrain-specific Ptgs2 gene-deficient
mouse lines (C57BL/6-129/Ola and C57BL/6, respectively) or to differential alterations
in early development. In the latter case, whereas the Ptgs2 gene was deleted
throughout all phases of development in the globally deficient mice, it was deleted
postnatally in the conditional knockout mice due to the characteristics of the promoter
used to target cre expression. It is relevant to note, however, that the native Ptgs2 gene
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reportedly becomes transcriptionally active in neurons in the second week postnatally
74,136

, suggesting that similar developmental concerns might apply to both genetic

approaches. Again, rofecoxib pretreatment enhanced PTZ induced acute seizure
incidence and severity 68, whereas neuronal COX-2 overexpression suppressed acute
seizure activity 177. Future studies are required to confirm the seizure modifying property
of the COX-2 pathway, and eventually, to determine the contributing PGs and their
receptors as well as the underlying molecular mechanisms.
The transient up-regulation of COX-2 expression observed after seizure was
accompanied by a less dramatic but prolonged PG production which can last hours to
days in epileptogenesis models 165,189. This biphasic PG production also leads to
controversial results when COX-2 expression or activity is blocked in seizure and
epileptogenesis models (Table 1.2 and summarized in detail in Appendix Table 1).
Clusters of studies seem to support the idea that prolonged or post-convulsion
administration of COX-2 inhibitors, which blocks the chronic phase of PG production,
delays epileptogenesis and attenuates associated neurodegeneration (Table 1.2,
column 2 & 3). On the other hand, acute pretreatment of COX-2 inhibitors, leads to
largely controversial results (Table 1.2, column 1) as described above. Distinct roles of
the various PGs and their receptors in different contexts likely determines the functional
outcome of PG signals. Therefore, it is possible that PG production during the
prolonged phase is involved in inflammation or brain blood barrier permeability through
non-neuronal PG receptors thus negatively affecting disease progression, whereas the
acute phase of PG production is anticonvulsive and helps prevent repetitive seizure
activity.

31

Table 1.2. Effects of COX-2 selective inhibition on acute seizure behavior, epileptogenesis and
associated neurodegeneration.
#

Acute Seizure
+
190 191 179 192

Pretreatment

Post/Chronic
treatment

,

,
,

,

182 180

,

Epileptogenesis
+
-

174 193 68 168

,

,

,

194 195

,

196 197 198

N/A

N/A

,

,

199 200

,

Neurodegeneration
+
-

N/A

137 201 199

,

N/A

174 168

N/A

,
,

,
,

176 200 164
202

,

,
,

N/A

+: Positive effects, i.e. anti-convulsive/ antiepileptic/ neuroprotective; -: Negative effects, i.e. increase
seizure severity and incidence/ facilitate epileptogenesis/ increase neurodegeneration; Pretreatment:
COX-2 inhibitors were given prior to convulsant administration; Post/Chronic treatment: COX-2 inhibitors
were given once after convulsant administration or throughout epileptogenesis process; Note that only
studies that applied selective pharmacological COX-2 inhibition are cited in this table, for a more
comprehensive summarization on effects of PTGS genes inhibition, please refer to Appendix Table 1. #,
antiepileptic effects are measured by attenuated spontaneous recurrent seizure and/or kindling
development.
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1.3 The role of RNA binding protein T-cell intracellular antigen-1 in regulating
gene expression levels
Messenger RNA (mRNA) transcripts undergo multiple post-transcription
modifications that are controlled and regulated by proteins. Regulatory proteins are
involved in every aspect of mRNA biology, from pre-mRNA processing and transport to
stability and translation.203,204 Key among these are a broad class of RBPs205 referred to
as heterogeneous nuclear ribonucleoproteins and mRNA binding proteins. RBPs exhibit
different patterns of expression (e.g., ubiquitous vs. tissue/cell specific; constitutive vs.
inducible) and can show different patterns of subcellular distribution (e.g., nuclear vs.
nuclear and cytoplasmic vs. cytoplasmic). As the name implies, RBPs possess domains
that recognize specific sequence codes, or docking sites, innate to the target mRNA
called cis-elements,206 which are commonly contained within RNA secondary structures.
A myriad of these cis-elements exists in the transcriptome.207-209 This interaction
between RBPs and RNA together with the ability of RBPs to form complexes with other
proteins dictates the functional outcome.
RBPs form complexes with other RBPs and non-RBP regulatory proteins referred
to generally as ribonucleoprotein particles (RNPs) or RNA granules. These membraneless macromolecular structures are remarkably heterogeneous and dynamic and often
exhibit overlapping components and functions. Nevertheless, several RNPs can be
distinguished by identifiable differences in protein composition and unique functional
characteristics. The major classes of cytoplasmic particles are transport
ribonucleoprotein particles (tRNPs), processing bodies (P-bodies), and stress granules
(SGs).210 Detailed descriptions of the composition, assembly, and function of these RNA
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structures can be found elsewhere.210-215 The following is a brief overview. The tRNPs
are heterogeneous structures that may represent a continuum between nuclear export,
cytoplasmic transport, and local translational particles. The specific aspects of the
mRNA cargo (e.g., cis-elements) together with its binding partners contribute
substantially to the composition of these particles. In neurons, for example, unique
proteins of tRNPs determine subcellular localization of the mRNA cargo (e.g.,
cytoplasm, axons, dendrites). Associated molecular motors that travel along
microfilament or microtubule tracks mediate this transport. Moreover, local demands
and stimuli within each compartment can influence both mRNA stability and translation.
P-bodies contain mRNA-degrading proteins, such as decapping enzyme, and are sites
of mRNA decay as well as translational repression.216,217 While P-bodies and tRNPs are
distinct particles, they appear to interact with each other at sites of translation. In this
regard, P-bodies are found docked with a large fraction of tRNPs in dendrites of
neurons.218 Interestingly, the stability of P-bodies in dendrites is inversely related to
excitatory synaptic activity, suggesting that P-bodies contribute to the control of local
activity-dependent translation. Finally, SGs sequester silenced mRNAs selectively and
reversibly and facilitate the reprogramming of translation in response to cellular stress
conditions. While these granule types have unique components that serve their
respective functions, some components overlap. A number of RNA granule components
are found in neuronal dendrites and spines (Appendix table 2).
The focus of my research is on the RBP T-cell intracellular antigen-1 (TIA-1) and
its role in regulating seizure threshold and epileptogenesis. This section will introduce
the structure of TIA-1 protein as well as its role as a regulator of mRNA life cycle.
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1.3.1 Discovery of TIA-1
TIA-1 is a multifunctional RNA binding protein that can influence alternative premRNA splicing in the nucleus and control post-transcriptional regulation of gene
expression in the cytosol 219. Discovery of TIA-1 was facilitated by the generation of TIA1 antibody through immunizing BALB/c mice with digitonin permeabilized T lymphocytes
220

. TIA-1 antibody reacted strongly with NK cells and CD8+ cytotoxic T cells (CTLs),

less strongly with CD4+ activated T cells, suggesting a preferential expression in cell
clones that express cytotoxic characteristics. The major protein isoform present in
cytolytic granules is a 15kDa TIA-1 protein isoform that appears to be derived from the
40 kDa isoform through proteolytic processing 221. Yet both isoforms are able to induce
DNA fragmentation in permeabilized thymocytes, suggesting that TIA-1 may form the
granule component responsible for inducing apoptosis in CTL targets. In addition, TIA-1
protein has been found to actively participate in immune defense against virus. TIA-1
knockdown or knockout led to susceptibility to TBEV (tick-borne encephalitis virus)
infection 222. TIA-1 also inhibited HBV (hepatitis B virus) surface antigen expression 223.
In both cases, TIA-1 functions as an RBP through interacting with virus RNA.
1.3.2 TIA-1 protein structure
TIA-1 is a member of the RNA-recognition motif (RRM) family of RBPs. RRM is
one of the most abundant protein domains in eukaryotes and is necessary and sufficient
for binding RNA molecules with a wide range of specificities and affinities 224. TIA-1
protein has three RRMs (RRM1, 2 and 3) that are functionally independent 225. RRM2 is
a canonical RNA recognition motif that can bind RNA by itself. Yet it shows a better
affinity when working with RRM1 and 3 together; RRM3 cannot bind RNA by itself, but it
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is a bona-fide RNA binding domain that has an auxiliary role in RNA binding, as
protonation/deprotonation of exposed histidine residues on RRM3 affects RNA binding
affinity of TIA-1 226; RRM1 has little RNA binding affinity 227, however it enhances
binding affinity in a sequence-dependent way, where RRM1 is required for high affinity
binding of poly-U RNA 228. Together, these three RRMs mediate the binding of TIA-1 to
its targets, which are often U-rich sequences located in either 5’ or 3’ end of mRNA.
Microarray analysis following TIA-1 immunoprecipitation identified a TIA-1 motif in
mRNAs that is capable of binding TIA-1 in Human colorectal RKO carcinoma cells 229.
Although this TIA-1 motif only presented in ~23% of these putative TIA-1 targets, it is
representative. COX-2 and tumor necrosis factor alpha mRNAs, which are known
targets of TIA-1, both possessed this motif. This motif also had a higher frequency in
3’UTRs 229. TIA-1 also possesses a glutamine (Q)-rich domain at its carboxyl (C)
terminus, which is structurally related to prion protein 221. This domain is capable of selfoligomerization in vivo and is required for TIA-1 aggregation under stress responses
(see below).
1.3.3 TIA-1 regulates pre-mRNA splicing
As a splicing regulator, TIA-1 associates selectively with pre-mRNAs that contain
a 5’ splice site followed by U-rich sequences, promoting U1 snRNP recognition 230. TIA1 has also been shown to directly bind to U1 snRNP 231. TIA-1 acts as splicing regulator
of the Fas receptor gene transcript. It facilitated Fas mRNA exon 6 inclusion and led to
increased production of the active form of Fas receptor, which promoted apoptosis 232.
Other targets of TIA-1-mediated regulation of alternative splicing include Msl-2 (malespecific-lethal 2) 230, lysyl hydroxylase 2 233, CFTR (cystic fibrosis transmembrane
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conductance regulator) 234, COL2A1 (type II procollagen gene)235 and FGFR-2
(fibroblast growth factor receptor-2) 236. Interestingly, splicing of TIA-1 mRNA is tightly
regulated by TIA-1 protein itself, as well as by another RBP, TIAR (TIA1 Cytotoxic
Granule Associated RNA Binding Protein Like 1), which has high homology with and
similar binding properties and functions as TIA-1 237. Overexpression of TIA-1 and TIAR
induced splicing of TIA-1 mRNA using novel alternative 5’ splice sites 238. These are
weak splice sites followed by U-rich stretches, the use of which possibly results in frame
shift or nonsense-mediated decay 238. Cells can express two TIA-1 mRNA transcripts,
TIA-1a and TIA-1b, which result from alternative splicing of exon 5 of the pre-mRNA
239,240

. TIA-1b encodes the active form of TIA-1 protein that has better splicing

stimulatory activity. TIAR depletion resulted in an increased ratio of TIA-1b over TIA-1a
240

. These results suggest the functional similarity between the two proteins and the

existence of an auto-regulatory mechanism that controls their expression levels. Both
TIA-1 and TIAR have indispensable physiological functions during development, as
double knockout or double knockdown of TIA-1/TIAR led to lethality in animals241 and
impaired viability in cells242. However, it has also been shown that TIA-1 and TIAR are
functionally distinct in that they may interact with different RBP partners 243.
1.3.4 TIA-1 regulates mRNA translation
As a post-transcriptional regulator, TIA-1 is known primarily as a negative
regulator of protein translation, binding to U-rich sequences in 3’UTR of mRNAs. TIA1knockdown in HeLa cells showed an increase in ribosomes and translational machinery
components.244 Specifically, TIA-1 suppressed cytochrome c translation in Hela cells in
response to ER stress through binding to its 3’UTR 245. In human hepatocellular
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carcinoma cells, TIA-1 binds to the 3’UTR of IGFBP-3 (Insulin-like growth factor binding
protein-3) mRNA. TIA-1 knock down led to increased IGFBP-3 protein level 246. TIA-1
binded to TNFα mRNA 3’UTR and acted as a translational suppressor. LPS induces
significantly more TNFα production in TIA-1 knockout macrophages 247, whereas TIA-1
knockout mice were more susceptible to endotoxic shock 241. Other targets of TIA-1mediated translational repression include ATP synthase β subunit gene 248, HIF-1α 249,
and β-actin 250. I became interested in this RBP because of its interaction with COX-2
mRNA. In non-neuronal cells, TIA-1 directly binded to adenosine/uridine (AU)-rich
elements (AREs) in the COX-2 mRNA 3’UTR to silence its translation 88. Dysregulated
RNA-binding of TIA-1 promoted COX-2 expression in neoplasia.88
The translational suppressor role of TIA-1 has been largely linked to its
involvement in the stress responses. TIA-1 is a key component of the protein complexes
that assemble translationally inactive mRNAs under stress conditions, namely, stress
granules (SGs) 251. After their recovery from stress, cells release these mRNAs from
SGs for translation. Thus SG-mediated translation suppression serves as a protective
mechanism against acute stress. Assembly of SGs is highly regulated and requires
functional TIA-1 protein. Under cellular stress, TIA-1 shuttles from the nucleus into
cytoplasm 252, facilitates the recruitment of stalled preinitiation complexes into SGs 253,
and self-aggregates via its prion-related C-terminus domain 254. RRM2 and the first half
of the C-terminal region are necessary for nuclear accumulation, whereas RRM3 is
required for its nuclear export 255. TIA-1-mediated SG aggregation is resistant to
protease treatment but can be inhibited by overexpression of heat shock proteins, such
as HSP70 254. This process resembles prion aggregation, which is further supported by
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the fact that substitution of the Q-rich domain with the aggregation domain of a yeast
prion, SUP35-NM, reconstitutes SG assembly 254. TIA-1 regulates SG formation
downstream of eIF-2α 254. TIA-1 self-aggregation and recruitment into SG has also been
shown to be Zn2+-dependent 256. SG formation is considered as a dynamic and
reversible process that coordinates mRNA triage and has been extensively studied in
mammalian peripheral tissues and cell lines.
It is worth mentioning that TIA-1 also suppresses mRNA translation through
binding to 5’-terminal oligopyrimidine tracts (TOP) sequences located in a class of
mRNAs that encoding ribosomal protein or translation factors which are more efficiently
repressed during amino acid starvation 257. Binding of TIA-1 to 5’ TOP is mediated by
RRM3 258. TIA-1 has also been shown to promote the decay of RNA in certain instances
241,259

. TIA-1-mediated mRNA decay requires polysome disassembly and utilizes both

5’-3’ and 3’-5’ decay pathway 259.
1.3.5 TIA-1 functions in central nervous system
Both TIA-1 transcripts and protein are detected in the CNS 177,239,260,261. TIA-1positive SGs appear acutely in hippocampal neurons following brain ischemia 93,94,262. In
addition, TIA-1 associates with pathological lesions in several neurodegenerative
diseases, including amyotrophic lateral sclerosis 263,264, Huntington’s disease 265 and
tauopathies 266. Overexpression of TIA-1 facilitates tau misfolding 267 whereas reduction
of TIA-1, in turn, rescues tau-mediated degeneration 268. These findings suggest that in
neurons, TIA-1 mediates SG formation, serving as a protective mechanism against
acute stress, but may also lead to deposition of pathological protein aggregations in
diseases associated with prolonged stress. On the other hand, due to its large number
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of mRNA targets and protein partners 229,267, TIA-1 may serve biological functions that
are independent of SG formation in brain. TIA-1 deficiency leads to changes in mRNA
levels of cell cycle and apoptosis regulators, as well as fat storage and membrane
trafficking factors in brain 269. TIA-1 is also recently implicated in physiological neuronal
function 261.
1.3.6 Interaction between TIA-1 and COX-2 mRNA
PGs are potent local mediators that control a wide range of functions under both
physiological and pathological conditions. COX-2, the key enzyme in the production of
prostaglandins within the CNS, may serve a neuromodulatory function in epilepsy.
Evidence from numerous studies have suggested that COX-2 expression is under tight
regulation of neuronal activity. Thus, constitutive COX-2 expression was found in
glutamatergic neurons of CNS 74, whereas convulsive seizure activity induced
upregulation of COX-2 expression in these cells 67,165. In the present study, it is
hypothesized that activity-dependent expression of COX-2 in neurons is regulated by
RNA binding proteins. In particular, TIA-1 has been shown to suppress COX-2 mRNA
translation by binding to its 3’UTR 88. Deletion of TIA-1 was associated with an increase
in COX-2 protein expression in non-neuronal cell types 88,270. Thus, it is posited that loss
of TIA-1 will lead to enhancement of COX-2 expression in neurons. It is further
hypothesized that this activity-dependent mechanism regulates seizure threshold in the
brain. This central hypothesis forms the basis for the proposed studies (Specific Aims)
of my thesis.
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1.4 Specific Aims
Studies in the Aims of this study may suggest novel genetic mechanisms by
which seizure threshold and epileptogenesis may be regulated. Studies in Aim 1 will
identify the ionotropic glutamate receptor that is responsible for controlling the activitydependent expression of COX-2 in neurons, and identify RNA binding proteins of COX2. Studies in Aims 2 will explore the possibility of TIA-1 in regulating the level of
neuronal COX-2 protein expression from its native gene. Studies in Aim 3 will further
confirm that whether the loss of TIA-1 will alter seizure threshold in brain or regulate the
progression of epilepsy, whereas studies in Aim 4 will explore the downstream effectors
of TIA-1 deletion-mediated plasticity changes in the brain.
1.4.1 Specific Aim 1: Regulation of neuronal COX-2 expression through NMDAR
activity-dependent mechanisms (Chapter 2)
Since COX-2 is constitutively expressed in glutamatergic neurons of the CNS
and neuronal COX-2 expression is coupled to changes in excitatory neuronal activity, it
is hypothesized that neuronal COX-2 expression is regulated via the excitatory NMDAR
activity. NMDAR inhibitor will be used to test whether constitutive or induced COX-2
mRNA levels are dependent on NMDAR activity. The mRNA levels of cPLA2α and
PGESs will be examined to test whether AA pathway genes are co-regulated with COX2 by NMDAR activity. COX-2 mRNA half-life will be measured to test whether NMDAR
activity regulates COX-2 expression through post-transcriptional mechanisms. It is
hypothesized that NMDAR activity regulates COX-2 expression in part through RNA
binding proteins. To test this, RBPs will be eluted from cultured neuron lysates using
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COX-2 3’UTR harboring probes and subjected to peptide mass finger printing to identify
potential candidates of COX-2 binding RBPs.
1.4.2 Specific Aim 2: Role of TIA-1 in neuronal COX-2 expression (Chapter 3)
TIA-1, which is expressed in excitatory neurons of the CNS, functions as a
translational silencer of COX-2 expression via binding to 3’UTR of COX-2 mRNA in nonneuronal cells. It is posited that TIA-1 inhibits neuronal COX-2 protein translation in
neurons as well. Because TIA-1 is known to suppress COX-2 translation in nonneuronal cells, it is hypothesized that TIA-1 deletion will result in increased COX-2
protein expression in brain. To test this, COX-2 protein levels will be measured in brains
of TIA-1 knockout mice.
1.4.3 Specific Aim 3: Effects of TIA-1 deletion on acute seizure generation and
epileptogenesis (Chapter 3 and 4)
If acute PGs production by COX-2 is anticonvulsive, enhanced COX-2
expression in TIA-1 null animals will antagonize acute seizure induction and may affect
epileptogenesis. To test this hypothesis, TIA-1 KO and their littermate controls will be
subjected to acute seizure and epileptogenesis models. Selective COX-2 inhibitor will
be applied during these assays to test if effects of TIA-1 deletion are due to increased
COX-2.
1.4.4 Specific Aim 4: Identification of molecular targets of TIA-1 in the
hippocampus (Chapter 5)
Since TIA-1 is also a regulator of mRNA transcription, it is hypothesized that
disruption of TIA-1 gene (Tia1) may alter mRNA transcriptome in the brain. It is also
hypothesized that if TIA-1 deletion altered epileptogenesis, it may contribute to disease
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progression by altering plasticity changes that promote or suppress this process. To test
this, brains from both wild-type and TIA-1 knockout animals that are subjected to
epileptogenesis paradigm will be analyzed by next generation sequencing analysis to
identify candidate molecular targets of TIA-1.
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CHAPTER 2 Regulation of COX-2 mRNA expression in neurons via NMDARa
2.1 Synopsis
The mechanisms through which constitutive or induced COX-2 expression in
neurons is regulated are not fully understood. Studies included in this chapter
investigated the mRNA expression of PTGS genes as well as PLA2 and PGS genes in
cultured cortical neurons. The NMDAR-dependent expression of COX-2, the activitydependent isoform of COX, has been thoroughly examined under basal and induced
neuronal activity.

a

Much of the work described in this chapter was originally published in the Journal of Biological
Chemistry. Hewett, S.J. et al. Spontaneous Glutamatergic Synaptic Activity Regulates Constitutive COX-2
Expression in Neurons: OPPOSING ROLES FOR THE TRANSCRIPTION FACTORS CREB (cAMP
RESPONSE ELEMENT BINDING) PROTEIN AND Sp1 (STIMULATORY PROTEIN-1). J. Biol. Chem.
2016; 291: 27279-27288. © the American Society for Biochemistry and Molecular Biology.
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2.2 Introduction
In neurons, excitatory synaptic activity triggers release of arachidonic acid (AA)
from membrane phospholipid stores via activation of phospholipase A2 (PLA2). Free AA
can then be rapidly metabolized by several different pathways. Among these pathways,
prostaglandin (PG) synthesis is catalyzed via concerted activation of cyclooxygenases
(COX) and prostaglandin synthases (PGS).
COX1 and COX-2 are homologous ER-resident N-glycoprotein isozymes that
catalyze the first committed reaction in metabolism of AA to PGs and thromboxanes
(section 1.2.2.1). Although they both metabolize AA to PGH2, the intermediate product
that serves as the substrate for various synthases, the transcriptional regulation of the
two isozyme genes differs. The promoter region of PTGS1 gene contains three Sp1
sites and lacks a TATA or CAAT box 75, which results in constitutive expression of COX1 protein in many cell types. In contrast, the PTGS2 gene promoter contains a TATA
box motif and a number of cis-acting elements that are recognized by various
transcription factors (section 1.2.2.2). This results in a typically transient expression
pattern of COX-2 protein in many tissue types, which is not expressed constitutively but
can be induced by a variety of other stimuli. However, an exception to this is the CNS,
where COX-2 expression is constitutively detected in glutamatergic neurons74,
mediating rapid, almost simultaneous PG production in response to convulsive stimuli
67,165

. In addition, COX-2 expression is coupled to N-Methyl-D-Aspartate (NMDA)

receptor activity. Hence, stimuli that enhance excitatory neurotransmission, such as
NMDA, coordinately up-regulate neuronal COX-2 expression. Conversely, induced
COX-2 expression is down-regulated by NMDAR antagonists. This is consistent with the
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notion that COX-2 catalyzes the activity-dependent production of PGE2. The molecular
and cellular mechanisms that contribute to the constitutive and induced expression of
COX -2 in these neurons are not fully understood. Therefore, the goal of the work
described in this chapter is to determine the transcriptional mechanisms regulating
basal COX-2 expression in cortical neurons and to examine the relationship between
transcriptional regulation and neuronal activity.
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2.3 Materials and methods
2.3.1 Measurement of COX-2 mRNA tissue expression
COX-2 mRNA was measured in kidney, lung, heart, cerebellum, hippocampus,
olfactory bulb, cerebral cortex and spinal cord from 8 weeks old male CD1 mice (Harlan;
Indianapolis, IN, U.S.A). Total RNA was extracted from homogenized tissue using
TRIZOL reagent (Invitrogen, Carlsbad, CA). First-strand cDNA synthesis and real-time
quantitative PCR were performed as described previously271 and in the quantitative realtime PCR section (2.3.4) below.
2.3.2 Generation of purified cortical neuronal culture
To generate purified cortical neuron cultures (PNCs), brains from day 15 CD-1
mouse embryos were placed into ice cold dissecting medium (Ca2+/Mg2+-free HBSS
containing 25mM glucose, 20mM sucrose, and 20mM HEPES), meninges removed,
and cortices dissected free from the rest of brain. Harvested tissue was minced and
incubated at 37oC for 15 min in dissecting medium containing 0.025% trypsin. Tissue
was then pelleted at 700xg for 3 min and re-suspended in modified Eagle’s medium
(MEM) supplemented with 5% (v/v) heat-inactivated bovine growth serum (BGS) and
5% (v/v) iron-supplemented calf serum (CS), 2mM L-glutamine, 25mM glucose, 28mM
sodium bicarbonate, and penicillin/streptomycin (50 IU/ml and 50 µg/ml, respectively).
Tissue was immediately dissociated by gentle trituration using fire-polished Pasteur
pipettes and single cell suspensions were plated at a density of 1.5 x 106/mL (measured
by Muse count & viability assay kit, Millipore) on polyethyleneimine-coated 4 or 24 well
tissue culture plates (400µL/well). Medium was replaced 4 hours later with neuron
growth medium (Neurobasal medium containing B27 supplement, 2mM glutamine,
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penicillin and streptomycin). Cytosine arabinoside (Ara-C; 1µM) was added after plating
(DIV2) to inhibit growth of contaminating glial cells. Cells were fed on DIV4 and 7 by
removing 250µL medium from each well and adding 250µL of fresh neuron growth
medium. All cultures were kept at 37oC in a humidified 5.5% CO2-containing
atmosphere.
2.3.3 Drug Exposure
To block NMDAR alone (Fig. 2.3 and 2.14), PNCs were treated with NMDAR
antagonist 5-amino-phosphonovaleric acid (APV; TOCRIS) for two days (DIV 5-7). Ten
µL stock solution of APV (1.2mM, dissolved in dH2O) was added in each well
(containing 400µL/well medium) for final concentration of 30µM. In a different
experiment (Fig. 2.4), to block either NMDAR or AMPAR, PNCs were exposed to APV
or AMPAR antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; Research
Biochemicals Inc.) for two days (DIV 5-7). Four hundred µL stock solution of APV or
CNQX (60μM, both dissolved in 0.6% DMSO) was added to each well (containing
400µL/well medium) to make a final concentration of 30µM. After gently swirling, 400µL
medium was removed from each well. DMSO was used as vehicle and all experimental
conditions contained 0.3% DMSO.
To block evoked synaptic exocytosis, PNCs were exposed to Tetanus Toxin
(TeNT; Calbiochem) for two days (DIV 5-7). Ten µL stock solutions of Tetanus Toxin
(12μg/ml, dissolved in dH2O) was added in each well (containing 400µL/well medium) to
make a final concentration of 300ng/ml.
To enhance excitatory neuronal activity (Fig. 2.6), 10µL stock solution of the
GABAA receptor antagonist bicuculline (Cayman Chemical, CAS 485-49-4) (4mM,
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dissolved in 0.6% DMSO) was added in each well (containing 400µL/well medium) to
make a final concentration of 100µM. DIV7 PNCs were either pre-treated with 300ng/ml
Tetanus Toxin for two days (DIV5-7) before being exposed to bicuculline at DIV7 for 4
hours at 37oC, or co-incubated with both bicuculline and 10µM NMDAR antagonist MK801 (dizocilpine maleate, Research Biochemicals Inc.) at DIV7 for 4 hours at 37oC.
DMSO was used as vehicle and all experimental conditions contained 0.3% DMSO.
To activate NMDAR directly, PNCs were exposed to NMDA (Sigma-Aldrich) and
glycine (Fisher Scientific) for 1 hour at DIV7. Ten µL 40x stock solution of NMDA and
glycine dissolved in 1x Hank's Balanced Salt Solution (HBSS) was added in each well
(containing 400µL/well medium) to make a final concentration of 50µM and 0.05µM for
NMDA and glycine respectively. HBSS (1x) was used as vehicle.
2.3.4 Quantitative Real-Time PCR
Gene expression was measured using real-time quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR). Cells from 3 to 4 wells of tissue
culture plates were harvested, combined and total RNA was extracted using TRIZOL
reagent (Invitrogen, Carlsbad, CA), suspended in RNase-free water, and quantified
using a NanoDrop UV-Vis Spectrophotometer (Thermo Sci). First-strand cDNA
synthesis was performed in a 20µL reaction mix containing 1µg total RNA, reverse
transcriptase (200U M-MLV, Life Tech.), 1x reaction buffer (Life Tech.), DTT (10mM,
Life Tech.), dNTPs (0.2mM each, Promega), and oligo (dT) primers (10µg/mL,
Promega). Reactions were performed at 42°C for 1 hour. qRT-PCR was performed
using Taqman® gene expression master mix and the following gene expression assays
(Applied Biosystems) for Actb (Mm01205647_m1), Grin1 (Mm00433790_m1), Fos
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(Mm00487425_m1), Ptgs1 (Mm00477214_m1), Ptges1 (Mm00452105_m1), Ptgs2
(Mm00478374_m1), Ptges2 (Mm00460181_m1), Pla2g4a (Mm00447040_m1) and
Ptgds (Mm01330613_m1) according to manufacturer’s instruction. Reactions were
performed using Mastercycler ep RealPlex2 Real-Time PCR System (Eppendorf North
America) under the following conditions: 50°C for 2 minutes and 95°C for 10 minutes,
followed by 40 amplification cycles (95°C for 15 s and 60°C for 1 minutes). Expression
was assessed using the comparative cycle threshold method (ΔΔCT), where CT values
of the transcript of interest were normalized to β-actin CT values from the same sample
to derive ΔCT. These values were compared to a calibrator ΔCT value to determine the
relative fold increase in mRNA. To assess primer efficiency for each analysis, reactions
were performed on a dilution series of known template concentrations (12.5, 25, 50, 100
and 200 ng/reaction, cDNA generated from DIV 7 PNC of CD-1 mice). Similar efficiency
across all input concentrations was confirmed (slope of relative efficiency plot <0.1)
between all primer pairs and housekeeping gene primer pair.
2.3.5 Western blotting
Purified neuron cultures were washed once with ice-cold PBS and harvested by
gentle scraping. Cells were spun (700 g; 5 minutes; 4◦C) and the resulting pellet was
suspended in lysis buffer containing: 20 mM HEPES (pH 7.4), 2 mM EGTA (pH 8.0), 50
mM β-glycerol phosphate (pH7.2), 1 mM DTT, 1 mM Na3VO4, 5 mM NaF, 1% Triton X100, 0.2 mM PMSF and 1 X Complete Protease Inhibitor (Roche). Lysates were then
incubated on ice (30 minutes), cellular debris was removed by centrifugation (12,000 g;
20 minutes; 4˚C), protein concentration was determined by BCA assay(Pierce;
Rockford, IL), protein (40µg) was separated by 15% SDS-PAGE under reducing
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conditions and electrophoretically transferred to a PVDF membrane (Bio-Rad; Hercules,
CA). Membranes were blocked (Odyssey® blocking buffer; at 25◦C for 1 hour) and then
probed (4◦C overnight) with an anti-synaptobrevin-2 rabbit polyclonal antibody (1:1000
dilution; Synaptic System) and a mouse monoclonal antibody directed against β-actin
(1:4000 dilution; Sigma). Species-specific secondary antibodies labeled with spectrally
distinct IRDye® fluorescent dyes (LI-COR Biosciences; Lincoln, NE) were used to
detect primary antibodies (1 hour at 25◦C). Results were recorded on LI-COR
ODYSSEY® Fc Imaging system (LI-COR Biosciences).
2.3.6 Measurement of COX-2 mRNA half-life
To determine if NMDAR activity mediates post-transcriptional regulation of COX2 by changing mRNA stability, the COX-2 mRNA half-life was measured in NMDAstimulated cortical neuron cultures that were incubated with or without the NMDAR
antagonist APV. DIV7 cortical neurons were treated with NMDA (50µM, Sigma-Aldrich)
and glycine (0.05µM, Fisher Scientific) for 1 hour, after which actinomycin D (ActD,
1µg/mL, Sigma-Aldrich) with or without APV (30µM) was added for various times and
COX-2 mRNA level was measured using real-time quantitative reverse transcriptasepolymerase chain reaction (qRT-PCR) as described in section 2.3.4. Non-linear
regression (one phase exponential decay) was then performed using GraphPad Prism,
Version 6.0.1 (GraphPad Software, Inc., La Jolla, CA, U.S.A.) on the time course
expression levels of COX-2 mRNA. The half-life of COX-2 mRNA was calculated from
the equation, t1/2= 0.693/k, where k= the rate constant for mRNA decay (i.e., percent
change over time).

51

2.3.7 Identification of NMDAR-responsive COX-2 RNA binding proteins
A 3’ biotinylated RNA probe representing the first 60nt of COX-2 mRNA 3’UTR
(UAUUUAUUUAUUUAUGUGAAGAAUUUAAUUUAAUUAUUUAAUAUUUAU)

was

obtained from Integrated DNA Technologies (Newark, NY). RNA probe (0.17mg) was
diluted in 170µL TE buffer containing 10 mM Tris-HCl (pH 8.0) and 0.1 mM EDTA,
supplemented with 20U/mL RNase Inhibitor (Human Placenta, NEB) and 400µM vanadyl
ribonuclease inhibitor (NEB), and stored at -80°C before use. To restore secondary
structure, RNA probe was heated at 90°C for 2 minutes and immediately transferred to
ice for 2 minutes. Probe was then incubated at room temperature with RNA structure
buffer containing 10mM Tris (pH 7.0), 0.1M KCl and 10mM MgCl2 supplemented with
Rnase inhibitor and vanadyl ribonuclease inhibitor. Cells were washed gently with cold
PBS, harvested and lysed in CE buffer containing 10mM HEPES (pH 7.4), 60mM KCl,
1mM EDTA, 0.075%(v/v) NP40 and 1mM DTT supplemented with 1mM PMSF, 1x
Proteinase inhibitor (Complete, Roche), 1x Rnase inhibitor, and 400µM vanadyl
ribonuclease inhibitor. Cellular debris was removed by centrifugation (12,000 g; 20
minutes; 4˚C). Lysates (1mg protein, determined via BCA assay) were precleared with
streptavidin agarose beads (Sigma-Aldrich), incubated with 12µg RNA probe at 4°C for 1
hour and then with streptavidin beads for an additional 45 minutes. Beads were washed
5 times at 4°C with CE buffer and loaded on a 4-15% Mini-PROTEAN TGX precast
polyacrylamide gel (Bio-Rad). Protein bands were electrophoretically separated via SDSPAGE and stained with a Pierce Silver Stain Kit (Thermo Fisher). Precision Plus Protein
Dual Color Standards (Bio-Rad) was used to indicate molecular weight of protein bands.
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2.3.8 Statistical analysis
All statistical analyses were performed using GraphPad Prism, Version 6.0.1
(GraphPad Software, Inc., La Jolla, CA, U.S.A.). For qRT-PCR, statistics were
performed on the logarithmic transformation of 2−ΔΔCT values. COX-2 mRNA tissue
expression was analyzed by a one-way ANOVA followed by Bonferroni’s multiple
comparisons test. Time course expression of AA pathway mRNA, effect of AMPA and
Kainate receptor antagonism on COX-2 mRNA levels and neuronal cell death measured
by lactate dehydrogenase release were analyzed by a one-way ANOVA followed by
Dunn’s multiple comparisons test. Effect of NMDAR antagonism on AA pathway mRNA
levels and effect of NMDAR activation on COX-2 mRNA levels were analyzed by an
unpaired Student’s t-test. Effect of NMDAR antagonism on bicuculline-induced COX-2
mRNA levels was analyzed by a two-way ANOVA followed by Tukey’s multiple
comparison test. The COX-2 mRNA half-life was calculated using one phase
exponential decay nonlinear regression analysis. Differences between remaining mRNA
levels were analyzed by a two-way ANOVA test. Significance was set at p < 0.05. In
figure legends, p values were reported as their exact values whenever available. For all
multiple comparison analysis, exact p values were not provided by Prism and were
reported as “p < 0.05”. Exact p values that are less than 0.0001 were not provided by
Prism and were reported as “p < 0.0001”.

53

2.4 Results
2.4.1 COX-2 mRNA is constitutively expressed in brain
Quantitation of COX-2 mRNA levels in different tissues revealed that the brain
possesses the highest levels of constitutive mRNA levels (Figure 2.1), with lung and
heart also expressing a considerable amount of the transcript. Analysis of isolated brain
areas demonstrated high levels in regions including cerebral cortex, hippocampus, and
olfactory bulb, but not in spinal cord and cerebellum. This endogenous expression
pattern of COX-2 mRNA correlates well with that of mouse COX-2 promoter activity 83,
with the exception of cerebellum and spinal cord where high COX-2 promoter activity
was detected.

Fig. 2.1 COX-2 mRNA levels in tissues. Three adult male CD-1 mice were anesthetized and
transcardially perfused with ice-cold saline. Organs were rapidly dissected and frozen, and mRNA levels
were measured via quantitative PCR as described in section 2.3.1. COX-2 mRNA levels in kidneys were
used as the comparator (set to 1). Significant difference between treatments was identified via one-way
ANOVA (p < 0.0001). *, p <0.05, Bonferroni’s multiple comparison test (vs Kidney) following one-way
ANOVA.
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2.4.2 Expression of COX-2 mRNA in cultures of cortical neurons is coupled with
NMDAR expression and neuronal activity
Neuronal COX-2 level (Fig. 2.2A) near perfectly paralleled the temporal
expression of the obligate NMDAR (NR) subunit, NR1 (Fig. 2.2B), as well as c-Fos (Fig.
2.2C), which is used herein as marker of excitatory neuronal activity272. All three
mRNAs increased steadily from DIV1 through DIV5 and dramatically increased on
DIV7, suggesting transcription of COX-2 mRNA is correlating with the expression and
activity of NMDAR. On the other hand, COX-1 mRNA level remained stable from DIV1
through DIV5 but increased modestly at DIV7 (Fig. 2.2D). These findings are consistent
with the notion that Ptgs1 gene is constitutively active in cells due to lack of a TATA box
motif in its 5′ promoter region273,274, whereas COX-2 is inducible due to the presence of
various transcription factor binding sites in its 5’ promoter region75.

Fig. 2.2 Correlation between increased excitatory activity and PTGS genes mRNA expression in
cultures of cortical neurons. Shown is a comparison of the temporal pattern of COX-2 (A), NR1 (B), cFos (C) and COX-1 (D) mRNA levels in pure wild-type neurons at 1, 3, 5, and 7 days in vitro as quantified
by real-time qRT-PCR. Relative mRNA levels on DIV 1 were set to 1 and used as the comparator (N = 35 from three independent experiments). Significant differences between treatments were identified via
one-way ANOVA (p = 0.0002 for COX-2, p < 0.0001 for NR1, p = 0.0002 for c-Fos, p = 0.0032 for COX1). *, p < 0.05, Dunn’s test (vs DIV1) for multiple comparison following one-way ANOVA.
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2.4.3 Constitutive COX-2 expression in neurons is regulated by NMDAR activity
Constitutive COX-2 mRNA levels measured in NR1−/− cultures at DIV7 were
dramatically reduced when compared with that found in NR1+/+ cultures 83, suggesting
that indeed NMDAR activity was necessary for constitutive expression of neuronal
COX-2 mRNA. In support of this, the addition of 30μM NMDAR antagonist APV, a
concentration that reduced NMDAR activity in pure neuronal cultures as evidenced by
block of c-Fos mRNA production (Fig. 2.3A), also significantly decreased the levels of
COX-2 mRNA (Fig. 2.3B). This effect was specific to NMDAR inhibition as functional
block of AMPARs or Kainate receptors by CNQX did not inhibit the constitutive neuronal
expression of COX-2 or c-Fos (Fig. 2.4A and B). Interestingly, neither c-Fos nor COX-2
mRNA levels in cultured neurons were affected by pretreatment with tetanus toxin
(300ng/ml), a Clostridium toxin that prevents evoked but not spontaneous, synaptic
vesicle exocytosis by cleaving the SNARE protein, synaptobrevin-2 273 (Fig. 2.5).
Together, these results indicate that constitutive COX-2 mRNA levels are strongly
correlated with basal neuronal activity.

Fig. 2.3 Effect of NMDAR antagonism on c-Fos and COX-2 mRNA levels. DIV 5 pure neuronal
cultures were treated with 30μM APV (+ APV) or its vehicle (−APV) and c-Fos (A) and COX-2 (B) mRNA
were quantified via qRT-PCR 2 days later. Relative mRNA levels on DIV 1 (dashed lines) were set to 1
and used as comparator (N = 4 from two independent experiments). *, p < 0.0001, unpaired
Student’s t test of the geometric means.
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Fig. 2.4 Effect of AMPA and Kainate receptor antagonism on COX-2 mRNA levels. DIV5 pure
neuronal cultures were treated with 30μM APV (in 0.3% DMSO), 30μM CNQX (in 0.3% DMSO) or their
vehicle control (0.3% DMSO) and COX-2 (A) and c-Fos (B) mRNA levels were quantified via qRT-PCR 2
days later. Relative mRNA levels in Control were set to 1 and used as comparator (N = 3-5 from two
independent experiments). Significant differences between treatments were identified via one-way
ANOVA (p = 0.0156 for COX-2 and p < 0.0001 for c-Fos). *, p < 0.05, Dunn’s test (vs Control) for multiple
comparison following one-way ANOVA.

Fig. 2.5 Lack of effect of tetanus toxin on c-Fos and COX-2 mRNA levels. Pure neurons were treated
with 300ng/ml tetanus toxin (+TeNT) or its vehicle (−TeNT) on DIV5 and c-Fos (A) and COX-2 (B) mRNA
levels quantified via qRT-PCR on DIV7. Results are expressed as fold change relative to vehicle (−TeNT,
set to 1). There was no significant difference (p = 0.1286 and 0.4421 for c-Fos and COX-2 respectively)
as determined via unpaired Student’s t test of the geometric means (N = 3 from three independent
experiments). Top blot in A: Western blot demonstrating Efficacy of TeNT-induced synaptobrevin-2 (SB2)
cleavage (representative of three blots) assessed at DIV7.
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2.4.4 Increased neuronal activity induces COX-2 mRNA levels via NMDAR activity
I next tested whether increasing neuronal activity via network disinhibition by
GABAA receptor antagonism145 is sufficient to enhance COX-2 mRNA level. Increased
neuronal activity was significantly induced by GABAA receptor antagonist bicuculline, as
measured via c-Fos mRNA (Fig. 2.6A). Indeed, COX-2 mRNA levels were also
significantly induced by bicuculline (p = 0.0077, two-way ANOVA, Fig. 2.6B), indicating
that enhanced neuronal activity resulted from disinhibition is sufficient to induce COX-2
mRNA levels. As would be expected if this was mediated by NMDAR activity, addition of
the NMDAR open channel blocker MK801 prevented the increase in c-Fos and COX-2
mRNA levels seen after the addition of bicuculline (Tukey’s multiple comparison test). In
addition, NMDAR antagonism completely blocked (Tukey’s multiple comparison test)
constitutive c-Fos and COX-2 mRNA levels. In contrast, block of evoked synaptic
vesicle exocytosis using TeNT did not reduce either basal or induced COX-2 mRNA
levels (Tukey’s multiple comparison test), suggesting that bicuculline-induced network
disinhibition must facilitate spontaneous, rather than evoked synaptic vesicle release
which then activate NMDAR. Together, these results suggest that COX-2 mRNA levels
induced by enhanced neuronal activity requires NMDAR activity. This conclusion is
further supported by direct induction of COX-2 mRNA via stimulation of NMDAR through
adding its co-agonists NMDA and glycine. One hour NMDA and glycine treatment
enhanced COX-2 mRNA levels nearly 4 folds (p = 0.0139, unpaired Student’s t-test, Fig.
2.7A) without inducing neuronal cell death as measured by lactate dehydrogenase
(LDH) release (Fig. 2.7B).
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Fig. 2.6 Effect of NMDAR antagonism on bicuculline-induced COX-2 mRNA levels. DIV7 pure
neuronal cultures were treated with 100μM bicuculline (+Bic) or its vehicle (-Bic). Cells were either pretreated with Tetanus toxin (+TeNT) for two days (DIV 5-7), or co-incubated with NMDAR antagonist MK801 (+MK801). c-Fos (A) and COX-2 (B) mRNA was quantified via qRT-PCR 4 hours later. Relative
mRNA levels in Control in absence of bicuculline were set to 1 and used as comparator (N = 3 from three
independent experiments). *, p < 0.05, two-way ANOVA followed by Tukey’s test (vs Control -Bic) for
multiple comparison. #, p < 0.05, two-way ANOVA followed by Tukey’s test (vs -Bic) for multiple
comparison. For two-way ANOVA, p < 0.001 for treatment (Control vs +TeNT vs +MK801) comparison, p
= 0.0077 for bicuculline (-Bic vs +Bic) comparison, p = 0.7019 for interaction.

Fig. 2.7 Effect of NMDAR activation on COX-2 mRNA expression. (A) DIV 7 pure neuronal cultures
were treated with 50μM NMDA and 0.05μM glycine (50μM NMDA) or its vehicle (Control) and COX-2
mRNA was quantified via qRT-PCR one hour later. Relative mRNA levels in Control were set to 1 and
used as comparator (N = 4 from four independent experiments). *, p = 0.0139, unpaired Student’s t-test.
(B) DIV7 pure neuronal cultures were treated with 25μM NMDA and 0.025μM glycine (25μM NMDA),
50μM NMDA and 0.05μM glycine (50μM NMDA), 100μM NMDA and 0.1μM glycine (100μM NMDA) or
vehicle (Control) for one hour. No neuronal cell death (p = 0.3971, one-way ANOVA) was found via
measurement of lactate dehydrogenase (LDH) release.
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2.4.5 COX-2 mRNA half-life in neurons is regulated by NMDAR activity
While both steady-state and induced COX-2 mRNA levels were strongly
correlated with neuronal activity (Fig. 2.2 to 2.7), it is not known that whether this is due
to transcription or post-transcriptional regulation of COX-2 mRNA. Post-transcriptional
control of COX-2 expression by elements in the mRNA 3’UTR has been well
established in non-neuronal cell types. However, in neurons, the importance of NMDAR
activity in post-transcriptional regulation of COX-2 expression has yet to be
demonstrated. To test this, COX-2 mRNA half-life was measured in control or NMDAstimulated cortical neuron cultures that were incubated with or without the NMDAR
antagonist APV. Results show that both constitutive COX-2 mRNA half-life (Fig. 2.8A,
from 1.9 ± 0.7 to 0.63 ± 0.17 hours) and NMDA-induced COX-2 mRNA half-life (Fig.
2.8B, from 0.78 ± 0.52 to 0.28 ± 0.18 hours) was reduced by APV treatment, suggesting
that NMDAR activity maintains the half-life of COX-2 mRNA in both conditions.
Interestingly, one hour NMDA and glycine stimulation reduced COX-2 mRNA half-life by
60% (from 1.9 ± 0.7 to 0.78 ± 0.52 hours). Thus, it appears that an NMDAR-dependent
mechanism controls the tradeoff between increase COX-2 mRNA level and decreased
mRNA half-life. Together these results support the conclusion that the 3’UTR is a key
site of post-transcriptional regulation by NMDAR activity.
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Fig. 2.8 Regulation of COX-2 mRNA half-life by NMDAR activity in neurons. DIV7 neurons were
treated with dH2O (A, labeled as –NMDA) or with NMDA (50µM) and glycine (0.05µM) (B, labeled as
+NMDA) for one hour. Cells were then treated with ActD (1µg/mL) for 0.5, 1, 2, 4 and 8 hours, with or
without APV (30µM). Remaining COX-2 mRNA levels at various time points after ActD treatments were
measured via quantitative PCR. The COX-2 mRNA half-life was calculated using nonlinear regression
analysis, specifically one phase exponential decay as described in section 2.3.6 (N = 3 from three
independent experiments). Significant differences were identified via two-way ANOVA for comparisons
between different time points after ActD treatments (p < 0.0001 for –NMDA and p = 0.0126 for +NMDA),
no significant difference was found between –APV and +APV comparisons (p = 0.5901 for –NMDA and p
= 0.3910 for +NMDA).

2.4.6 Identification of NMDAR activity-responsive COX-2 mRNA binding proteins
Post-transcriptional regulation of mRNA expression could be mediated by
interaction between RBPs and mRNA 3’UTR. COX-2 mRNA 3’UTR has been shown to
bind a number of RBPs as described above (Chapter 1). Therefore, it is hypothesized
that NMDAR activity maintains COX-2 mRNA levels through regulating neuronal RBPs
that recognize COX-2 mRNA 3’UTR.
To identify neuronal RBPs for COX-2, an RNA probe containing the first 60nt of
COX-2 mRNA 3’UTR was generated. This segment has been shown to bind numerous
RBPs in a macrophage cell line 89. Indeed, this probe was able to pull down several
possible RBPs for COX-2 in cultured cortical neurons harvested at DIV7, visualized as
protein bands on silver stained gels (Fig. 2.9, one band of size 15kD~20kD, bands
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between 25kD~37kD and bands between 75kD~100kD). To confirm the strong protein
bands observed near 10kDa were not coming from protein degradation during sample
preparation or during immunoprecipitation, neuron lysates were incubated with lysis
buffer on ice for different times. No protein degradation was detected (Fig. 2.10).
Rather, the 10kDa band appeared to be fragmented streptavidin beads, as it became
more prominent when a higher concentration of beads was applied (Fig. 2.11). To test
the possible NMDAR-mediated alteration of binding affinity between RBPs and the
probe, neurons were treated with 50µM NMDA and 0.05µM glycine or their vehicle for 1
hour at DIV7. The profile of protein bands that were visualized on gels did not differ
drastically between control and NMDA treated samples (Fig. 2.12), with the intensity of
protein bands slightly reduced after NMDA/glycine treatment. This result may imply that
the binding of most RBPs with COX-2 mRNA may be negatively affected by acutely
altered NMDAR activity. Thus, NMDAR activation during excitatory transmission
stimulates disassembly of RBPs from COX-2 mRNAs, which may further lead to altered
half-life of COX-2 mRNAs (as seen in Fig. 2.8). Indeed, evidence has suggested that
such RBPs (e.g. Smaug1) are presented in neurons (section 6.4.5.3). Lastly, the
proteins on gel were subjected to peptide mass finger printing in order to identify
neuron-specific RNA binding protein of COX-2. Unfortunately, although protein bands
were visible through silver staining, mass spectrometry failed to detect any specific
protein (data not shown), possibly due to insufficient protein concentration. Thus, these
experiments will need to be repeated with an improved design in the future (discussed
in section 6.4.2).
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Fig. 2.9 Pull down of neuronal RNA binding proteins of COX-2 mRNA. Lysates harvested from DIV 7
cortical neurons were incubated with an RNA probe representing the first 60nt of COX-2 mRNA 3’UTR.
RNA and their putative RNA binding proteins were pulled down with Streptavidin beads, loaded on a 4–
15% polyacrylamide gel, electrophoretically separated via SDS-PAGE, and visualized by silver staining.
Left, molecular size of the standards (Marker). IP input, 5µg protein obtained before immunoprecipitation.
Pull-down, 10%(v/v) protein on Streptavidin beads obtained after immunoprecipitation. No Probe Control,
10%(v/v) protein lysate harvested after mock immunoprecipitation with Streptavidin beads only.

Fig. 2.10 Validation of protein lysis procedure. Lysates harvested from DIV 7 cortical neurons were
incubated with lysis buffer containing Proteinase inhibitors and RNase Inhibitors for 0, 1, 2, and 3 hours.
5µg lysates were then loaded on a 4–15% polyacrylamide gel, electrophoretically separated via SDSPAGE, and visualized by silver staining. Right, molecular size of the standards (Marker).
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Fig. 2.11 Validation of pull down procedure. Lysates harvested from DIV 7 cortical neurons were
incubated with Streptavidin beads of different concentrations. Supernatant containing protein lysate was
separated from beads via centrifugation. Both supernatant (5µL) and beads (5µL) were loaded on a 4–
15% polyacrylamide gel, electrophoretically separated via SDS-PAGE, and visualized by silver staining.
Right, molecular size of the standards (Marker). Arrows indicate the concentration-dependent increase in
staining intensity of the 10kDa bands.

Fig. 2.12 Pull down of RNA binding proteins of COX-2 mRNA from NMDA stimulated neurons. DIV
7 cortical neurons were treated with 50µM NMDA and 0.05µM glycine or their vehicle for 1 hour. Lysates
were harvested and incubated with an RNA probe representing the first 60nt of COX-2 mRNA 3’UTR.
RNA and their putative RNA binding proteins were pulled down with Streptavidin beads, loaded on a 4–
15% polyacrylamide gel, electrophoretically separated via SDS-PAGE, and visualized by silver staining.
Input, 20µg protein obtained before immunoprecipitation. Pull down, 1mg protein on Streptavidin beads
obtained after immunoprecipitation.
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2.4.7 Expression of components of the arachidonic acid metabolism pathway
While previous sections (2.4.2 to 2.4.5) have demonstrated a clear association
between neuronal COX-2 expression and excitatory neuronal activity, it is not known
that whether this association remains true for the putative enzyme partners of COX-2. It
appears that the mRNA levels of two downstream prostaglandin synthases, mPGES-1
and PGDS, changed in a manner that only weakly coupled to synaptic activity. mPGES1 mRNA level dropped dramatically at DIV5 and remained low at DIV7 (Fig. 2.13A),
whereas PGDS mRNA level decreased dramatically from DIV3 through DIV7 (Fig.
2.13B), with the decrease starting well before the onset of increased neuronal activity at
DIV5 (Fig. 2.2C). On the other hand, the mRNA levels of mPGES-2, another
downstream prostaglandin synthase, steadily increased from DIV1 through DIV7 (Fig.
2.13C), an effect that parallel to change in COX-2 mRNA level. Interestingly, a modest
increase in upstream phospholipase cPLA2 mRNA level was observed at DIV7 (Fig.
2.13D), also paralleled to the drastic increased neuronal activity at DIV7.
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Fig. 2.13 Time course mRNA levels of arachidonic acid pathway in cultures of cortical neurons.
Shown is a comparison of the temporal pattern of mPGES-1 (A), PGDS (B), mPGES-2 (C) and cPLA2
(D) mRNA levels in pure wild-type neurons at 1, 3, 5, and 7 days in vitro as quantified by real-time qRTPCR. Relative mRNA levels on DIV 1 was set to 1 and used as the comparator (N = 3-5 from three
independent experiments). Significant differences between treatments were identified via one-way
ANOVA (p = 0.0002 for mPGES-1, p = 0.0002 for PGDS, p = 0.0032 for mPGES-2, p = 0.0031 for cPLA2
). *, p < 0.05, Dunn’s test for multiple comparison following one-way ANOVA.

To further test whether the expression of these arachidonic acid pathway enzyme
genes is directly dependent on NMDAR activity, mRNA expression levels were
measured in cortical neurons at DIV7 after NMDAR antagonism with APV. No
significant change was observed in the mRNA expression levels of NR1 after APV
treatment (Fig. 2.14A), indicating that the reduction in neuronal activity did not result
from altered expression level of NMDAR. Similarly, APV did not alter the mRNA levels
of mPGES-1, mPGES-2 and PGDS (Fig. 2.14B, C and D), indicating that the expression
of prostaglandin synthases is not stringently co-regulated with COX-2 by NMDAR
activity in cultured cortical neurons. It is worth mentioning that neuronal cPLA2 mRNA
levels were increased by APV treatment (Fig. 2.14F), but not by CNQX treatment (data
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not shown), suggesting that reduced NMDAR activity results in enhanced expression of
this enzyme.

Fig. 2.14 Effect of NMDAR antagonism on arachidonic acid pathway mRNA levels. DIV5 pure
neuronal cultures were treated with 30μM APV (+APV) or its vehicle (−APV) and NR1 (A), mPGES-1 (B),
mPGES-2 (C), PGDS (D), COX-1 (E) and cPLA2α (F) mRNA were quantified via qRT-PCR two days
later. Relative mRNA levels on DIV1 were set to 1 and used as comparator (N = 3-9 from five
independent experiments. For unpaired Student’s t-test, p = 0.1821 (NR1), p = 0.9819 (mPGES-1), p =
0.7762 (mPGES-2), p = 0.6964 (PGDS), p = 0.1171 (COX-1), p = 0.0244 (*, cPLA2α).
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2.5 Discussion
In many peripheral tissues, COX-2 expression has been shown to be primarily
inducible by various stimuli75. In contrast, constitutive expression of COX-2 in
physiologically significant levels has been found in tissues such as kidney150 and in
neurons from spinal cord162 and brain136. Despite knowing that the COX-2 gene
expression is under transcriptional and post-transcriptional regulation by various cisacting elements, the molecular mechanisms underlying constitutive neuronal COX-2
expression remain largely unknown. With respect to this, I investigated the expression
of COX-2 mRNA in cultured cortical neurons and presented several original findings.
First, COX-2 mRNA is expressed constitutively in brain and is especially high in cerebral
cortex. Second, constitutive expression in cortical neurons depends largely on the
presence of functional NMDARs as functional block of NMDARs prevents the
constitutive neuronal expression of COX-2. Third, increased neuronal activity is
sufficient to induce COX-2 mRNA via activation of NMDARs. Fourth, spontaneous
glutamatergic synaptic activity may be involved in both constitutive and induced
expression as shown by the lack of effect of tetanus toxin in both conditions.
Consistent with the mRNA expression profile from the Allen Brain Atlas (© 2004,
Allen Institute for Brain Science. Allen Mouse Brain Atlas. Available from:
http://mouse.brain-map.org/), high level endogenous COX-2 mRNA is found in
hippocampus, olfactory bulbs and cortex (Fig. 2.1). A low-level expression of COX-2
mRNA was also found in cerebellum and in spinal cord, consistent with previous
observation that COX-2 protein and mRNA are expressed constitutively in cerebellum
astrocytes 275 and in both neurons and astrocytes from spinal cord 162. Interestingly,
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mice harboring a transgenic construct consisting of −371/+70 bp of the
proximal Ptgs2 gene promoter fused 5′ of a luciferase transgene exhibited high
luciferase expression in both cerebellum and spinal cord83. These results suggest that
native expression of COX-2 mRNA in these two CNS structures may be regulated by
elements located outside the proximal region of COX-2 promoter, such as those located
in the COX-2 3′-UTR. It is also possible that other elements in COX-2 promoter confer
the brain region-specific suppression of COX-2 mRNA, as the full-length Ptgs2 gene
promoter drives high level of luciferase expression in cortex and hippocampus, with little
expression in cerebellum in a knock-in mouse line73,276.
The high-level expression of endogenous COX-2 mRNA in cerebral cortex was
faithfully reflected in cultured cortical neurons. COX-2 mRNA was constitutively
expressed in cultures in a temporal pattern which coincided with the developmental
expression of NMDAR proteins confirmed via measurement of NR1 mRNA level (Fig.
2.2). Constitutive COX-2 expression also correlated with the temporal pattern of
NMDAR activity reported previously 277, suggesting that it is NMDAR-dependent.
Indeed, pharmacological block of NMDAR effectively suppressed neuronal COX-2
mRNA expression (Fig. 2.3 and 2.4), consistent with previous results that genetic
inhibition of NMDAR reduced constitutive neuronal expression of COX-2 mRNA 83. Bath
NMDA and bath glutamate treatments have been reported to induce neuronal COX-2
activity and expression in dissociated cultures141,143. This was confirmed in my cultures,
where acute (1 hour) bath NMDA and glycine-induced COX-2 mRNA expression (Fig.
2.7A). In this case, excitotoxicity did not seem to contribute to the induced COX-2
expression as shown by others143, as no obvious cell death was observed during the
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treatment paradigm (Fig. 2.7B). Increased neuronal activity facilitated by blocking
inhibitory neurotransmission also induced COX-2 mRNA levels, an effect that was
blocked by NMDAR inhibition (Fig. 2.6). Together these results indicate that NMDAR
activity is both sufficient and required for up-regulation of COX-2 mRNA levels. In
addition, the ineffectiveness of tetanus toxin in reducing both constitutive and induced
COX-2 mRNA levels (Fig. 2.5) suggests that spontaneous synaptic activity regulates
both basal and induced neuronal COX-2 expression in this in vitro model. Tetanus toxin
is a Clostridium toxin that prevents evoked, but not spontaneous, synaptic vesicle
exocytosis in neurons 278. It has been shown that in immature hippocampal neurons
(DIV 4-5 cultured hippocampal neurons), spontaneous vesicular release level was high
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. In addition, young neurons are known to respond to low concentration of glutamate

via NR2B containing NMDAR280, and that spontaneous glutamate release may signal
distant NMDAR to provide dendritic guidance or branching cues281. It is possible that
spontaneous glutamate release is high and can be further elevated via inhibition of
inhibitory neurotransmission at DIV 7 cultured cortical neurons, which activates
NMDAR-dependent downstream signaling cascades through a mechanism that does
not involve ion-influx282.
Although compelling evidence indicates that neuronal COX-2 expression is
regulated by NMDAR-dependent excitatory synaptic activity, the molecular mechanisms
by which glutamate (or NMDA) regulates COX-2 expression are poorly understood.
Interestingly, the NMDAR-dependent factor(s) that regulate constitutive neuronal COX-2
expression seem to be intrinsic to neurons, as COX-2 mRNA level in neurons was not
altered by co-culture with astrocytes or treatment with astrocyte-conditioned media83.
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These factor(s) could be acting transcriptionally, as Ptgs2 gene promoter is known to
contain a TATA box motif and a number of cis-acting elements, including CREB,
C/EBP, NF-IL6, AP-1, Sp1, and NF-κB consensus sequences 283. Among these
transcription factors, constitutive neuronal COX-2 transcription seems to be
independent of NF-κB, as a COX-2 promoter segment that lacks the NF-κB site was still
able to drive constitutive expression of luciferase in neurons 83. Rather, constitutive
expression of COX-2 appears to be negatively regulated by Sp1 and is positively
regulated by CREB, as shown by promoter mutation studies 83. On the other hand, posttranscriptional regulation of COX-2 expression may also exist. The COX-2 mRNA
3’UTR, which in the mouse is >2kb in length, has been shown to possess cis-acting
elements that regulated RNA stability and translation efficiency 76,84,85 76,84,85. My results
indicate, for the first time, that NMDAR-dependent COX-2 expression in neurons
involves posttranscriptional regulation. The half-life of COX-2 mRNA was reduced by an
antagonist of basal NMDAR activity suggesting that the half-life of the COX-2 transcript
is maintained by glutamate signaling through the NMDAR (Fig. 2.8). This notion is
further supported by unpublished observations (J.A.Hewett) from cultures of cortical
neurons showing that the COX-2 mRNA 3’UTR enhanced expression of a luciferase
reporter gene in a manner that was dependent on functional NMDARs in cultures of
cortical neurons. Additionally, NMDAR inhibition attenuated the effect of the COX-2
mRNA 3’UTR on reporter gene upregulation. These results support the conclusion that
the 3’UTR is a key site of post-transcriptional regulation by NMDAR activity.
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CHAPTER 3 Maintenance of the innate seizure threshold by COX-2 is not influenced by
the translational silencer TIA-1b
3.1 Synopsis
COX-dependent PG production has been shown to possess anti-convulsive
properties. COX-2 gene expression levels are subjected to post-transcriptional
regulation by RBPs. In non-neuronal cells, it is known that the RBP TIA-1 enhances
COX-2 protein translation via direct binding to COX-2 3’UTR. Therefore, studies
included in this chapter tested the hypothesis that in neurons, TIA-1 regulates COX-2
expression and by doing so influences the innate seizure threshold.

b

This chapter is a near duplicate of the previously published work in Neuroscience. Gong, Y. & Hewett,
J.A. Maintenance of the Innate Seizure Threshold by Cyclooxygenase-2 is Not Influenced by the
Translational Silencer, T-cell Intracellular Antigen-1. Neuroscience. 2018; 373: 37-51. © IBRO. Published
by Elsevier Ltd.
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3.2 Introduction
Activity of neuronal COX-2 is enhanced by excitatory neurotransmission and this
is thought to be involved in seizure suppression. COX-dependent PG production
increases rapidly and transiently in the brain following acute convulsive seizures.
Pharmacological inhibitors of COX-2 activity or inactivation of the Ptgs2 gene reduced
the innate seizure threshold 68,69,174,176,187, an effect that is thought to be due to the loss
of anticonvulsant PGs 67,170. On the other hand, genetic overexpression of COX-2
suppressed the incidence of pentylenetetrazole (PTZ)-induced convulsions 177. These
results suggest that COX-2 contributes to the maintenance of an elevated seizure
threshold in the normal brain.
Control of COX-2 expression is complex, involving transcriptional,
posttranscriptional, and posttranslational mechanisms 75,81. While the regulation of
COX-2 expression has been studied extensively in non-neuronal cell types, much less
is known about its regulation in neurons. The 3′UTR of COX-2 mRNA is a regulatory
region that has the capacity to bind numerous RBPs, which can affect stability and/or
translation of the transcript 76. T-cell intracellular antigen-1 (TIA-1) is one such RBP. In
non-neuronal cell types, inactivation of the TIA-1 gene (Tia1) was associated with an
increase in COX-2 protein expression indicating that TIA-1 functions to repress COX-2
mRNA translation 88. Whether TIA-1 performs a similar function in the regulation of
COX-2 expression in neurons has yet to be explored.
The goal of the work described in this chapter is to test the possibility that TIA-1
regulates COX-2 expression in neurons and by doing so influences the innate seizure
threshold. Specifically, because inhibitors of COX-2 activity lower the acute seizure
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threshold and TIA-1 deletion enhances COX-2 expression, it is reasoned that
inactivation of the Tia1 will increase neuronal COX-2 expression in the brain and
consequently will increase resistance to acute seizures.
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3.3 Materials and methods
3.3.1 Animal housing
Mice were housed on a 12 h light/dark schedule in the vivarium at Syracuse
University, which is accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International. Standard mouse chow and water were
provided ad libitum. Except for breeding units, mice were housed three to five per cage.
All animal procedures conformed to the National Academy of Sciences Guide for the
Care and Use of Laboratory Animals (NRC, 2011) and were approved by the Syracuse
University Institutional Animal Care and Use Committee (IACUC).
3.3.2 Animal breeding
The TIA-1 gene mutant mouse line (Tia1−/−) was obtained from cryostorage at
The Jackson Laboratory (stock # 009248) and a colony established by crossing
heterozygous founder mice (Tia1+/−) with their wild-type (Tia1+/+) C57BL/6J counterparts
(stock #000664). Tia1+/+ and Tia1−/− littermates were generated for studies by crossing
Tia1+/− breeding pairs from this colony. Genotyping of both mouse lines was performed
at weaning by PCR analysis of genomic DNA isolated from tail biopsies. To ensure the
integrity of the C57BL/6J genetic background, the line was backcrossed with wild-type
female C57BL/6J mice from The Jackson Laboratory every 3–5 generations.
3.3.3 Dosing paradigms
The acute PTZ-induced seizure model was used to examine changes in the
innate seizure threshold. All mice were acclimated to handling for 5–7 days prior to each
experiment. Injection solutions were prepared freshly by dissolving PTZ (Sigma
Chemical Co., St. Louis, MO) in 0.9% saline, which was sterilized by filtration and
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administered in a volume of 10 ml/kg body weight, i.p. Male littermates were randomly
segregated at weaning without knowledge of genotype and treated with a single dose of
PTZ or saline vehicle between 8 and 12 weeks of age. Seizure activity was monitored
for 25 min after PTZ administration and graded by an observer blinded to genotype
using a previously established scoring system181: stage 0, normal behavioral
activities; stage 1, hypoactivity; stage 2, ≥two isolated myoclonic jerks; stage 3,
generalized clonic convulsions with preservation of righting; stage 4, generalized clonic
or tonic–clonic convulsions with loss of righting. Maximal seizure score and latency to
seizure onset were recorded for individual mice and the incidence of convulsions (stage
3 or 4) in a given cohort was determined by the ratio of # of mice convulsed per total #
treated.
3.3.4 Immunofluorescence staining
Mice were deeply anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine
administered i.p. in saline and exsanguinated by transcardial perfusion with
0.05 M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde fixative
(PFA) in PBS. After post-fixing at 4 °C for 8–16 h in PFA solution, brains were saturated
with 20% sucrose in PBS, embedded in O.C.T. compound (Tissue Tek), and rapidly
frozen on dry ice prior to storage (−80 °C). Serial 12-µm-thick coronal sections were cut
within 1.34–2.06 mm posterior to bregma using a cryostat (Microm HM550, Thermo
Scientific) and mounted on microscope slides prior to storage at −20 °C. Sections were
washed in PBS and incubated in PBS containing 0.25% Triton-X100 (PBT).
Permeabilized sections were incubated overnight at 4 °C in blocking solution containing
PBT with 5% normal donkey serum (Jackson ImmunoResearch Inc.) and 1%
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bovine serum albumin (BSA; Sigma, A2153) then incubated overnight at 4 °C with
antigen-specific primary antibody diluted in PBT containing 1% normal donkey serum
and 1% BSA. After washing 5 times with PBT, sections were incubated at 20 °C with
secondary antibody for 4 h, washed again, then incubated for 5 minutes with PBS
containing 1 µg/ml DAPI (Life Technology) to label cell nuclei. Images were captured
with ZEN 2 software (Version 2.0.0.0) using an Axio Imager.A2 microscope fitted with
an AxioCam MRc digital camera (Zeiss United States). Images from individual studies
were processed identically using Adobe Photoshop (Adobe Systems, Inc., San Jose,
CA, USA).
Primary and secondary antibodies for immunostaining were goat anti-TIA-1
(1 µg/ml, Santa Cruz Biotechnology Cat# sc-1751, RRID: AB_2201433), rabbit antiCOX-2 (1:200, Cayman Chemical Cat# 160126-1, RRID: AB_327872), mouse antiGFAP (1:50, Genetex, GeneTex Cat# GTX73615, RRID: AB_378828), Alexa Fluor 594
donkey anti-Goat IgG (7.5 µg/ml, Jackson ImmunoResearch Labs Cat# 705-585-147,
RRID: AB_2340433), Alexa Fluor 488 AffiniPure Donkey anti-rabbit IgG (7.5 µg/ml,
Jackson ImmunoResearch Labs Cat# 711-545-152, RRID: AB_2313584), and Alexa
Fluor 488 AffiniPure Donkey anti-mouse IgG (7.5 µg/ml, Jackson ImmunoResearch
Labs Cat# 715-545-150, RRID: AB_2340846). Specificity of the anti-TIA-1 antibody was
confirmed using comparable sections from Tia1+/+and Tia1−/− mice processed in parallel.
For GFAP/TIA-1 double staining, sections were processed for antigen-retrieval as
described (Abcam, http://www.abcam.com/protocols/ihc-antigen-retrieval-protocol).
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3.3.5 Quantification of fluorescent intensity
Images were converted to 8-bit grayscale and fluorescent intensity quantified
using NIH Image J, version 1.50i284. For each brain, two images were taken from
coronal sections at −1.7 ± 0.12 relative to bregma. Maximal threshold was set to 255
and minimal threshold was set to 55 (TIA-1) or 40 (COX-2), using the default auto
thresholding method. The mean integrated density in 8 non-overlapping regions of
interest (ROIs) with fixed size (100 × 100 pixel2) was calculated for CA1 and CA3
pyramidal and DG granule cell layers of the hippocampal formation. Results were
averaged across duplicate sections from each brain.
3.3.6 Generation of purified cortical neuron and astrocyte cultures
Pure cultures of cortical neurons were prepared from gestational day 15
C57BL/6J fetuses as detailed in section 2.3.2. To generate purified cortical astrocyte
cultures, brains from postnatal day 1–3 pups were placed into ice cold dissecting
medium (Ca2+/Mg2+-free HBSS containing 25mM glucose, 20mM sucrose, and 20mM
HEPES), meninges removed, and cortices dissected free from the rest of brain.
Harvested tissue was minced and incubated at 37oC for 15 min in dissecting medium
containing 0.025% trypsin. Single cell suspensions were plated at a density of two
hemispheres/plate on Falcon Primaria 24-well culture plates (BD Biosciences, Lincoln
Park, NJ) in media stock (MS) supplemented with 10% FBS (Hyclone, Logan, UT), 10%
calf serum (CS; Hyclone), 10 ng/ml epidermal growth factor (Life Technologies,
Grand Island, NY), and penicillin/streptomycin (50 IU/ml and 50 µg/ml, respectively). MS
is composed of modified Eagle’s medium (MEM, Earle’s salts; Mediatech, Herndon, VA)
supplemented with 2 mM glutamine and 20 mM glucose. Upon reaching confluence, the
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cultures were treated once for 2 days with cytosine arabinoside (8 µM) and were
maintained thereafter in maintenance media (MS plus 10% CS and antibiotics). One
day before experimentation, cells were treated with l-leucine methyl ester (75 mM,
30 min) to remove microglia285. Astrocyte cultures were used on DIV 30.
3.3.7 Measurement of TIA-1 mRNA expression
TIA-1 mRNA was measured in lung, spleen, liver, kidney, heart, and brain from
8-week-old male C57BL/6J mice, as well as from cultures of cortical neurons and
astrocytes. Real-time quantitative PCR was performed as described previously 271 and
in quantitative real-time PCR section (2.3.4). Mouse TIA-1 (Mm00441742_m1) or βactin (Mm01205647_m1) TaqMan gene expression assay probes were used in
singleplex reactions. The TIA-1 assay detects mRNA splice variants 1a and 1b that
contain or lack exon 5, respectively.
TIA-1 isoform expression was measured by reverse transcriptase-polymerase
chain reaction. cDNA was subjected to RT-PCR in a 25µl reaction containing either the
amplimer pairs for TIA-1 (5’-AAGTGAATTGGGCAACAACC-3’, sense; 5’TGAATGGCATTTTCTGCATC-3’, anti-sense) or β-actin (5’GTGGGCCGCTCTAGGCACCAA-3’, sense; 5’-CTCTTTGATGTCACGCACGAT-3’,
anti-sense), along with Taq DNA polymerase (Promega). Reactions were run in a MJ
Mini (Bio-Rad) personal thermal cycler. Each cycle consisted of a denaturation step
(94°C for 30s), an annealing step (45s), and a primer extension step (72°C, 1 minute).
Annealing temperatures and cycle number were as follows: TIA-1 (48°C, 28 cycles); βactin (63°C, 25 cycles).

79

3.3.8 Measurement of arachidonic acid pathway mRNA expression
Total RNA was extracted from hippocampus of Tia1+/+ and Tia1−/− animals 3
hours after acute PTZ-induced convulsion. Control group received Saline injection.
Real-time quantitative PCR was performed as described in quantitative real-time PCR
section (2.3.4). The following mouse-specific primer pairs (Applied Biosystems) were
used: Actb (Mm01205647_m1); Fos (Mm00487425_m1); Ptgs2 (Mm00478374_m1);
Ptges1 (Mm00452105_m1); Ptges2 (Mm00460181_m1); Pla2g4a (Mm00447040_m1)
according to manufacturer’s instruction. Efficiency of all primers were analyzed as
described in section 2.3.4.
3.3.9 Statistical analysis
All statistical analyses were performed using GraphPad Prism, Version 6.0.1
(GraphPad Software, Inc., La Jolla, CA, U.S.A.). For qRT-PCR, statistics were
performed on the logarithmic transformation of 2−ΔΔCT values. TIA-1 mRNA tissue
expression was analyzed by a one-way ANOVA followed by Dunnett’s multiple
comparisons test. TIA-1 mRNA expression between astrocytes and neurons was
analyzed by unpaired t-test. AA pathway mRNA expression was analyzed by a two-way
ANOVA followed by Sidak’s multiple comparison test. Quantitative protein expression of
TIA-1 or COX-2 immunoreactivity was analyzed by a two-way ANOVA on the
logarithmic transformation of gray values. Latency to convulsion after acute PTZ
injection between genotypes was assessed using two-tailed Mann–Whitney test.
Datasets representing proportions (percentage mortality or incidence of convulsions)
were analyzed using a two-tailed Fisher’s exact test. Significance was set at p < 0.05. In
figure legends, p values were reported as their exact values whenever available. For all
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multiple comparison analysis, exact p values were not provided by Prism and were
reported as “p < 0.05”. Exact p values that are less than 0.0001 were not provided by
Prism and were reported as “p < 0.0001”.
3.4 Results
3.4.1 TIA-1 mRNA expression profile in the brain
Prior to assessing the role of TIA-1 in the regulation of neuronal COX-2
expression and seizure threshold maintenance, a comprehensive analysis of its
expression profile in the brain was performed. High levels of TIA-1 mRNA were found in
the normal brain. Indeed, a quantitative analysis of its tissue distribution demonstrated
that the relative expression in various tissues was
brain > heart > kidney > liver ≈ spleen ≈ lung (Fig. 3.1A). Within the brain, high levels of
TIA-1 mRNA were detected in the cerebral cortex and hippocampus. A comparison
between cultures of cortical neurons and astrocytes shows that neurons expressed 4fold higher TIA-1 than astrocytes (Fig. 3.1B), suggesting that neurons are a primary
contributor to TIA-1 mRNA expression in this brain region.
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Fig. 3.1. TIA-1 mRNA is expressed constitutively at high levels in normal mouse brain tissue and
cells. (A) Tissue expression. Relative TIA-1 mRNA in mouse tissues was assessed by qRT-PCR
analysis. Results are expressed as Mean ± Standard Error of the Mean relative to lung (N = 3 mice). *,
significantly higher than lungs (p < 0.0001, Dunnett’s multiple comparisons test following one-way ANOVA
−ΔΔCT
on log-transformed 2
values). (B) Neural cell expression. TIA-1 mRNA levels were assessed in
primary cultures of astrocytes and neurons by qRT-PCR. Results are expressed as Mean ± Standard
Error of the Mean relative to astrocytes (N = 3 independent cultures). #, significantly higher than
−ΔΔCT
astrocytes (p = 0.002, unpaired Student’s t-test on log-transformed 2
values).
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TIA-1 has two major isoforms (TIA-1a and TIA-1b) generated by alternative
splicing 239,240. Both isoforms were detected in all tissue types examined (Fig. 3.2).
Interestingly, astrocytes appear to present a much higher TIA-1a over TIA-1b ratio than
neurons, shown by RT-PCR, although this requires further confirmation in a quantitative
assessment.

Fig. 3.2. Expression of TIA-1 isoforms in tissue samples. Top, TIA-1 mRNA isoforms (TIA-1a, 265bp
and TIA-1b, 232bp) were measured by RT-PCR from primary astrocyte and neuron cultures derived from
C57BL/6J animals or tissue samples isolated from adult male C57BL/6J mice. Bottom, β-actin (500bp)
mRNA expression was shown as loading control for each sample. Lanes from left to right: M, marker
(100bp DNA Ladder, New England BioLabs Inc.); N1, DIV1 cultured cortical neurons; N7, DIV7 cultured
cortical neurons; A, DIV30 astrocytes; C, cortex; Hi, hippocampus; Li, liver; K, kidney; He, heart; Lu, lung;
S, spleen; Ng, negative control. Image represents N = 3 cultures or mice.

3.4.2 TIA-1 protein expression profile in the brain
To examine in detail the distribution of constitutive TIA-1 expression in the brain,
a comprehensive analysis of protein expression was performed. Prior to performing this
analysis, the specificity of the TIA-1 antibody was assessed in the mouse brain (Fig.
3.3). Strong TIA-1 protein expression was detected in the DG of wild-type mice
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possessing two functional Tia1 alleles (Tia1+/+). This was reduced in brains from mice
containing only one functional allele (Tia1+/−) and no staining was detected in brains
from mice in which both alleles were inactivated (Tia1−/−). This gene dosage effect
confirms the specificity of the TIA-1 antibody and verifies the genotype of Tia1 mutant
mice at the protein level.

Fig. 3.3. Verification of TIA-1 protein deletion and validation of anti-TIA-1 antibody. Brains of adult
+/+
+/−
−/−
Tia1 (A), Tia1 (B), and Tia1 (C) animals were fixed, sectioned (12 µm) and stained with anti-TIA-1
antibody (red). White scale bar = 100 µm. Images are representative of brains from two mice per
genotype.

TIA-1 protein was expressed broadly in the brain under basal conditions (Figs.
3.4 and 3.5). Particularly high constitutive levels were detected in the hippocampal
formation (Fig. 3.4A), where the primary excitatory neurons of the CA3 and CA1, as well
as the DG, strongly express TIA-1 protein (Fig. 3.4B–D). Although the protein appeared
to be concentrated in the nucleus of these cells, TIA-1 was detected in the cytoplasm of
neurons in the less densely populated CA3 layer (Fig. 3.4D). A small number of cells
outside of the primary cell layers expressed TIA-1 protein as well, including within the
hilus of DG (Fig. 3.4C). A subset of TIA-1-positive cells appeared to coexpress GFAP (Fig. 3.5), consistent with mRNA expression in astrocyte cultures (Fig.
3.1B). TIA-1 expression was detected in layers 2–6 of the somatosensory cerebral
cortex (Fig. 3.6A) and particularly prominent expression was observed in layer 2 of the
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retrosplenial and piriform cortical regions (Fig. 3.6B and C, respectively). Scattered TIA1-positive cells, possibly oligodendrocytes and/or white matter astrocytes, were
detected in the myelinated fiber tracts of the fimbria and corpus callosum (Fig. 3.6E, F,
respectively). Expression was also detected in numerous other brain regions,
including choroid epithelium, caudoputamen, hypothalamus, and amygdala (Fig. 3.6G–
J, respectively). It is also noteworthy that whereas many cells of the
medial habenula express TIA-1, many fewer cells express the protein in the lateral
habenula. These observations are in agreement with the TIA-1 mRNA profile in the
normal mouse brain (Tia1 – RP_041122_01_B01 – sagittal, © 2004, Allen Institute for
Brain Science. Allen Mouse Brain Atlas. Available from: http://mouse.brain-map.org/).
Finally, the level of TIA-1 protein expression was not altered by a convulsive stimulus,
suggesting that its expression is not linked to excitatory neuronal activity (Figs.
3.7 and 3.9A).
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Fig. 3.4. TIA-1 protein is expressed in the primary neuronal layers of the hippocampal formation.
Coronal sections (12 µm, bregma −1.70 ± 0.12 mm) were obtained from normal C57BL/6J mouse brains
and stained for TIA-1 (red), GFAP (green) and DAPI (blue). Magenta indicates co-localization of TIA-1
and DAPI. (A) Brain hemisphere along the dorsal–ventral axis between the cerebral cortex (CTX)
and thalamus (TH) and laterally between the third (V3) and lateral ventricles (VL); RSPv,
ventral retrosplenial cortex; DG, dentate gyrus; CA1/CA3, hippocampal layers; CP, caudoputamen;
MH/LH, medial/lateral habenula; cc, corpus callosum; fi, fimbria. White scale bar = 200 µm. (B) CA1; (C)
DG and hilus; and (D), CA3. White bar represents 50 µm. Image panels B–D were taken from a different
+/+
section than panel A. Images are representative of brains from two Tia1 mice.

Fig. 3.5. Hippocampal astrocytes express TIA-1 protein. Images were acquired from the molecular
+/+
layer of the dentate gyrus in the adult Tia1 mouse brain (12 µm). (A, E) TIA-1 (red);
(C, G) GFAP (green); (B, F) nuclei (blue). (D, H) overlay of A–C and E–G, respectively. Arrows,
astrocytes expressing TIA-1 protein (magenta/green). White scale bar = 10 µm. A–D and E–H are
representative images from two mice.
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+/+

Fig. 3.6. TIA-1 protein expression profile in the brain of wild-type (Tia1 ) mice. TIA-1 protein
(red), GFAP protein (green), and cell nuclei (DAPI, blue) were visualized by epifluorescence microscopy
in 12 µm thick coronal sections obtained at bregma −1.70 ± 0.12 mm. Magenta indicates co-localization of
TIA-1 and DAPI. TIA-1 expression in: (A) somatosensory cortical layers 1–6; (B) ventral retrosplenial
cortical layers 1–6 (RSPv); (C) piriform cortical layers 1–3 (Pir); (D) medial (MH) and
lateral habenula (LH); (E) thalamus (TH) and fimbria (fi); (F) corpus callosum (cc); (G) choroid
plexus (ChP), lateral ventricle (LV); (H) caudoputamen (CP); (I) hypothalamus, 3rd ventricle (V3); (J)
medial amygdalar nuclei, anterodorsal (MEApd) and anteroventral (MEApv) parts. CTX, cerebral cortex;
DG, dentate gyrus; CA1, cornu ammonis area 1. White scale bar = 100 µm. Images are representative of
two mouse brains.
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Fig. 3.7. Effect of acute convulsive seizures on TIA-1 protein expression in the hippocampal
+/+
formation. Cohorts of Tia1 mice were treated with saline or 54 mg/kg PTZ (N = 4). Brains from PTZtreated animals were harvested 3 h following convulsions, fixed, sectioned (12 µm) and stained with TIA1 antibody (red) and DAPI (blue). Brains from saline-treated mice were processed in parallel.
(A, E, I, C, G, K) Representative images from a saline-treated mouse. (B, F, J, D, H, L) Representative
images from PTZ-treated mouse. (A–D) CA1; (E–H) CA3; (I–L) dentate gyrus. High/low magnification
images showing the same brain structure were taken from different sections. White scale bar = 100 µm (J)
and 10 µm (L). Images are representative of four mice from each treatment group.
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3.4.3 Effect of TIA-1 gene deletion on neuronal COX-2 protein expression in the
brain
Next, the expression profile of COX-2 protein in the hippocampus of Tia1+/+ mice
was compared to Tia1−/− littermates. In Tia1+/+ mice under basal conditions, constitutive
expression of COX-2 protein was detected in only a few granule neurons of the DG,
whereas it was broadly expressed by pyramidal neurons of the CA3 region (Fig. 3.8A, E,
respectively). This expression pattern was modified following a PTZ-induced convulsion.
Specifically, expression was induced strongly in neurons of the DG and enhanced in
CA3 neurons (Fig. 3.8C, G, respectively). Importantly, this expression profile was not
altered in mutant mice lacking TIA-1 as hypothesized. Thus, the COX-2 expression
patterns in the DG and CA3 regions of Tia1+/+ and Tia1−/− mice were comparable under
both basal conditions and after the PTZ-induced convulsion (Fig. 3.8B/F and D/H,
respectively). Note that COX-2 protein expression was undetectable in the pyramidal
neurons of the CA1 in both genotypes and this was not changed following an acute
PTZ-induced convulsion (data not shown). It is noteworthy that under either basal or
induced conditions, COX-2 protein was detected only in the outer layer of DG,
consistent with previous results that COX-2 protein is absent from neural progenitor
cells in subgranular zone286. Together, these results indicate that TIA-1 does not control
COX-2 expression in neurons under normal conditions or in response to a marked
increase in excitation induced by inhibition of endogenous GABA neurotransmission by
PTZ. Quantitative analysis of the expression changes further supports this contention
(Fig. 3.9B).

89

Fig. 3.8. Basal and convulsion-induced COX-2 expression in the hippocampal formation.
+/+
−/−
Tia1 and Tia1 littermate mice were treated with saline or 54 mg/kg PTZ. Brains from saline- and PTZtreated animals that had convulsive seizures were harvested 3 h later, fixed, sectioned (12 µm) and
stained with COX-2 antibody (green) and DAPI (blue). (A, B, E, F) COX-2 expression in a saline-treated
mouse brain. (C, D, G, H) COX-2 expression in a PTZ-treated mouse brain. (A–D) Dentate gyrus; (E–
H) CA3. White scale bar = 100 µm. Images are representative of three mice per genotype.
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Fig. 3.9. Quantification of basal and convulsion-induced TIA-1 and COX-2 expression in
+/+
the hippocampal formation of Tia1 mice. Fluorescent intensity in brain images was quantified using
NIH Image J (version 1.50i). (A) TIA-1 protein expression in CA1, CA3 and DG. Results were analyzed by
a two-way ANOVA on log-transformed gray values. Results are the average of duplicate sections from
four mice. A significant difference was detected between brain regions (p < 0.0001) but not between
treatment (p = 0.6181). (B) COX-2 protein expression in CA1, CA3 and DG. Results are the average of
duplicate sections from three mice. CA3, significant difference between treatments (p = 0.0017) but not
genotypes (p = 0.3185). DG, significant difference between treatments (p = 0.0001) but not genotypes
(p = 0.8467). Minimal COX-2 protein expression was detected in CA1.

3.4.4 Effect of TIA-1 gene inactivation on the arachidonic acid pathway gene
expression
Besides translational suppression, TIA-1 has been shown to participate in premRNA splicing, through interacting with 5’ splice sites and U1 snRNP 230,231. TIA-1 also
mediates mRNA decay through polysome disassembly 259. To test whether deletion of
TIA-1 results in alteration of COX-2 mRNA levels, real-time qPCR was performed on
hippocampal tissue harvested from Tia1+/+ and Tia1−/− mice, 3 hours after acute PTZ91

induced convulsions. As expected, PTZ significantly increased COX-2 (Fig. 3.10A) and
c-Fos (Fig. 3.10B) mRNA levels in hippocampus in both genotypes, however, knockout
animals showed a slightly higher induction of COX-2 mRNA but a slightly lower
induction of c-Fos. Although PTZ-induced convulsion did not change the mRNA levels
of mPGES-1 (Fig. 3.10C) or mPGES-2 (Fig. 3.10D) dramatically, a significant genotypic
difference (p = 0.0210, two-way ANOVA) was observed for mPGES-1 where knockout
showed slightly reduced expression. A significant treatment difference (p = 0.0268, twoway ANOVA) was observed for mPGES-2 where PTZ-induced convulsion slightly
decreased its mRNA levels in both genotypes. Interestingly, cPLA2α mRNA was
significantly reduced by convulsive seizures in both genotypes (Fig. 3.10E, p = 0.0045,
two-way ANOVA), consistent with the results that its expression is inversely correlated
with excitatory neuronal activity (Fig. 2.13D). TIAR is an RBP that has high homology
with and similar binding properties and functions as TIA-1 89,227. TIAR is constitutively
expressed in the brain and its mRNA expression profile is remarkably similar to TIA-1
287

. Since COX-2 3’UTR ARE also serves as a docking site for TIAR, to test the

possibility that TIAR may compensate for the absence of TIA-1 in neurons, TIAR mRNA
levels were measured. Interestingly, TIAR mRNA was slightly elevated in TIA-1
knockout hippocampus, but only after PTZ-induced convulsion (no statistical
significance by Sidak’s multiple comparison test following two-way ANOVA), suggesting
that TIAR may indeed be up-regulated by excessive neuronal activity.
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+/+

Fig. 3.10. Effect of acute convulsive seizures on AA pathway mRNA levels. Tia1 and
−/−
Tia1 littermate mice were treated with saline or 42 mg/kg PTZ. Brains from saline- and PTZ-treated
animals that had convulsive seizures were harvested 3 h later. Relative mRNA levels for COX-2 (A), cFos (B), mPGES-1 (C), mPGES-2 (D), cPLA2α (E) and TIAR (F) in mouse hippocampal tissues were
assessed by qRT-PCR analysis. Results are expressed as Mean ± Standard Error of the Mean relative to
+/+
saline treated Tia1 (N = 3 mice). *, p < 0.05, significant between genotype difference identified via twoway ANOVA. #, p < 0.05, significant between treatment difference identified via two-way ANOVA.
Table 3.1. Effect of acute convulsive seizures on AA pathway mRNA levels (p values)
Gene
COX-2
c-Fos
mPGES-1
mPGES-2
cPLA2a
TIAR

-/-

Saline vs PTZ convulsion
< 0.0001
0.0003
0.1866
0.0268
0.0045
0.4196

Tia1 vs
0.6974
0.4654
0.0210
0.7432
0.5975
0.2420

+/+

Interaction
0.0052
0.3321
0.6874
0.9310
0.3732
0.0351

Between group differences were analyzed using two-way ANOVA and p values for between treatment
comparison, between genotype comparison and interaction are presented in Table 3.1.
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3.4.5 Effect of Tia1 gene inactivation on the innate seizure threshold
To test the possibility that TIA-1 influences the innate seizure threshold
independent of regulating COX-2 expression, the PTZ-induced seizure threshold was
assessed in mice lacking TIA-1 protein (Fig. 3.11). The results indicate that seizure
severity and incidence of or latency to convulsions was not altered in Tia1−/− mice
relative to Tia1+/+. These results were the same regardless of whether mice were
treated with 42 or 54 mg/kg PTZ. Within this dose range, convulsion-induced mortality
was low regardless of genotype. Thus, TIA-1 does not appear to influence the sensitivity
of mice to acute PTZ-induced seizures.

Fig. 3.11. TIA-1 does not influence the innate seizure threshold. Seizure severity is shown for
+/+
−/−
Tia1 (●) and Tia1 (○) littermates that were treated with PTZ i.p. (A–C) 54 mg/kg; N = 11 per
+/+
−/−
genotype). (D–F) 42 mg/kg; N = 20 and 18 for Tia1 and , respectively. Symbols indicate maximum
seizure scores for individual mice. Horizontal lines indicate median seizure score. Ratio in parentheses
indicates incidence of convulsions. Genotype responses are not significantly different (p = 1.0, two tailed
Fisher’s exact test). (B, E) Latency to convulsive seizures. Symbols indicate latencies for mice in A and D.
Horizontal lines indicate mean values. No significant difference was detected between genotypes
(p = 0.5714 and p = 0.474, for B and E respectively, two-tailed Mann Whitney test). (C, F) Mortality. No
significant difference was detected between genotypes (p = 1.0, two-tailed Fisher’s exact test).
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3.5 Discussion
In glutamatergic neurons of the cerebral cortex, activation of post-synaptic
NMDARs triggers the release of AA from membrane stores, which is rapidly
metabolized to biologically active prostaglandins via the COX pathway 71. The capacity
for basal prostaglandin production by neurons is increased more than 10-fold by COX-2
overexpression 157. The observation that these COX-2 overexpressor mice exhibited
reduced sensitivity to a convulsive stimulus177 is consistent with an increasing body of
evidence suggesting that this pathway may serve as a homeostatic control mechanism
to maintain an elevated seizure threshold in the normal brain, antagonizing abnormal
excitation and epileptiform activation of circuits 67-69,174,288. The fact that COX-2
expression is coupled positively to NMDAR activity is consistent with this notion 74,136,141.
A better understanding of the molecular mechanisms that link NMDAR activity to
changes in COX-2 expression could facilitate development of novel approaches for
antiepileptic therapies. In this regard, I investigated COX-2 expression in brain after
acute seizure generation and whether it is regulated by the RNA binding protein TIA-1.
TIA-1 mRNA and protein expression was found in both neuron and astrocyte. However,
knockout of TIA-1 did not alter COX-2 protein expression under basal conditions or after
acute PTZ-induced convulsion. In addition, TIA-1 deletion did not alter acute seizure
threshold.
TIA-1 mRNA distribution in mouse tissues has been shown previously using
Northern blot 239. The highest level of TIA-1 mRNA was observed in brain, consistent
with our result (Fig. 3.1A). Perplexingly, TIA-1 mRNA levels were suggested to be low in
human brain 240,260. This disparity suggests species difference in TIA-1 mRNA in the
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brain. For example, TIA-1 mRNA was highly expressed in mouse cortex (Fig. 3.1A), but
was surprisingly low in human cortex 260. In addition, TIA-1 mRNA appeared to be more
restrained to certain brain areas (Fig. 3.6). Results from Allen Human Brain Atlas 289
also suggest low to absent level of TIA-1 mRNA in cerebral cortex, in contrast to the
enriched mRNA levels in cerebellum. Notably, hippocampi from all human donors
showed high TIA-1 mRNA levels, matching the high mRNA and protein level we showed
in mouse hippocampus (Fig. 3.1 and 3.2). This may suggest a conserved physiological
role of TIA-1 in this structure. Although TIA-1-positive SGs have been previously found
in astrocytes in mouse brains with tauopathies 266, we are the first to show endogenous
TIA-1 mRNA and protein expression in astrocytes. TIA-1 mRNA was found in untreated
primary astrocyte culture (Fig. 3.1B) and co-localization of TIA-1 protein and astrocyte
marker GFAP was found in wild-type mouse brain (Fig. 3.5). Compared to neurons,
astrocytes showed less mRNA and protein expression, along with a higher ratio of TIA1a over TIA-1b mRNA isoform (Fig. 3.2). TIA-1b isoform was suggested to have
increased alternative splicing activity, as compared to the TIA-1a isoform in mammalian
cell lines 240. However, it is not clear whether this remains true in neurons and
astrocytes.
While the posttranscriptional regulation of COX-2 expression has been studied
extensively in other cell types, the extent to which these mechanisms control expression
of COX-2 in glutamatergic neurons is not known. TIA-1 has been shown to suppress
basal expression of COX-2 in embryonic fibroblasts 88 as well as induction of COX-2
expression by proinflammatory mediators in macrophages 270 and this is likely by virtue
of its ability to bind to the COX-2 mRNA 3′UTR and repress translation. It does not
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appear, however, to perform a similar function in neurons. Despite the fact that COX-2
and TIA-1 proteins are constitutively expressed by CA3 pyramidal neurons, basal COX2 protein expression was not altered in brains of mutant mice lacking TIA-1 (Fig. 3.9).
Furthermore, in granule cells of the DG, which are largely devoid of COX-2 expression
under basal conditions, induction of COX-2 expression by an acute convulsive seizure
was not affected by deletion of TIA-1. Thus, TIA-1 regulates neither constitutive nor
activity-dependent neuronal COX-2 expression. It is worth to note, however, that COX-2
mRNA induction by acute convulsive seizure was slightly enhanced in TIA-1 knockout
hippocampus (Fig. 3.10), raising the possibility that TIA-1 may still regulate COX-2
mRNA turnover, independent of its translation.
In addition to its broad mRNA binding specificity 229, TIA-1 protein interacts
extensively with other proteins in the brain 267. However, the lack of an effect of TIA-1
gene deletion on PTZ-induced acute seizures (Fig. 3.11) suggests that TIA-1 does not
function in the maintenance of the innate seizure threshold of the brain either by
affecting COX-2 expression or by mechanisms other than via COX-2 regulation.
Nevertheless, the prominent and widespread expression of TIA-1 in neurons,
particularly in excitatory neurons of the cerebral cortex and the hippocampal formation,
suggests that this protein may modulate physiological activities, either through its role
as a pre-RNA splice regulator or silencer of mRNA translation, or via its ability to
interact with other neuronal proteins. Although the TIA-1-deficient mice appear to
behave normally, a more careful analysis of the role of this protein in normal brain
function warrants further investigation. The significance of the comparative difference in
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mRNA levels between neurons and astrocytes reported herein is not clear, particularly
since this cell-type difference was not observed by others 290.
It could be argued that compensatory mechanisms in the Tia1 mutant mice may
have masked its role in the regulation of COX-2 expression in neurons. For example,
the COX-2 mRNA ARE also serves as a docking site for TIAR, an RBP that has high
homology with TIA-1 89,227. TIAR is constitutively expressed in the brain and its mRNA
expression profile is remarkably similar to TIA-1 239. It was also observed that TIAR
mRNA was elevated only in TIA-1 knockout hippocampus after acute convulsive seizure
(Fig. 3.10). Thus, the possibility that TIAR may compensate for the absence of TIA-1 in
neurons cannot be excluded. However, the observation that COX-2 expression was
enhanced in embryonic fibroblasts derived from the same TIA-1 mutant mouse line
employed herein argues against this possibility 88. On the other hand, it is possible that
TIA-1 indeed has no role and that another RBP regulates COX-2 expression posttranscriptionally in neurons (see below). In this case, TIA-1 would not be expected to
bind to the ARE of the COX-2 mRNA in neurons, a possibility that requires verification.
This could be achieved by RNA immunoprecipitation.
In addition to TIA-1 and TIAR, a number of mRNA stability factors and
translational regulators bind to this region of the COX-2 mRNA, including CELF2
(CUGBP2), HNRNPD (AUF1), hnRNPK and the ELAVL proteins, HuR and HuD 87,89,117.
Like TIA-1, each of these RBPs is broadly expressed throughout the brain (Allen Brain
Atlas). Whether these or other novel RBPs bind to and regulate COX-2 expression in
neurons has to be investigated in future. It is hoped that a better understanding of the
molecular mechanisms that link NMDAR activity to changes in COX-2 expression could
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identify approaches for the development of novel antiepileptic therapies that target
enhancement of the level of COX-2 expression in neurons.
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CHAPTER 4 Deletion of TIA-1 increases incidence of PTZ-induced kindling and
increases risk of death during epileptogenesis
4.1 Synopsis
TIA-1 has recently been implicated in several acute and chronic
neurodegenerative conditions, including cerebral ischemia and Alzheimer’s disease.
Because brain damage is an important risk factor for development of epilepsy, a chronic
disorder that is characterized by spontaneous seizures, the purpose of the studies
included in this chapter was to examine the possibility that TIA-1 functions in
epileptogenesis, the process by which normal brain becomes prone to spontaneous
seizures.
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4.2 Introduction
Through the course of studying whether TIA-1 regulates COX-2 expression and
in turn modulates seizure threshold in brain (Chapter 3), I did not observe any change in
COX-2 protein level in TIA-1 deficient brain under basal levels, nor did I see an altered
acute seizure response in TIA-1 knockout animals 177. However, it is known that TIA-1 is
a key component of the protein complexes that assemble translationally inactive
mRNAs under stress conditions, namely, stress granules (SGs) 251. Assembly of SGs is
highly regulated and requires functional TIA-1 protein. Under cellular stress, TIA-1
shuttles from nucleus into cytoplasm 252, facilitates the recruitment of stalled preinitiation
complexes into SGs 253, and forms aggregation with its prion-related C-terminus domain
254

. TIA-1-mediated SGs formation is considered as a dynamic and reversible process

that coordinate mRNA triage and has been extensively studied in mammalian peripheral
tissue and cell lines.
In the CNS, TIA-1 transcripts and proteins are also detected 239,260,261. A growing
interest has developed only recently to uncover the largely unknown role of TIA-1 in
brain. TIA-1 positive SGs appear acutely in hippocampal neurons following brain
ischemia 93,94,262. In addition, TIA-1 has been found to associate with pathological
lesions in several neurodegenerative diseases, including amyotrophic lateral sclerosis
263

, Huntington’s disease 265 and tauopathies 266. TIA-1 facilitated tau misfolding and

tau-mediated neurodegeneration whereas tau, in turn, promotes SGs formation 267.
Evidence suggests that depletion of tau ameliorated the epileptic phenotype in a model
of Dravet Syndrome 267,291 . These findings suggest that in neurons, TIA-1-mediated
SGs formation serves as a protective mechanism against acute stress, but may lead to
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deposition of pathological protein aggregations in diseases associating with prolonged
stress. On the other hand, due to its large number of mRNA targets and protein partners
229,267

, TIA-1 may serve biological functions that are independent of SGs formation in

brain. TIA-1 deficiency led to changes in mRNA expression of cell cycle and apoptosis
regulators, as well as fat storage and membrane trafficking factors in brain 269. TIA-1
was also recently implicated in physiological neuronal function 261.
Since TIA-1 and SG have been shown to contribute to chronic pathologies,
including taupathies, it is possible that loss of TIA-1 in brain could lead to alterations in
neuroplasticity. Therefore, the goal of the work described in this chapter is to investigate
the role of TIA-1 in PTZ-induced kindling model of epileptogenesis.

102

4.3 Materials and methods
4.3.1 Animal housing and breeding
The housing and breeding of the TIA-1 gene mutant mouse line (Tia1−/−) has
been described in section 3.2.1. All animal procedures conformed to the National
Academy of Sciences Guide for the Care and Use of Laboratory Animals (NRC, 2011)
and were approved by the Syracuse University Institutional Animal Care and Use
Committee (IACUC).
4.3.2 Dosing paradigms for kindling
Male mice of different genotypes (Tia1-/-, Tia1+/- and Tia1+/+) were randomly
segregated without knowledge of genotype. All mice were acclimated to handling by
performing mock daily intraperitoneally (i.p.) injections 5-7 days prior to each study.
During kindling paradigm, mice were treated daily with PTZ (freshly diluted in 0.9%
saline, filter sterilized and administered i.p. in a volume of 10ml per kg body weight) for
up to 21 days. Seizure activity was monitored daily immediately after PTZ injection for
25 minutes and graded by an observer blinded to genotype using a previously
established scoring system 181 as described in section 3.2.3. Doses of PTZ used in
kindling studies were determined by a dose-ranging study (data not shown) where
Tia1+/+ mice were treated acutely with a single dose of PTZ (36-54 mg/kg). Doses were
chosen to ensure that no convulsive seizure (score 3 or 4) activity was recorded during
acute PTZ injection.
Two kindling studies (study 1 and 2) applying slightly different experimental
settings were conducted in chronological order. In study 1, 36 mg/kg PTZ was given to
the animals daily. Successive exposure of mice to PTZ resulted in a progressive
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reduction in PTZ seizure threshold. Mice were considered kindled after exhibiting three
consecutive convulsive seizures, after which daily PTZ injections were stopped. In study
2, a slightly higher daily injection dose of PTZ (39 mg/kg) was applied in order to
achieve an increased kindling incidence. Due to high mortality found in Tia1-/- mice
during kindling paradigm of study 1, I also used a less stringent rule in study 2 to
determine kindling establishment in order to minimize mortality. Specifically, mice were
considered kindled in study 2 when three total convulsive seizures (they may not be
consecutive) were recorded, after which PTZ injections were stopped. In both studies,
the permanence of the kindled state was assessed by re-challenging mice with 36mg/kg
(study 1) or 39mg/kg (study 2) PTZ one week after cessation of the PTZ injection. A
permanent reduction of seizure threshold is confirmed by the presence of a stage 3 or 4
convulsive seizure. Kindling latency was defined as the number of days of PTZ
injections required to establish kindling status. For study 2, brain tissues were harvested
72 hours after the re-challenge injection.
4.3.3 Immunofluorescence staining
Immunofluorescence staining was performed as described previously in section
3.2.4. Primary and secondary antibodies for immunostaining were goat anti-TIA-1
(1 µg/ml, Santa Cruz Biotechnology Cat# sc-1751, RRID: AB_2201433) and Alexa Fluor
594 donkey anti-Goat IgG (7.5 µg/ml, Jackson ImmunoResearch Labs Cat# 705-585147, RRID: AB_2340433). Specificity of the anti-TIA-1 antibody was confirmed using
comparable sections from Tia1+/+and Tia1−/− mice processed in parallel.
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4.3.4 Quantification of fluorescent intensity
Fluorescent intensity was quantified using NIH image J (version 1.50i) 284. Raw
images in .czi format were exported to .jpg files and converted into 8bit grey scale.
Maximal threshold and minimal threshold was set to 35 and 255 respectively using the
Default auto thresholding method. For each animal, mean intensity of TIA-1 fluorescent
within an ROI (region of interest) of 100 *100 pixel2 in dentate gyrus granule cell layer
was measured from coronal sections obtained near Bregma -1.70. Results were
averaged across duplicate sections.
4.3.5 Statistical analysis
All statistical analyses were performed using GraphPad Prism, Version 6.0.1
(GraphPad Software, Inc., La Jolla, CA, U.S.A.). Survival curves and curves depicting
the percentage of mice kindled as a function of time were compared using a log-rank
test. Unpaired Student’s t-test was used to compare latency to kindling between
knockout and wild-type groups. Acute convulsive seizure latency during the kindling
treatment was analyzed by two-way ANOVA followed by Bonferroni's multiple
comparisons test. Datasets representing proportions (percentage mortality and
percentage kindled) were analyzed using a two-tailed Fisher’s exact test. TIA-1 protein
expression in kindled brain was analyzed by Kruskal-Wallis test. Significance was set at
p < 0.05. In figure legends, p values were reported as their exact values whenever
available. For all multiple comparison analysis, exact p values were not provided by
Prism and were reported as “p < 0.05”. Exact p values that are less than 0.0001 were
not provided by Prism and were reported as “p < 0.0001”.
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4.4 Results
4.4.1 Effect of TIA-1 gene inactivation on PTZ-induced kindling progression and
acquisition
Kindling is frequently used to model the plasticity changes that occur during
epileptogenesis, the process by which the normal brain becomes epileptic 292. In the
PTZ model of kindling, daily injection of a dose initially elicits mild seizure responses
(seizure severity scores ≤ 2) that progress to convulsive seizures (seizure severity score
≥3) over the 2-3 weeks period of dosing, indicating a reduction in seizure threshold. This
reduction in seizure threshold persists once established 181. This model was used to test
the role of TIA-1 in epileptogenesis. In the present study, two kindling studies were
conducted as described in section 4.3.2. Whereas study 2 applied a higher dose of PTZ
and a less stringent definition of kindling establishment compared to study 1, both
studies produced persistently kindled animals. Incidence of convulsive seizure during
re-challenge was 93.3% and 93.8% for study 1 and 2 respectively. The time course of
kindling acquisition (Fig. 4.1) and the latencies to acute PTZ-induced convulsive
responses during the kindling paradigm (Fig. 4.2) in Tia1+/+ and Tia1-/- littermates are
shown for both studies.
In study 1, kindling acquisition in the two genotype groups occurred over a similar
time course (p = 0.8157, log-rank test, Fig. 4.1A). The mean latency period to kindling
acquisition did not differ significantly between Tia1+/+ and Tia1-/- for study 1 (p = 0.3993,
unpaired Student’s t-test; 16.4 ± 1.6 days and 14.0 ± 2.5 days, Mean ± SEM,
respectively, Fig. 4.1B). Similarly, no change was observed between the two genotype
groups in their average latency time to first acute convulsion following PTZ
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administration, which was 436s for Tia1+/+ mice and 456s for Tia1-/- mice respectively
(Fig. 4.2A). Successive daily exposures of mice to PTZ resulted in a progressive
reduction in their latencies to convulsive seizures. At the time of the 3rd convulsive
response, the latency to convulsion was shortened in both groups to 245 and 309s,
respectively.
Although no genotypic difference was observed during kindling paradigm in study
1, it is possible that the dose applied (36 mg/kg) is not sufficient to induce kindling within
21 days in both genotypes. Therefore, a higher daily PTZ dose (39 mg/kg) was applied
in study 2. As expected, the mean latency to kindling was reduced as as a result of
higher daily PTZ dose, yet did not differ between genotypes (p = 0.2786, unpaired
Student’s t-test; 8.3 ± 2.3 days and 11.8 ± 1.7 days for Tia1+/+ and Tia1-/-, respectively,
Fig.4.1D). However, whereas the percentage of kindled animals in wild-type group
plateaued at day 14 within the paradigm, knockout group exhibited a steep and steadily
increasing kindling progression curve (p = 0.017, log-rank test) and achieved a
significantly higher kindling incidence by the end of the protocol (p = 0.0176, fisher’s
exact test; 69.7% and 23.5% for Tia1-/- and Tia1+/+, respectively). A similar reduction in
latency to convulsion was observed from first to 3rd convulsive response (597 to 485s
for Tia1+/+ and 598 to 458s for Tia1-/- mice, Fig. 4.2B).
Interestingly, in both studies, latencies to convulsions after kindling was
established (Fig.4.2, “Re-challenge”) remained low for Tia1+/+ mice (280 vs 274s for
study 1 and 2 respectively), but seemed to rebound in Tia1-/- mice (504s and 428s for
study 1 and 2 respectively). However, this difference was not statistically different
(Bonferroni's multiple comparisons test following two-way ANOVA).
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+/+

-/-

Fig 4.1. Analysis of TIA-1 function in PTZ-induced kindling acquisition. Tia1 and Tia1 littermates
were treated daily with 36 mg/kg (Study 1; A, B) or 39 mg/kg (Study 2; C, D) PTZ i.p. and seizure severity
was scored. Mice were considered kindled after having either 3 consecutive convulsive seizures in Study
1, or 3 total convulsive seizures in Study 2. (A) Time course of kindling acquisition for Study 1 (N=24 and
+/+
-/20 for Tia1 and Tia1 genotypes, respectively). Neither the rate nor incidence of kindling acquisition
differed significantly between groups (p = 0.8157, log-rank test). (B) Latency to kindling acquisition for
Study 1. Scatter plot represents latency times for individual mice. Horizontal lines indicate median values.
No significant difference was detected between genotypes (p=0.3696, Mann Whitney test). (C) Time
+/+
-/course of kindling acquisition for Study 2 (N=17 and 18 for Tia1 and Tia1 genotypes, respectively).
Progression of kindling acquisition differed significantly between groups (p = 0.017, log-rank test). (D)
Latency to kindling acquisition for Study 2. No significant difference was detected between genotypes (p =
0.2736, Mann Whitney test).
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Fig. 4.2. Acute convulsive seizure latencies during the kindling treatment paradigm. For Study 1 (A,
36mg/kg PTZ) and Study 2 (B, 39mg/kg PTZ), latencies between PTZ dosing and onset of convulsive
st
nd
rd
seizures for each individual animal are shown for the 1 , 2 and 3 convulsive responses in the kindling
paradigm. The latencies to convulsion is also shown for re-challenge convulsion in kindled brain.
Horizontal lines indicate median values, error bars represent standard errors. No significant difference
+/+
-/was detected between Tia1 and Tia1 mice (p = 0.6035 and p = 0.8515 for study 1 and 2 respectively,
two-way ANOVA).

4.4.2 Role of TIA-1 in mortality associated with PTZ-induced kindling
Although the dose of PTZ was chosen to maximize kindling acquisition while
minimized mortality, lethality occurred in each genotype group. Incidences of mortality
were observed either during the PTZ dosing paradigm or after the kindling phenotype
was established (at re-challenge injections). All mortality, regardless of genotype,
resulted acutely from PTZ-induced convulsions. No spontaneous mortality was
observed at any time during the kindling paradigm.
Incidence of mortality associated with the kindling paradigm was shown for both
studies (Fig. 4.3). In study 1, the total mortality was 12.5, 17.8, and 26%, for Tia1+/+,
Tia1+/-, and Tia1-/- genotypes, respectively (Fig. 4.3A). All wild-type lethality occurred
during re-challenge. Hence, no mortality occurred in the Tia+/+ genotype group during
the PTZ dosing paradigm (Fig.4.3B). Of the mice possessing one functional Tia1 allele
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(Tia1+/-), ~7% succumbed during the treatment paradigm. This increased to 17% in mice
lacking both alleles (Tia1-/-). Thus, the increased mortality during kindling acquisition
was proportional to the number of inactivated TIA-1 alleles. Additionally, the lethality in
these mice occurred late in the kindling paradigm (second and third weeks, Fig. 4.3B).
In study 2, a similar total mortality was observed (11.8 and 33.3% for Tia1+/+ and Tia1-/genotypes, Fig. 4.3C). In Tia1+/+, ~6% succumbed during the treatment paradigm
whereas in Tia1-/- this ratio is 16.7% (Fig. 4.3D). In both studies, the total incidence of
lethality in -/- mice was higher than that of their +/+ littermates, yet not significant (p =
0.6686 and 0.2285, for study 1 and 2 respectively, two tailed Fisher’s exact test).

+/-

Fig. 4.3. Mortality associated with the PTZ-induced kindling paradigm. In Study 1 (A, B), Tia1 ,
-/+/+
Tia1 mice and their wild-type littermates (Tia1 ) were treated with PTZ (36 mg/kg, i.p.) to induced
-/+/+
kindling and then re-challenged after kindling was established. In Study 2 (C, D), Tia1 and Tia1 mice
were treated with PTZ (39 mg/kg, i.p.) to induced kindling. (A, C) Each bar shows the total % mortality for
-/+/+
each genotype group. No significant differences were found between Tia1 and Tia1 genotypes (For
Study 1 and 2, p = 0.6686 and 0.2285, respectively, two tailed Fisher’s exact test). (B, D) Each line
shows % survival for each genotype group during kindling paradigm. For Study 1, significant difference in
trend was observed (p = 0.0369, log-rank test).
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4.4.3 Expression of TIA-1 in kindled brain
Kindling is known to induce oxidative stress in the hippocampus, resulting in
excessive lipid peroxidation and altered anti-oxidant enzymatic activities 293,294. Since
oxidative stress is a known inducer of SGs, I measured TIA-1 expression and TIA-1positive SG formation in kindled wild-type hippocampus (Fig.4.4). In kindled animals or
animals that received PTZ injections for 3 weeks but shows no convulsion (nonkindled), TIA-1 protein expression remained unchanged in dentate gyrus (Fig.4.4A, p =
0.1964, Kruskal-Wallis test), compared with saline treated animals. In granule cells of
control hippocampus, TIA-1 protein exhibited a pattern of strong nuclear expression and
weak cytosol expression (Fig.4.4B). This pattern remained the same in kindled brain,
with no SG detected in cytoplasm (Fig.4.4C). SG formation was not found in CA1 and
CA3 pyramidal cells in kindled hippocampus either (Fig. 4.5).
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+/+

Fig. 4.4. TIA-1 protein expression in DG of kindled brains. Wild-type (Tia1 ) mice were treated with
PTZ (39 mg/kg, i.p.) to induced kindling and then re-challenged one week after kindling was established.
Controls were treated with saline for 3 weeks and received an additional injection of saline one week
after. Brains of saline controls, kindled mice and non-kindled mice (animals that showed no convulsive
seizure throughout the protocol) were harvested 72 hours after their last injection, fixed, sectioned (12
µm) and stained with TIA-1 (red; B, C) antibody. The nucleus were outlined by DAPI (blue; B, C) staining.
Mean intensity on a grey scale of TIA-1 staining was quantified by image J. (A) Each bar (N = 3 animals)
shows the relative mean intensity of TIA-1 protein over saline controls. No significant differences were
found between groups (p = 0.1964, Kruskal-Wallis test). TIA-1 staining was observed in the nucleus and
cytoplasm of dentate gyrus granule cells in saline treated brains (B). No stress granule (visualized as TIA1-positive cytoplasmic aggregates) formation was observed in kindled brains (C). White scale bar
represents 20 µm.
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+/+

Fig. 4.5. TIA-1 protein expression in CA1 and CA3 of kindled brains. Wild-type (Tia1 ) mice were
treated with PTZ (39 mg/kg, i.p.) to induced kindling and then re-challenged one week after kindling was
established. Controls were treated with saline for 3 weeks and received an additional injection of saline
one week after. Brains of saline controls, kindled mice and non-kindled mice (animals that showed no
convulsive seizure throughout the protocol) were harvested 72 hours after their last injection, fixed,
sectioned (12 µm) and stained with TIA-1 (red; B, C) antibody. The nucleus were outlined by DAPI (blue;
A-D) staining. TIA-1 staining was observed in the nucleus and cytoplasm of CA1 (A) and CA3 (C)
pyramidal neurons in saline treated brains. No stress granule (visualized as TIA-1-positive cytoplasmic
aggregates) formation was observed in kindled brains (B, D). White scale bar represents 20 µm.
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4.5 Discussion
Little is known about TIA-1 function in brain. In the present study, we investigated
the effect of TIA-1 deletion on epileptogenesis. Knockout of TIA-1 led to enhanced
kindling acquisition and increased mortality during kindling paradigm. In addition, no
neuronal TIA-1 aggregation was found in kindled brain of wild-type animals (Fig. 4.5).
Thus, it is possible that the Tia1-/- phenotypes observed during kindling progression may
not result from altered formation or degradation of stress granules. However, the
assembly of SGs has never been evaluated during kindling progression. It is known that
oxidative stressors such as arsenite is sufficient to induce SG formation in neurons261,
whereas this type of stress has been identified in brains that had acute seizures and in
kindled brains293,295,296. Thus, to confirm the absence of SG formation in kindling model,
future studies are required to thoroughly investigate the presence of SG during kindling
paradigm and at various time points after kindling is established (section 6.3.1).
It is also possible that SG formation should be examined in other cell types of the
brain, rather than in the neurons. Astrocytes are important cells that support neuron
development and functionality in many different ways297,298. They are capable of
releasing and responding to various neurotransmitters and are able to maintain
homeostasis of reactive oxygen species, neurotransmitters and ions in the extracellular
space. Under pathological stress such as brain trauma, astrocytes go through a
transformation named reactive astrogliosis, which is a defensive reaction against acute
stress that restores CNS homeostasis and limits tissue damage299. Reactive gliosis
marked by increased GFAP immunereactivity in astrocytes has been observed in
epileptic patients and animal models for epileptogenesis including kindling19, suggesting
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a functional role of astrocytes during epileptogenesis. While TIA-1 and SG formation
have been previously examined in other cell types, their function or even presence in
astrocytes has never been thoroughly investigated thus far. Evidence exists that brain
microglia and astrocyte were capable of forming SG in Alzheimer brain and in P301L
Tau transgenic mice266. In the present study, I showed TIA-1 mRNA expression in
primary cultures of astrocytes (Fig. 3.1) and TIA-1 protein expression in hippocampal
astrocytes (Fig. 3.5). In addition, astrocytes in the brain of Tia1-/- mice showed
decreased level of GFAP protein expression (Yifan Gong and James Hewett,
unpublished observations), suggesting an altered astrocyte reactivity in knockout brain.
In future studies, it will be necessary to determine if astrocytic TIA-1 plays a role in
epileptogenesis progression (section 6.4.3).
It is worth noting that TIA-1 function in epileptogenesis may be independent of its
role in forming SGs, but may rather dependent on its direct or indirect roles as an RNA
binding protein in alternative splicing, translational repression and message stability.
TIA-1 recognizes a large number of mRNA transcripts via binding to AREs located
within their 3’UTR 229, among them are COX-2 and Tumor necrosis factor alpha (TNFα).
TIA-1 directly binds to an ARE in the COX-2 mRNA to silence its translation 88.
Thus, basal COX-2 protein expression and activity were elevated in embryonic
fibroblasts from mice lacking TIA-1. In the CNS, COX-2 is constitutively expressed in
discrete subpopulations of glutamatergic neurons 66,74. Yet we did not find elevated
COX-2 in naïve Tia1-/- brains nor after acute convulsive seizure, suggesting TIA-1 may
not regulate COX-2 expression in brain. However, it is known that COX-2 mRNA and
protein expression are markedly induced in the dentate gyrus neurons by high
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frequency stimulation of the perforant pathway or by acute convulsive seizures 66,136,181,
and are induced in non-neuronal cell types including endothelial cells, microglia and
astrocytes in epileptogenesis models that involve inflammation 202,300. Future studies will
be looking at COX-2 expression in Tia1-/- neurons and astrocytes during
epileptogenesis, in order to confirm whether TIA-1 interact with COX-2 in the CNS and
whether such interaction, if any, contributes to acute seizure generation and
epileptogenesis.
The role of TIA-1 in post-transcriptional control of TNFα expression has been well
characterized in macrophage in the context of inflammation 241, as well as in
cardiomyocytes 301. TIA-1 deletion promotes TNFα translation and leads to increased
TNFα protein production. This pro-inflammatory cytokine is a putative neuromodulator
that regulates synaptic transmission through scaling of the receptors and mediating
glutamate release from microglia and astrocytes 302,303. Kindling induced by PTZ and
electrical stimulation of amygdala result in increased TNFα production 304,305, whereas
administration of TNFα leads to prolonged epileptiformic discharges in amygdala
kindling model 306. It is possible that TIA-1 deletion lead to overexpression of TNFα in
hippocampus, which contributes to the accelerated reduction of seizure threshold during
kindling development. Therefore, in future studies, as an established target of TIA-1,
TNFα production in kindled brain need to be further characterized.
It is intriguing that not only kindling acquisition was enhanced in mice lacking
TIA-1, these mice showed an increase in incidence of mortality (Fig. 4.3). Typically,
mortality is not associated with the progression of epileptogenesis in this model as
demonstrated by wild-type mice herein. Thus, the increase in lethality in TIA-1 deficient
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mice during this phase of epileptogenesis is unusual and an unanticipated outcome.
The incidence of lethality was low but exhibited a gene dosage effect (study 1, Fig. 4.3A
and B), increasing in proportion to the number of functional TIA-1 alleles from 0% in
mice with two functional alleles to 7% and 17% with loss of one or both alleles,
respectively. This is compelling evidence to support the notion that this effect was
indeed due to loss of TIA-1 function. It is interesting that TIA-1 deficiency did not
enhanced lethality associated with acute convulsive seizures in naïve mice 177 or in
kindled mice after kindling acquisition was complete and a sustained reduction in
seizure threshold was established (i.e., re-challenge with PTZ kindling dose). This
indicates that TIA-1 suppresses lethality specifically during the process of
epileptogenesis (i.e., during the process of kindling acquisition). The reason for this will
require further investigation.
Together, the results described in this chapter suggest that TIA-1 functions to
antagonize the progressive changes in neuroplasticity associated with kindling
development. The observations suggesting that TIA-1 suppresses lethality associated
with epileptogenesis could lead to a better understanding of the molecular mechanisms
in unexpected death in epileptic individuals (section 6.3.2).
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CHAPTER 5 Transcriptome analysis in kindled brain of TIA-1 knockout animals
5.1 Synopsis
Since TIA-1 deletion results in enhanced kindling acquisition (Chapter 4), it is
hypothesized that kindling progression leads to gene expression changes in
hippocampus that may differ between TIA-1 knockout and wild-type. The work
described in this chapter identified differentially expressed transcripts in hippocampi of
TIA-1 knockout mice that received repeat convulsant stimuli using next generation
sequencing approach.
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5.2 Introduction
In the kindling model of epileptogenesis, repeated application of electrical
stimulation or chemical agents (including but not limited to PTZ) leads to a reduction in
seizure threshold and enhanced behavioral seizure responses. This is associated with a
variety of neurobiological changes in neuroanatomy and channel electrophysiology 307.
Importantly, the increased susceptibility to seizure can last nearly indefinitely 308,309. This
suggests that the underlying mechanism of kindling is due to a long-lasting and
profound perturbation of neuronal function, which could result from altered expression of
mRNAs or proteins, as well as post-translational changes in key protein products.
Indeed, some of the very early studies demonstrated that protein synthesis inhibitors,
such as cycloheximide and anisomycin significantly delay kindling development 310.
Enhanced kindling acquisition was found in TIA-1 deleted mice (Chapter 4),
suggesting that TIA-1 may function to antagonize the progressive neuroplastic changes
associated with kindling development. TIA-1 is a multifunctional RBP that can influence
alternative pre-mRNA splicing in the nucleus and control post-transcriptional regulation
of gene expression in the cytosol 219. In the latter case, it is known primarily as a
negative regulator of protein translation, although it has also been shown to promote
decay RNA transcripts in certain instances 241,259. Due to the large number of targets of
TIA-1 protein, as well as its multi-dimensional regulation of mRNA life cycle, it is
hypothesized that deletion of TIA-1 will result in a genome wide alteration of the
expression levels of genes. In fact, deletion of TIA-1 has a major effect on mRNAs
encoding cell cycle and apoptosis regulator genes, as well as lipid homeostasis factor
genes in the brain, as identified by microarray technique 269. Therefore, the work
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described in this chapter takes advantage of the next-generation sequencing technique
to study potential transcriptome alterations in hippocampus of mice that received
repeated convulsant stimuli and attempts to unravel the molecular mechanism by which
TIA-1 deletion facilitates kindling progression.
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5.3 Materials and methods
5.3.1 Animal housing and breeding
The housing and breeding of the TIA-1 gene mutant mouse line (Tia1−/−) has
been described in section 3.2.1. A total number of 18 adult male mice were used in this
study.
5.3.2 Dosing paradigms
A modified PTZ-induced kindling model of epileptogenesis was used to examine
genetic changes during epileptogenesis. The purpose of this study is to identify
plasticity changes that occur during kindling progression, rather than changes in the
expression levels of immediate early genes or metabolism genes induced by acute
convulsive seizures. Therefore, among all animals that received daily PTZ injections,
only those that did not have convulsive responses were used. In addition, due to the
high incidence of lethality found in Tia1-/- mice during kindling paradigm (Chapter 4), a
shortened (10-day) injection paradigm was applied compared to the original 21-day
paradigm to minimize the number of convulsive seizures induced by PTZ injections.
Thus, male Tia1+/+ and Tia1-/- littermates were randomly segregated at weaning without
knowledge of genotype and were used between 8-12 weeks of age. All mice were
acclimated to handling for 5-7 days prior to studies. PTZ (39mg/kg, dissolved in 0.9%
saline) was delivered daily for 10 days, whereas six mice served as control group were
administrated with 0.9% saline delivered daily for 10 days. Seizure activity was
monitored for 25 minutes after PTZ administration and graded by an observer blinded to
genotype using a previously established scoring system 181. Animals that showed any
seizure activity of stage 3 or above were removed from the study.
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Table 5.1. Groups of mice used in the study.
Genotype\Treatment

Tia1

-/-

Tia1

+/+

Total

PTZ

5

5

10

saline

3

3

6

Total

8

8

16

5.3.3 Sample Preparation
Mice were deeply anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine
administered i.p. in saline and perfused transcardially with 0.05 M phosphate-buffered
saline (PBS). Left and right dorsal hippocampi were dissected, combined, snap-frozen
using a dry ice/ethanol slurry, and stored at -80 ˚C before use.
5.3.4 RNA-Seq
RNA-Seq was performed in the SUNY Molecular Analysis Core (SUNYMAC) at
Upstate Medical University. Briefly, total RNA was purified using the RNeasy kit
(Qiagen), followed by quantification and assessment of RNA quality (Fig. 5.1A) on an
Agilent Technologies 2100 Bioanalyzer (Agilent Technologies) using the Agilent RNA
6000 Nano kit (Agilent Technologies). The RNA integrity number (RIN) algorithm311 was
used to assess integrity of RNA by utilizing the ratio between the 28S and 18S rRNA.
cDNA libraries were prepared following TruSeq® Stranded mRNA Sample Preparation
Guide (Illumina). cDNAs quantity and integrity were assessed (Figure 1B) on an Agilent
Technologies 2100 Bioanalyzer using the Agilent DNA 1000 Kit (Agilent Technologies)
by looking for a peak between 200bp to 500bp. Samples were sequenced with an
Illumina NextSeq 500 instrument using 2 x 75 bp paired end reads, with a targeted
depth of coverage of 25 million reads per sample (NextSeq 500/550 High Output Kit v2
(150 cycles), Cat# FC-404-2002, Illumina).
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Fig. 5.1 Bioanalyzer electropherograms of samples. (A) Representative electropherogram pattern of
extracted mRNA from hippocampal tissue, noting the peaks at ~1,900nt and ~ 4,000nt for 18S and 28S
rRNA respectively. All mRNA samples have RNA integrity number (RIN) > 9 (RIN assigns an
electropherogram a value of 1 to 10, with 10 being the least degraded). (B) Representative
electropherogram pattern of synthesized cDNAs, noting the highest abundancy of cDNAs between 200400 bp, with the peak lies at ~ 260bp, indicating successful cDNA library preparation. nt, nucleotide. bp,
base pair. FU, fluorescence units.

5.3.5 Alignment, quantification and normalization of raw sequence reads
After obtaining the raw sequence reads (Appendix Table 3), FASTQ files were
generated on the SUNYMAC iCompute server and initial read quality metrics generated.
Adapter were trimmed via Partek Flow Trim Adapters v1.12 using the following adapter
sequences: AGATCGGAAGAGCACACGTCTGAACTCCAGTCA (first mate adapter
sequences); AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT (second mate
adapter sequences). Alignment was performed on trimmed reads (Appendix Table 4) to
version Mm10 of the mouse genome using the Bowtie2 algorithm within the TopHat2
application deployed in Partek Flow. Aligned BAM file reads were subjected to QC
analysis (Fig. 5.2) and quantification of RNA alignments was performed using the
Partek E/M algorithm based on the May 2017 RefSeq annotation. Quantified reads
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(Appendix Table 5) were subjected to QC analysis (Fig.5.3 and Fig.5.4). Normalization
of reads to the length of genes and the depth of sequencing was performed using either
the TPM (Transcripts Per Million) method (Fig. 5.5A) or FPKM (Fragments Per Kilobase
Million) method (Fig. 5.5B) as described previously 312.
5.3.6 Generation of correlation matrix
Correlation matrix was generated from normalized raw gene counts (TPM) using
the gplot package 313 in R (version 3.3.2) 314. Samples were clustered via a complete
linkage method with Euclidean distance measure.
5.3.7 PCA analysis
PCA analysis was performed using TPM values on a subset of genes first.
Genes that show a TPM value < 1,350 in >= 50% of the tissue samples (8 out of 16
mice) were filtered out from the analysis. In total, 4,965 out of 24,543 genes remained in
the dataset after the filtering step. Further analysis was performed online via
MetaboAnalyst 315. TPM values were uploaded in comma separated values (.csv)
format, with 16 samples in rows and 4,965 genes in columns. No data filtering was
performed. Data were normalized row-wise by the sum, followed by a generalized log
transformation. The PCA analysis is performed using the prcomp R package. The
calculation is based on singular value decomposition. The gene expression data were
summarized into PCs, which were weighted average of the original variables (genes).
PCA analysis was then performed on the entire dataset (24,543 genes) using the
FactoMine R package.
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Fig. 5.2 Post-Alignment QA/QC. Left, green bars represent the average read depth (average number of
reads representing a given nucleotide in the reconstructed sequence) for each sample. Average
alignment per read is 1 for all samples (data not shown). Right, hollowed dots connected by the black line
represent the percentage of the genome covered by aligned reads. Genotype and treatment of each
animals is labeled as horizontal text in the center of each bar.
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Fig. 5.3 Post-Quantification Analysis. Top left, box-whisker plot displays expression signal distribution
for each sample. Top right, histogram of genes of different expression levels for each sample. Bottom, bar
chart on distribution of raw read counts in each sample. Note that a high frequency of genes has raw
gene counts that are between 100-10,000.
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Fig.5.4 Coverage of reads. Coverage breakdown bar chart summarizes the mapping of raw reads to
transcription based on the annotation file provided. The distribution of aligned reads within exons, introns,
intergenic regions was noted. Genotype and treatment of each animals is labeled as horizontal text in the
center of each bar.

Fig. 5.5 Post-Normalization Analysis. (A) Box-whisker plot displays expression signal distribution after
TPM normalization for each sample. Error bar represent standard deviation of TPM values. (B) Bar plot
displays mean and standard deviation of FPKM values of each sample.
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5.4 Results
5.4.1 Samples show overall similarity in their gene expression profiles
By day 10 of the paradigm, two Tia1-/- mice were removed from the study after
showing stage 4 convulsive seizures, whereas the remaining 16 mice (Table 5.1) were
used in tissue preparation, with 12 mice received daily PTZ injection and 6 mice
received daily saline injection. A high correlation in general was observed between
samples (Fig. 5.6). Although all samples show an overall similarity in their gene
expression profiles, three knockout animals that received PTZ showed lower correlation
when compared with the rest of the animals.

Fig. 5.6 Sample correlation on TPM of 24,543 genes. A heat map of the average Pearson correlation
coefficients of normalized raw gene counts (TPM) of 24,543 genes from 16 samples. The legend on the
top left depicts the correlation color scale from low (blue) to high (red). Samples are categorized into two
groups (WT or KO, black or gray bars on the left side of the matrix table). The two axes of the
dendrogram represents the distance or dissimilarity between clusters and the samples and clusters.
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5.4.2 Choroid plexus genes account for major variation between samples
Principal component analysis (PCA) is an unsupervised statistical approach to
reduce the dimensions of a data set. PCA uses linear combinations of the original data
to define a new set of variables called principal components (PCs). These PCs are
orthogonal to each other, thus each contributing to the total variation independently.
Here, PCA was used to find the directions that best explain the between-samplevariance in normalized raw gene counts (TPM). PCA analysis was performed on filtered
TPM values (Materials and methods). The variances explained by each PC was
depicted in the scree plot (Fig. 5.7). PC1 alone was responsible for 64.9% of the total
variation while PC1 and 2 together accounted for 74.4% of the total variance. The score
plot (Fig. 5.8) displays the PCA score of each sample with respect to the first two PCs.
The same three knockout animals that received PTZ (TB3, TC3 and TA2) were
clustered on PC1 axis.
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Fig. 5.7 Variance explained by each PC in PCA of top 5000 highly expressed genes. The scree plot
visualizes which principal components (PCs) account for which fraction of total variance in the data. The
PCs are listed by decreasing order of contribution to the total variance. The green line on top shows the
cumulative variance explained; the blue line underneath shows the variance explained by each individual
PC.

Fig. 5.8 Scores plot of PC1 and 2 in PCA of top 5000 highly expressed genes. Two principal
components (PCs) responsible for 74.4% of the total variance of the original 4,965 variables (The
explained variances are shown in brackets), PC1 alone accounts for 64.9% of the total variance. Shading
eclipse represent the 95% confidence interval showing the estimated population mean.
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The loadings plot shows the relationship between original variables (genes) and
subspace dimensions (PCs). It allows the identification of genes that are most strongly
correlated or anti-correlated with the selected PCs. The contributions of each gene to
the first two PCs are shown in Fig. 5.9. While most genes had almost zero weight in
PC1 loading, a few genes showed a significant contribution towards PC1. Surprisingly,
all of these genes (Ttr, Kcnj13, F5, Clic6, 1500015O10Rik, Sulf1, Prlr, Enpp2, Ace, Kl,
Igf2, Igfbp2, Vat1l, Col9a3) are highly expressed in mouse choroid plexus (ChP),
according to Allen Brain Atlas (© 2004, Allen Institute for Brain Science. Allen Mouse
Brain Atlas. Available from: http://mouse.brain-map.org/). Among them, Ttr gene, which
encodes transthyretin, a transport protein for thyroxine and retinol, has long been
considered as a unique marker for ChP 316.

Fig. 5.9 Loadings plot of PC1 and 2 in PCA of top 5000 highly expressed genes. Loading plot
reveals the contribution of each feature in creating the first two principal axes.
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Similar results were obtained when the analysis was performed on the entire
dataset (24,543 genes). Principal Component Analysis was used to compare the
normalized raw gene counts (TPM) profiles across all samples (i.e. samples were
plotted as variables). PC1 alone consist of 95.74% of total between-sample variation
whereas PC2 and PC3 account for 3.32% and 0.64%, respectively. Whereas all
samples have strong positive loadings on PC1, the same three animals (TB3, TC3 and
TA2, circled in Fig. 5.10A) showed strong positive loadings on PC2, which, was
contributed almost exclusively by two ChP genes, Ttr and Enpp2 (Fig. 5.10B).

Fig. 5.10 Variable and individual factor map of PC1 and 2 in PCA of 24,543 genes. (A) Principal
Component Analysis variables factor map. The direction of the arrows represents the relative loadings of
all 16 samples on the first (Dim1) and second (Dim2) dimension. All samples had strong positive loadings
on dimension 1; Red circle, three KO-PTZ samples (TB3, TC3 and TA2) had significant positive loadings
on dimension 2. (B) Individual factor map. Ttr and Enpp2 had strong positive loadings on the second
(Dim2) dimension.

ChP is a small cauliflower-like tissue located inside the ventricles that produces
cerebral spinal fluid (CSF) and maintains blood-brain homeostasis. ChP is presented in
lateral ventricle, which is anatomically adjacent to hippocampus, and both ChP and
hippocampus can be closely associated with meninges. This raises the possibility that
contamination from ChP tissues occurred during tissue preparation and thus may be a
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confounding factor in the RNA-seq analysis. Indeed, a previous study has suggested
that detection of ChP genes in other brain structures is contributed by ChP
contamination during dissections317.
To account for variances in gene expression profiles between samples caused
by differentially expressed ChP tissues, a factor analysis via PCA was performed using
StatView (Version 5.0.1, SAS Institute Inc.). A total number of 15 genes that are
specifically expressed in either ChP or in three different CNS cell types (i.e. neuron,
astrocyte and oligodendrocyte) were selected. The panel of ChP specific genes (Table
5.2) was selected based on mouse expression profile data from a previous study 318 and
further verification via Allen Brain Atlas. Panels of genes (Table 5.2) that are specifically
expressed in oligodendrocytes, neurons or astrocytes were selected based on mouse
expression profile data from another study 319. Factor analysis via PCA was performed
on normalized raw gene counts (FPKM) of these 15 genes in all 16 samples. Results
(Table 5.3) indicated that the first four PCs accounted for ~90% of the total variance
whereas PC1 alone accounted for 67% of the total variance. Specifically, all 6 ChP
specific genes had large positive contributions to PC1 (Table 5.4) as expected, whereas
all 3 oligodendrocytic genes had mild positive contributions to PC1 as well. Interestingly,
all 3 neuronal genes had negative contributions to PC1, further supporting the notion
that the variance captured by PC1 were indeed due to increased proportion of ChP
versus neuronal tissues.
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Table 5.2 Cell/Tissue specific marker genes used for PCA

Gene Category

Gene
symbol
Ttr
Otx2

ChP genes

Emb
Col8a1
Arsg
Kcnj13
Mag

Oligodendrocytic genes

Myrf
Tmem125
Calb1

Neuronal genes

Camkv
Nefl
Aqp4

Astrocytic genes

Slc1a3
Slc25a18

Table 5.3 Variances explained by PCs

PC1

Eigenvalue
(nonzero)
42.88

Proportion
(%)
66.99

Cumulative
(%)
66.99

PC2

9.63

15.05

82.04

PC3

2.83

4.42

86.47

PC4

2.03

3.17

89.64

PC5

1.58

2.48

92.11

PC6

1.28

1.99

94.11

PC7

0.93

1.46

95.57

PC8

0.82

1.28

96.85

PC9

0.51

0.80

97.65

PC10

0.41

0.64

98.29

PC11

0.34

0.52

98.81

PC12

0.30

0.46

99.27

PC13

0.22

0.35

99.62

PC14

0.14

0.22

99.84

PC15

0.10

0.16

100.00
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Table 5.4 Loadings of individual genes to PC 1-4

Gene Category

Gene symbol
Ttr
Otx2
Emb

ChP genes

Col8a1
Arsg
Kcnj13
Mag

Oligodendrocytic genes

Myrf
Tmem125
Calb1

Neuronal genes

Camkv
Nefl
Aqp4

Astrocytic genes

Slc1a3
Slc25a18

PC1
0.937
0.941
0.939
0.939
0.951
0.935
0.714
0.654
0.439
-0.57
-0.345
-0.376
0.131
-0.566
0.168

PC2
-0.264
-0.225
-0.225
-0.255
0.014
-0.252
0.623
0.573
0.567
-0.501
0.469
0.44
-0.241
-0.059
0.613

PC3
-0.19
-0.124
0.014
-0.189
-0.218
-0.204
0.108
0.089
-0.231
-0.136
-0.631
-0.225
0.79
-0.44
0.542

Table 5.5 Unrotated factor scores of individual samples

Sample ID
TA5_S1
TB2_S2
TB5_S3
TA1_S11
TD3_S9
TD4_S10
TC1_S4
TC2_S5
TE5_S6
TF1_S7
TF4_S8
TE2_S15
TE3_S16
TA2_S12
TB3_S13
TC3_S14

Genotype
WT
WT
WT
KO
KO
KO
WT
WT
WT
WT
WT
KO
KO
KO
KO
KO

Treatment
Saline
Saline
Saline
Saline
Saline
Saline
PTZ
PTZ
PTZ
PTZ
PTZ
PTZ
PTZ
PTZ
PTZ
PTZ
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PC1
0.101
1.303
0.494
0.194
1.246
-0.480
0.499
0.674
-0.557
0.427
0.974
0.213
-0.059
-1.044
-2.023
-1.962

PC2
-0.067
0.501
-0.164
-1.123
3.007
-0.351
-0.425
-0.634
0.144
-0.408
-0.158
-1.278
-0.489
-0.061
1.243
0.264

PC3
-0.660
0.615
-0.306
-1.307
-0.950
-1.940
0.293
0.644
0.032
0.078
2.369
-0.229
-0.529
0.843
0.472
0.574

PC4
-0.230
-1.909
0.131
0.431
0.705
-1.040
-1.281
-0.378
1.553
-0.390
1.057
1.280
1.123
-0.398
0.300
-0.953

PC4
0.103
0.193
0.083
0.098
0.084
0.125
0.039
0.018
-0.482
0.364
0.43
0.703
0.376
-0.107
0.226

Next, the unrotated factor scores (Table 5.5) for PC1 of each sample were used
to normalize raw gene counts (FPKM) for 19,762 genes. Consistent with the correlation
matrix (Fig. 5.6), the same three animals (KO-PTZ) showed large negative factor scores
for PC1, indicating their biased ChP genes expression level. These factor scores were
fed to the batch effect removal algorithm in Partek Genomic Suite (Partek Inc., St.
Louis, Missouri) as covariates, which calculates the variation attributed to these factor
scores and adjusts the original FPKM values to remove the variation.
To validate whether the batch effect removal process (referred to as “the
correction” from here on) successfully adjusted the biased expression of ChP genes, a
correlation matrix was generated from normalized raw gene counts (FPKM) before and
after the correction. Before the correction, three KO PTZ animals presented a low
correlation score when compared with the rest of all samples (Fig. 5.11A). The
correction increased the overall correlation scores between these samples (Fig. 5.11B).
In addition, samples from wild-type and knockout animals showed a clearer clustering
according to their genotypes (vertical bars with grey and black shading in Fig. 5.11A
and B).
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Fig. 5.11 Sample correlation on FPKM of 19,762 genes before and after correction of ChP bias. A
heat map of the average Pearson correlation coefficients of normalized raw gene counts (FPKM) of
19,762 genes from 16 samples computed before (A) and after (B) the batch effect removal correction.
The legend on the top left depicts the correlation color scale from low (blue) to high (red). Samples are
categorized into two groups (WT or KO, black or gray bars on the left side of the matrix table). The two
axes of the dendrogram represents the distance or dissimilarity between clusters and the samples and
clusters.

To further confirm that the correction indeed adjusted the biased expression of all
ChP genes without introducing new bias in reference gene expression, I then computed
the correlation scores between the PC1 unrotated factor score (Table 5.5) and the
original (before correction) FPKM values of each gene. I filtered the result list with 1) a
list of ChP genes; 2) a list of neuronal specific genes and 3) a list of reference genes.
The list of genes that are highly expressed in ChP of young (two-month-old) CD1 mice
was obtained from a previous study 320. Briefly, for each microarray Probe Set ID, an
average expression value (log2-transformed expression levels) was calculated between
the 3 young CD1 mice. Probe Set IDs were then sorted from high to low based on the
average expression value. For each gene, only the Probe ID with the highest
expression level was kept. A list of the top 34 highly expressed genes (column 1, Table
5.6) in ChP was generated. A list of 35 neuronal specific genes and a list of 100
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reference genes (column 2 and 3, Table 5.6) were obtained from the Harmonizome
database321. The ChP specific genes all seemed to have strong negative correlation
scores with unrotated factor scores of PC1 (Table 5.7), whereas the majority of
neuronal specific genes had positive correlation scores. This is consistent with the
pattern observed in the loadings of the 6 ChP specific genes and 3 neuronal genes
(Table 5.4) where the two groups had an opposite contribution towards PC1. On the
other hand, both positive and negative correlations scores were observed in reference
genes. Many reference genes that showed a high negative correlation score are indeed
genes that are also highly expressed in ChP (Table 5.8). The FPKM values of both CP
specific genes and reference genes that are highly expressed in ChP were normalized
after the correction (Fig. 5.12). Finally, to confirm that the correction did not alter the
within or between group variation across the entire transcriptome, I calculated the mean
within and between group coefficient of variation (CV) values averaged across all
genes. The correction process did not alter either within or between group CV across all
genes significantly (Table 5.9a). In contrast, the CV values of ChP specific gene, such
as Ttr (Table 5.9b), were significantly improved (tightened) by the correction process.
On the other hand, between-sample variation of genes that showed a small within or
between group CV before the correction process remained unchanged (Table 5.9c). In
sum, the correction process successfully improved the between-sample variation
caused by biased expression of ChP genes.
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Table 5.6 List of ChP, neuronal and reference genes

ChP

Neuron

Reference

Ttr

Afp

F5

B2m

Ckm

Rpl41

Apoe

Ace

Aldh1b1

Vdr

Enpp2

App

Slc22a8

Ccl3

Crybb2

Pebp1

Arrb1

Aldh2

Tk1

Tpo

Rps27

Atp1a3

Wfdc2

App

Lcn2

Gm1821

Bdnf

Nqo1

Tnfsf11

Gsk3a

Rpl36

Caly

Clu

Cckar

Mapt

Hnrnpab

Casp3

Ctdspl

Rbp4

Adarb1

Hbb-b1

Clvs1

Emp3

Tnfsf13b

Mpo

Clu

Clvs2

Pon1

Pparg

Adipoq

Rps29

Eno2

Gstt1

Thbd

Il6

Rplp2

Fez1

Plxnb1

Cst3

Slpi

Chchd10

Gfap

Cryab

Tnnt2

Eno1b

Rpl38

Grin1

Rpl41

Gstm1

Pik3ca

Cox7a2

Gsk3b

Rpl13a

Adora3

Dsg3

Kxd1

Itsn1

Brca2

Epo

Ipo8

Rps28

Lims1

Erbb2

Slc22a4

P2ry12

Ptgds

Muc1

Gpt

Ubb

Ptpn22

Ndufa13

Ngb

Igf1r

Nup153

Egfr

Atp6ap2

Ntrk2

Scn5a

Afm

S100a2

Sod1

Plch2

Mfap5

Pum1

Tfrc

Rpl31

Prkca

Eno1

Gapdh

Shbg

Cox6a1

Ptprs

Brca1

Tshb

Nat1

Rpl35

Rbfox3

Gstp1

Igfbp3

L1cam

Cox6c

Reep1

Cd14

Asxl1

Atxn10

Cox5b

Rest

Mlh1

Amh

Fmr1

Ndufb11

Rit2

Itgb3

Pgf

Rb1

Vdac1

S100b

Rplp0

Tnf

Igf1

Rpl26

Shc3

Cntf

Fanci

Kras

Atp5e

Srpk1

Drd4

Rpl4

Htr1a

Igf2

St8sia5

Park7

Actb

Rps21

Syp

Afp

Ercc1

Ndufb7

Taf1

Spp1

Ifrd1

Uqcrh

Ube3a

Tnfrsf11b

Gsk3b

Vldlr

Snrpa1
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Table 5.7 Correlation of ChP, neuronal and reference genes with unrotated factor scores

ChP

Neuron

Reference

Ttr

-0.94

Afp

-0.41

F5

-0.95

B2m

-0.35

Ckm

0.02

Rpl41

-0.73

Apoe

-0.70

Ace

-0.94

Aldh1b1

-0.34

Vdr

0.05

Enpp2

-0.94

App

-0.31

Slc22a8

-0.94

Ccl3

-0.34

Crybb2

0.05

Pebp1

-0.67

Arrb1

0.15

Aldh2

-0.93

Tk1

-0.32

Tpo

0.07

Rps27

-0.59

Atp1a3

0.03

Wfdc2

-0.92

App

-0.31

Lcn2

0.08

Gm1821

-0.47

Bdnf

0.72

Nqo1

-0.88

Tnfsf11

-0.29

Gsk3a

0.09

Rpl36

-0.63

Caly

0.21

Clu

-0.87

Cckar

-0.27

Mapt

0.11

Hnrnpab

-0.46

Casp3

-0.28

Ctdspl

-0.84

Rbp4

-0.25

Adarb1

0.13

Hbb-b1

0.11

Clvs1

0.78

Emp3

-0.84

Tnfsf13b

-0.24

Mpo

0.14

Clu

-0.87

Clvs2

0.59

Pon1

-0.83

Pparg

-0.23

Adipoq

0.18

Rps29

-0.47

Eno2

0.33

Gstt1

-0.81

Thbd

-0.22

Il6

0.20

Rplp2

-0.40

Fez1

0.56

Plxnb1

-0.75

Cst3

-0.21

Slpi

0.21

Chchd10

-0.92

Gfap

-0.17

Cryab

-0.74

Tnnt2

-0.19

Eno1b

0.24

Rpl38

-0.24

Grin1

0.12

Rpl41

-0.73

Gstm1

-0.19

Pik3ca

0.25

Cox7a2

-0.61

Gsk3b

0.01

Rpl13a

-0.73

Adora3

-0.18

Dsg3

0.28

Kxd1

-0.54

Itsn1

0.09

Brca2

-0.73

Epo

-0.18

Ipo8

0.29

Rps28

-0.26

Lims1

0.00

Erbb2

-0.73

Slc22a4

-0.18

P2ry12

0.30

Ptgds

-0.67

Muc1

0.07

Gpt

-0.71

Ubb

-0.18

Ptpn22

0.31

Ndufa13

-0.70

Ngb

-0.54

Igf1r

-0.69

Nup153

-0.15

Egfr

0.32

Atp6ap2

-0.73

Ntrk2

-0.73

Scn5a

-0.67

Afm

-0.13

S100a2

0.33

Sod1

-0.56

Plch2

0.40

Mfap5

-0.67

Pum1

-0.13

Tfrc

0.37

Rpl31

-0.20

Prkca

0.58

Eno1

-0.64

Gapdh

-0.13

Shbg

0.38

Cox6a1

-0.64

Ptprs

-0.01

Brca1

-0.61

Tshb

-0.12

Nat1

0.40

Rpl35

-0.30

Rbfox3

0.24

Gstp1

-0.60

Igfbp3

-0.12

L1cam

0.47

Cox6c

-0.34

Reep1

0.33

Cd14

-0.57

Asxl1

-0.11

Atxn10

0.49

Cox5b

-0.49

Rest

-0.60

Mlh1

-0.53

Amh

-0.10

Fmr1

0.60

Ndufb11

-0.79

Rit2

0.11

Itgb3

-0.52

Pgf

-0.08

Rb1

0.60

Vdac1

-0.26

S100b

0.18

Rplp0

-0.49

Tnf

-0.08

Igf1

0.61

Rpl26

-0.29

Shc3

0.06

Cntf

-0.48

Fanci

-0.03

Kras

0.66

Atp5e

-0.82

Srpk1

0.31

Drd4

-0.48

Rpl4

-0.03

Htr1a

0.71

Igf2

-0.95

St8sia5

0.36

Park7

-0.45

Actb

0.00

Rps21

-0.59

Syp

0.48

Afp

-0.41

Ercc1

0.00

Ndufb7

-0.55

Taf1

0.69

Spp1

-0.41

Ifrd1

0.01

Uqcrh

-0.66

Ube3a

-0.18

Tnfrsf11b

-0.37

Gsk3b

0.01

Vldlr

-0.82

Snrpa1

0.02
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Table 5.8 Reference genes that are highly expressed in ChP
Gene
Symbol
F5

Correlation
-0.947

Ace

-0.944

Aldh2

-0.931

Wfdc2

-0.923

Clu

-0.866

Cryab

-0.738

Rpl13a

-0.732

Eno1

-0.644

Gstp1

-0.602

Rplp0

-0.488

Park7

-0.445

B2m

-0.351

App

-0.311

Cst3

-0.212

Fig. 5.12 Normalized gene counts (FPKM) before and after batch effect removal. The FPKM values
of a choroid plexus specific gene, Ttr (A) and a reference gene that is highly expressed in choroid plexus,
Ace (B) before (blue bars) and after (orange bars) batch effect removal correction.
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Table 5.9a Mean within and between group CV

Mean

Within Group CV

Between Group CV

WT Saline

KO Saline

WT PTZ

KO PTZ

Before Normalization

0.24

0.30

0.31

0.33

0.26

After Normalization

0.23

0.31

0.31

0.41

0.26

Table 5.9b Ttr within and between group CV

Ttr

Within Group CV

Between Group CV

WT Saline

KO Saline

WT PTZ

KO PTZ

Before Normalization

1.40

1.66

1.54

0.87

1.00

After Normalization

0.47

1.13

0.24

0.59

0.20

Table 5.9c Tia1 within and between group CV

Tia1

Within Group CV

Between Group CV

WT Saline

KO Saline

WT PTZ

KO PTZ

Before Normalization

0.03

0.07

0.02

0.08

0.18

After Normalization

0.07

0.04

0.04

0.06

0.20
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5.4.3 Differential gene expression in TIA-1 knockout brain
After batch effect removal correction, genes that showed a normalized raw count
(FPKM) < 0.05 in >= 50% of the tissue samples (8 out of 16 mice) were further filtered
out from the analysis. In total, 16,066 out of 19,762 genes remained in the dataset after
this filtering step. Further analysis was performed online via MetaboAnalyst 315. FPKM
values were uploaded in comma separated values (.csv) format, with 16 samples in
rows and 16,066 genes in columns. Data were then normalized row-wise by the sum,
followed by a generalized log transformation and auto scaling (mean-centered and
divided by the standard deviation of each variable).
Differential gene expression was analyzed via one-way Analysis of Variance
(ANOVA) followed by Fisher's least significant difference method (Fisher's LSD).
Multiple testing correction is applied using the Benjamini-Hochberg False Discovery
Rate (FDR) algorithm. Seventy-four genes (Fig. 5.13) were identified to be differentially
expressed (FDR < 0.1) among the four experimental groups. Among them, 11 genes
(Table 5.10) had a FDR < 0.05. Hierarchical clustering was performed on all 16 samples
across all genes (Fig. 5.14) or across the 74 genes with FDR < 0.1 (Fig. 5.15) identified
via ANOVA with the hclust function in package stat. Similarities between samples was
measured via Euclidean distance measure. Samples were clustered using Ward’s
linkage clustering algorithm. In wild-type animals, PTZ treatment did not seem to induce
dramatic alteration in gene expression profiles as the heat map patterns between the
two treatment groups (WT-Saline and WT-PTZ) remained largely unchanged (Fig.
5.15). However, PTZ treatment induced a shift of gene expression profiles in knockout
animals (KO-PTZ compared to KO-Saline). This is supported by the clustering of
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samples in the heat map computed across all genes (Fig. 5.14), where KO-Saline and
KO-PTZ samples tended to cluster into different groups but WT-Saline and WT-PTZ
samples were intermingled with each other. Lastly, genotype, rather than PTZ
treatment, contributed more significantly to the differential expression of genes as
visualized by Venn diagram (Fig. 5.16). This stays true before and after the adjustment
of the biased expression of ChP genes (Fig. 5.16 Left vs Right). Although the
adjustment greatly increased the number of differentially expressed genes between KO
and WT or between PTZ and Saline groups, it did not alter the number of genes that are
differentially expressed between WT-Saline and WT-PTZ, which is 0 before adjustment
and 1 after adjustment, suggesting that the adjustment process did not introduce new
bias in WT gene expression profiles. Interesting, among the differential expressed
genes identified via two-way ANOVA between knockout and wild-type groups, 339/413
genes were down-regulated, indicating a global reduction of mRNA levels in knockout
tissues.
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Fig. 5.13 Important features selected by ANOVA plot with FDR threshold 0.1. Important features
identified by ANOVA analysis. Each dot on the 2-D plane represents an individual gene. Y-axis
represents the –log10 transformation of the ANOVA p value. Red dots represent genes with an adjusted
p value (FDR) < 0.1.
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Table 5.10 Important features identified by One-way ANOVA with FDR threshold 0.05

Gene
Symbol

Entrez Gene Name

FDR

Major Gene Ontology

Vamp2

vesicle associated membrane
protein 2

0.01

calmodulin binding, syntaxin binding

Aak1

AP2 associated kinase 1

0.01

transferase activity, transferring
phosphorus-containing groups and
protein tyrosine kinase activity

Tia1

TIA1 cytotoxic granule associated
RNA binding protein

0.01

nucleic acid binding and nucleotide
binding

Asprv1

Aspartic Peptidase Retroviral Like 1

0.03

aspartic-type endopeptidase activity

Napb

NSF Attachment Protein Beta

0.03

syntaxin binding, soluble NSF attachment
protein activity

Ldb3

LIM Domain Binding 3

0.03

cytoskeletal protein binding, muscle
alpha-actinin binding

Ift20

intraflagellar transport 20

0.03

opsin binding

Ppp1r1a

Protein Phosphatase 1 Regulatory
Inhibitor Subunit 1A

0.03

protein phosphatase inhibitor activity,
protein serine/threonine phosphatase
inhibitor activity

Smpd5

Sphingomyelin Phosphodiesterase 5

0.03

NA

Magi1

membrane associated guanylate
kinase, WW and PDZ domain
containing 1

0.05

protein C-terminus binding and alphaactinin binding

Bri3bp

BRI3 binding protein

0.05

mitochondrial outer membrane
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Fig. 5.14 Clustering result for 16,066 genes shown as heat map. Top, the vertical axis of the
dendrogram represents the distance or dissimilarity between clusters. The horizontal axis represents the
samples and clusters. Left, the horizontal axis of the dendrogram represents the genes and clusters, the
vertical axis represents the distance or dissimilarity between clusters. Heat map grids of different colors
represent the expression level (normalized raw gene counts) of each feature from low (blue) to high (red).
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Fig. 5.15 Clustering result for 74 genes shown as heat map. Top, the vertical axis of the dendrogram
represents the distance or dissimilarity between clusters. The horizontal axis represents the samples and
clusters. Left, the horizontal axis of the dendrogram represents the genes and clusters, the vertical axis
represents the distance or dissimilarity between clusters. Heat map grids of different colors represent the
expression level (normalized raw gene counts) of each feature from low (blue) to high (red).
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Fig. 5.16 Venn diagram of differentially expressed genes. Overlapping of differentially expressed
genes between PTZ and Saline or between knockout and wild-type groups are shown. Left, before ChP
gene expression adjustment; Right, after ChP gene expression adjustment. Gene lists were derived from
two-way ANOVA performed on the corrected FPKM values across 19,762 genes with the cutoff in FDR
set as 0.1.
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A

B

Fig. 5.17 TIA-1 mRNA levels in all samples. (A) Top, the red line indicates the part of the chromosome
that is currently depicted on the canvas. Middle, alignments of reads to genome are shown as stacked
histograms. The y-axis shows number of base calls per position. Reads are colored by sample. Bottom,
structure of TIA-1 transcripts variants are shown. Exons are plotted as boxes and introns as lines
connecting them. Untranslated regions (UTRs) are seen as narrow boxes. The arrows on the lines
indicate directionality. Black arrow points to exon 4 of Tia1 gene. (B) Enlarged view of absent peak in TIA1 knockout sequences.
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A closer examination of the top 11 genes with smallest FDR values in one-way
ANOVA revealed that 2 out of 11 genes (Vamp2 and Napb) are synaptic vesicle
associated genes. Both genes were increased in knockout groups, indicating altered
synaptic plasticity after TIA-1 deletion. In addition, 2 out of 11 gene products (Ldb3 and
Magi1) are able to bind alpha-actin proteins, which is an isoform of actin found primarily
in muscle tissues. This suggests a potential alteration in brain blood vessel physiology.
Interestingly, TIA-1 mRNA itself was elevated in the knockout animals regardless of
their treatment paradigm (Fig. 5.17). This might be a feedback regulation occurred in
response to knockout of this important gene product. Importantly, although TIA-1 mRNA
was increased in knockout animals, it has been shown previously that these animals
lack TIA-1 protein expression 241. Moreover, the increased TIA-1 mRNA reads in
knockout animals lacks a peak within its coding region comparing to wild type animals
(Fig. 5.17A and B). The missing sequence was confirmed to represent exon 4 (Fig.
5.17B) via BLAST. This is in consistent with the previously reported targeted gene
knockout schema where parts of intron 3 and exon 4 are replaced by a neomycin
resistance gene cassette 241.
5.4.4 Pathway analysis of differentially expressed genes
Gene network analysis was performed to test for over-representation in different
Gene Ontology (GO) categories using Ingenuity Pathway Analysis (IPA) software
(QIAGEN). A two-way ANOVA analysis was performed in Partek Genomic Suite to
generates a list of between-genotype (KO vs WT) p-values for each gene in the list of
19,762 genes. A threshold of p < 0.02 was set to keep a list of 1,851 genes with the
lowest p-values. The IPA software then performed an enrichment detection algorithms
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to obtain sets of gene networks which showed over-representation in the differentially
expressed genes. The top canonical pathways (Fig. 5.19) and the number of their
shared genes (Fig. 5.20) are shown. Among these pathways are EIF2 signaling and
regulation of eIF4 and p70S6K signaling pathways, both are comprised of numerous
ribosomal proteins and translation initiation factors. TIA-1 function has been largely
linked to its interaction with translation initiation complex, and eIF-2α has been shown to
be both necessary and sufficient for TIA-1-mediated assembly of stress granules 253,254.
The presence of translation initiation complex components in the dataset further support
the specificity of the observed genetic alterations in TIA-1 knockout brain. Higher-level
analyses of upstream regulatory networks and molecular and cellular functional
pathways were also performed via IPA (Table 5.11 and Fig. 5.20). Pathways of protein
and RNA metabolism including RNA post-transcriptional modification, protein synthesis,
protein degradation, post-transcriptional modification, and gene expression were among
the top of the list.
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Fig. 5.18 Top 10 canonical pathways altered in KO. Yellow dots indicate the ratio of genes in the
dataset over genes in the pathway. Blue bars indicate the negative logarithm transformation of the fisher’s
exact test p-values. Only pathways with –log(p-value) > 3.15 are shown.
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Fig. 5.19 Overlapping of the top 10 canonical pathways altered in KO. Red boxes indicate the top 10
significant pathways. Numbers indicate the number of shared genes between two pathways connected by
blue lines.
Table. 5.11 Top 20 upstream regulators
Upstream Regulator
RICTOR
ST1926
MYCN
L-dopa
CD 437
sirolimus
KLF3
5-fluorouracil
HNF4A
GnRH analog
CDK2AP1
IL3
1,2-dithiol-3-thione
TCR
RRP1B
ZFHX3
HRAS
ciprofloxacin
beta-1,3-glucan
lanthanum chloride

Molecule Type
other
chemical drug
transcription regulator
chemical - endogenous
mammalian
chemical drug
chemical drug
transcription regulator
chemical drug
transcription regulator
biologic drug
other
cytokine
chemical reagent
complex
transcription regulator
transcription regulator
enzyme
chemical drug
chemical drug
chemical reagent
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p-value of overlap
8.44E-12
8.46E-10
2.66E-09
4.33E-08
8.04E-08
0.00000193
0.00000459
0.00000645
0.0000191
0.0000342
0.0000869
0.0000933
0.0000936
0.000119
0.000165
0.000206
0.000321
0.00036
0.000417
0.000493

Fig. 5.20 Top molecular and cellular functional pathways altered in KO. Blue bars indicate the
negative logarithm transformation of the fisher’s exact test p-values. Only pathways with –log(p-value) >
1.3 are shown.
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Similar gene network analysis was performed on the gene list generated from ttest between the KO-PTZ and WT-PTZ groups. A threshold of p < 0.02 was set to keep
the top 906 genes with the lowest p-values. The top canonical pathways (Fig. 5.21) are
shown. Among these pathways are synaptic long term potentiation and calcium
signaling pathways, both are comprised of numerous protein phosphatase subunit
genes.

Fig. 5.21 Top canonical pathways altered in KO PTZ. Blue bars indicate the negative logarithm
transformation of the fisher’s exact test p-values. Yellow dots indicate the ratio of genes in the dataset
over genes in the pathway. Only pathways with –log(p-value) > 2.72 are shown.
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5.5 Discussion
To date, several attempts have been made to investigate the transcriptome
profile alterations in kindling using global expression profiling techniques, mainly via
microarray. However, among the thousands of genes that have been identified to be
differentially expressed in all studies, only a small proportion (~3%) showed changes in
more than two publications 322. This could be due to the variation in kindling models
(electrical or chemical), stimulation of distinct brain sub-regions (hippocampus or
amygdala) or different treatment paradigm and animal species (mouse or rat). Most
importantly, significant variations exist in microarray studies even under the same
experimental conditions. Compared to the microarray technique, RNA-Seq data
generated from Illumina sequencing platform has been shown to be highly reproducible,
with relatively little technical variation 323. Therefore, in the present study I chose to use
next-generation sequencing technique to study transcriptome alteration.
RNA-seq analysis detected a significant upregulation of Tia1 mRNA levels in
knockout animals, regardless of their treatment group (Fig. 5.17). This observation is in
good agreement with a previous study 269 where TIA-1 mRNA was found increased in
spinal cord and cerebellum of TIA-1 knockout brain. In this study, TIA-1 oligonucleotides
covering exons 9–11 detected significant upregulation of expression, whereas
oligonucleotide corresponding to sequences at exon 4 was found to be absent from the
knockout samples, consistent with my finding that the peak corresponding to exon 4 of
TIA-1 mRNA is missing (Fig. 5.17). These results together are consistent with the
original report describing the generation of TIA-1 knockout mice stating that the
homologous recombination to delete exon 4 of TIA-1 mRNA resulting in shortened
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stable mRNA and absent TIA-1 protein 241. In other words, the mouse line is a protein
but not RNA knockout mutant. In addition, the increased expression of TIA-1 mRNA in
knockout transcriptome suggests that the mutant TIA-1 mRNAs escape from
surveillance mechanism in the cells (discussed in section 6.3.3).
TIA-1 is a key component in stress granule assembly. As a consequence, one
might expect that an alteration of expression levels of other SG components after the
loss of TIA-1 in the hippocampus. In cells undergoing different types of stresses, αsubunit of eukaryotic translation initiation factor 2 (eIF2α) was phosphorylated at serine
51 by various type of stress-activated kinases 237. Phosphorylation of eIF2α blocks
translation initiation by preventing formation of eIF2-GTP-Met-tRNAi ternary complex
and the further assembly of 43S pre-initiation complex. Instead of the ternary complex,
TIA-1 and other RNA binding proteins interact with mRNA in the 43S complex, resulting
in the formation of a non-canonical 48S complex that is translationally suppressed.
Meanwhile, self-oligomerization of TIA1 or other RNA binding proteins then promotes
the aggregation of these 48S complexes into stress granules. In the present study, eIF2
signaling pathway was significantly altered between wild-type and knockout
hippocampus. It is worth noting that the majority of these genes, including many
translation initiation factors and small ribosomal subunit genes, are slightly reduced in
their mRNA levels. It is possible that without TIA-1, a global translation disinhibition
occurs which then triggers a feedback regulation mechanism to down-regulate genes
that are associated with translational initiation. Moreover, although preliminary results
fail to detect stress granule formation in kindled brains (Fig.4.4 and 4.5), it would be
necessary to confirm whether stress granules are indeed formed in the process of
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kindling. However, it is worth mentioning that stress granule may be assembled without
eIF2α phosphorylation. For example, pharmacological inhibition of eIF4A inhibited
translation initiation and initiate stress granule assembly independently of eIF2α
phosphorylation324.
Other than altered expression in mRNA levels of genes from eIF2 pathway, there
was no obvious dysregulation for any other known SG components. Possible
explanations for this are: 1) the loss of TIA-1 might be compensated by expression
changes in other genes. Upregulation of related genes, such as the RBP TIAR, may
occur as a direct consequence of the loss of TIA-1 protein function (section 6.3.3); 2)
knockout of Tia1 may have resulted in changes on the localization of SG components
without influencing their expression levels; or 3) Tia1 deletion might only have an effect
on SG gene expression levels under acute stress, which was absent from the current
kindling model used in the study. Thus, I was unable to detect TIA-1-positive SG in
hippocampus of brains that undergone convulsive seizure activities (Chapter 3) or of
kindled brain (Chapter 4), suggesting kindling may not induce prolonged aggregation of
TIA-1 protein and other SG components (discussed in section 6.3.1).
Another important finding of the present study is that the vast majority of altered
transcripts are identified by the comparison between knockout group and wild-type
group, rather than by the comparison between saline and PTZ treated groups (Fig.
5.16). It is possible that the shortened 10-day PTZ injection paradigm is not sufficient
enough to induce transcriptome-wide alteration in the brains, especially considering that
we removed animals that had any convulsive seizures during the paradigm. Therefore,
knockout animals may already possess alterations in gene expression levels under
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basal condition. These alterations may have occurred during development and
contribute to the regulation of neuroplasticity under pathological conditions such as
epileptogenesis. Indeed, many of the altered transcripts that were identified in knockout
brains (Table 5.10) are important regulators of physiological and pathological brain
functions (discussed in section 6.3.3). For example, genes that regulate synaptic
neurotransmission such as Vamp2, Napb and Aak1 (described in detail in section 6.3.3)
were identified in the transcriptome analysis, implying a dysfunction in neurotransmitter
releasing and recycling. Alteration in mRNA expression levels of genes that regulate
cytoskeleton dynamics such as Ldb3 and Magi1 is consistent with previous findings that
TIA-1 proteins can function as long-term regulators of the β-actin mRNA metabolism in
mouse and human cells250. This result suggests the role of TIA-1 in synaptic plasticity
and/or axonal cytoskeleton rearrangement. Indeed, disruption of axonal cytoskeletondependent processes has been identified in many neurodegenerative diseases and
affects axonal transport, outgrowth, targeting and synapse functioning325.
In conclusion, my data showed that loss of TIA-1 in mice led to altered
expression levels of mRNA processing machinery, of specific eIF2 pathway
components, and of various regulators of physiological and pathological brain functions.
These findings may be relevant to elucidate the downstream regulators of TIA-1 in
regulating epileptogenesis and in aberrant RNA processing mediated via TIA-1 in motor
neuron diseases and neurodegenerative diseases.
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CHAPTER 6 Discussion
6.1 Main findings
In the present study, COX-2 mRNA was found to be highly expressed in cerebral
cortex (Chapter 2) in vivo and in cultured cortical neurons in vitro. In addition,
expression of COX-2 mRNA in cortical neurons correlated with neuronal activity and
with NMDAR expression. NMDAR activity was found to be required for maintaining
constitutive COX-2 mRNA levels, as well as for maintaining COX-2 mRNA stability. It is
hypothesized that activity-dependent expression of COX-2 in neurons is regulated by
RNA binding proteins. In particular, it is posited that loss of TIA-1, an RNA binding
protein that suppresses COX-2 mRNA translation by binding to its 3’UTR, will lead to
enhancement of COX-2 expression in neurons.
However, through the course of studying whether TIA-1 regulates COX-2
expression and in turn modulates seizure threshold in the brain (Chapter 3), I did not
observe a changed COX-2 protein level in TIA-1 deficient brain under basal conditions,
suggesting that TIA-1 does not contribute to regulation of COX-2 protein expression in
neurons. The acute PTZ-induced seizure threshold was also unchanged in mice lacking
TIA-1 protein, indicating that this RNA binding protein does not influence the innate
seizure threshold. However, I discovered novel roles of TIA-1 in brain plasticity during
epileptogenesis (Chapter 4). Mutant mice lacking TIA-1 exhibited significantly higher
kindling incidence relative to their wild-type littermates (+/+). Moreover, a higher
mortality rate was associated with convulsions during kindling acquisition in -/- mice
relative to +/+. Interestingly, whereas a lower kindling dose of PTZ yielded similar
kindling incidences, enhanced mortality was still detected in mutant vs. wild-type mice.
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Together, these results suggest that TIA-1 functions to antagonize the progressive
changes in neuroplasticity associated with kindling development.
Finally, transcriptome alteration in TIA-1 knockout brains after a 10-day PTZ
injection paradigm was analyzed (Chapter 5). After correction for biased expression of
ChP genes, I found that the majority of differentially expressed genes between all
experimental groups were between knockout vs wild-type genotypes, rather than
between PTZ vs saline treatment. Moreover, transcripts from eIF2 signaling pathway
are among the most significantly altered pathways in knockout transcriptome.
6.2 Mechanisms that regulate neuronal COX-2 expression
This section is devoted to discussing the question as to how COX-2 expression
in neurons may be regulated, specifically via NMDAR activity.
6.2.1 Evoked and spontaneous release of glutamate in neurons
The amino acid, glutamic acid, is the primary excitatory neurotransmitter of the
CNS. It is vital to the transmission and processing of information, and consequently, to
key functions of the CNS, including cognitive processes, sensory perception, affective
behaviors, and motor control.326-328 Glutamate is stored in synaptic vesicles. Some of
these vesicles are found in active zones located in the axon termini of glutamatergic
neurons. Active zones are specialized structures where activity-dependent exocytosis of
vesicles occurs. These zones are juxtaposed with dendritic protrusions, or spines, on
the target neuron.329 Spines are dynamic structures that harbor postsynaptic densities
(PSDs),330,331 the electron dense signaling scaffolds where glutamate receptors are
concentrated across from the active zones. Together, the axon termini and dendritic
spines form the excitatory synapse between the presynaptic and the postsynaptic
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neurons, respectively. Activity-dependent release of glutamate triggered by action
potentials in the presynaptic neuron activates ionotropic glutamate receptors in the PSD
of the postsynaptic neuron. Key among these is the NMDAR subtype.332 This receptor is
a heteromeric complex composed primarily of GluN1 (NR1) and GluN2 (NR2), which
form a ligand- and voltage-gated ion channel.333 NMDAR activation allows Na+ and Ca2+
entry into the cell down their concentration gradients.334 This contributes to synaptic
transmission by producing an excitatory postsynaptic potential (EPSP) which makes the
postsynaptic neuron more likely to fire an action potential. Thus, the influx of the ions
that causes EPSP is called an excitatory postsynaptic current (EPSC). The increase in
intracellular Ca2+ can also drive persistent changes in the physiology of the
synapse.335,336
Although action potential-driven evoked neurotransmitter release as described
above has been extensively studied, the release of neurotransmitters from presynaptic
cells can be spontaneous and does not require action potential in presynaptic neurons,
a mechanism that is poorly understood functionally and mechanistically. This so called
spontaneous neurotransmitter release typically occurs with a low probability when a
single vesicle is released into the synapse, generating miniature EPSPs (mEPSPs). The
quantal nature of synaptic transmission was revealed first by Bernard Katz at
the neuromuscular junction in 1951337.
6.2.2 Functional roles of spontaneous glutamate release
Whether this extremely low-frequency communication between neurons carries
information or merely represents “noise” has been debated since its discovery. Recent
studies have provided substantial evidence that these spontaneously release events
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can indeed modulate or even drive action potential firing in neurons, similar to their
evoked counterpart. In rat cerebellar stellate cells, individual quanta strongly influences
firing338. Specifically, an excitatory quantum increases the peak firing rate of these
neurons, and the sizes of quanta are positively correlated with their ability to rapidly
trigger an action potential. Similarly, in hippocampus, a prolonged activation of nicotinic
acetylcholine receptors at presynaptic mossy fibers caused a burst of high-frequency
and large-amplitude glutamatergic mEPSCs in postsynaptic pyramidal cells339. These
large amplitude mEPSCs are consistent with the synchronized release of glutamate
from the mossy fiber terminals and are sufficient to drive the postsynaptic pyramidal cell
above its firing threshold. These results support the hypothesis that spontaneous
neurotransmission can actually contribute to electrical signaling in neuronal networks. In
addition, an increasing number of studies have also revealed that spontaneous release
events trigger biochemical signaling leading to development of synaptic network and
local protein synthesis in dendrites, thus regulating synaptic plasticity. For instance, in
CA1 pyramidal cells, blocking both spontaneous and evoked glutamate release led to
loss of dendritic spines, an effect that was not seen when blocking evoked glutamate
release alone340. Moreover, AMPA receptor activation by spontaneous vesicular
glutamate release is sufficient to maintain dendritic spines. Interestingly, blocking
evoked neurotransmitter release in mice did not impair normal brain development 341.
However, deletion of Munc18-1 protein in mice, resulting in complete loss of
neurotransmitter secretion including spontaneous release of synaptic vesicles341, led to
wide spread neurodegeneration after assembly of synaptic network, suggesting that the
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maintenance of synaptic connectivity requires spontaneous secretion of
neurotransmitters.
Spontaneous neurotransmission not only contributes to both the firing of action
potentials and the formation of synaptic network, but also activates different
downstream signaling pathways compared to evoked neurotransmission. In cultured
hippocampal neurons, prolonged blocking of all neurotransmission diminished protein
synthesis in dendrites, whereas blocking of only the spontaneous neurotransmission
enhances protein synthesis342. This suppression of miniature synaptic events on local
protein synthesis in neurons is rapid and can occur in both dendritic and somatic
compartments, revealing its role in the acute regulation of local dendritic protein
synthesis in neurons. Furthermore, it has also been shown that spontaneous
neurotransmitter release, rather than evoked release, specifically suppressed dendritic
protein translation by phosphorylating and inactivating a critical catalytic factor for
ribosomal translocation, eukaryotic elongation factor-2 (eEF2), during protein
synthesis343.
6.2.3 Regulation of COX-2 expression by spontaneous glutamate release via
NMDAR activity, a hypothesis
The Results described above raise the question as to whether signaling by
mEPSCs mechanistically differs from that triggered by evoked release of glutamate.
Studies have shown that differential regulation of synaptic plasticity by evoked or
spontaneous neurotransmission may be mediated by differential glutamate receptor
activation. It has been shown that spontaneous neurotransmission activated a distinct
pool of NMDARs and/or AMPAR with unique physiological functions compared with
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receptors activated via evoked neurotransmission344,345. For example, application of
NMDAR antagonist MK-801 at rest led to rapid reduction of NMDAR-mediated
mEPSCs, which did not significantly hinder receptor activation in response to
subsequent evoked release, suggesting that evoked and spontaneous release of
glutamate activate largely non-overlapping populations of NMDAR345. Another example
is that brief blockade of NMDAR-mediated miniature synaptic events induced a protein
synthesis-dependent synaptic insertion of AMPARs that lack the GluR2 subunit344.
In summary, spontaneous glutamate release regulates local gene expression in
postsynaptic dendrites, possibly via targeting a distinct group of NMDARs. Linking back
to my findings in Chapter 2 that tetanus toxin blocked neither constitutive nor activityinduced COX-2 mRNA levels and that NMDAR activity was both sufficient and required
in regulating COX-2 mRNA levels, it is entirely possible that spontaneous synaptic
activity regulates basal and activity-induced neuronal COX-2 mRNA expression via
activating NMDAR. Whether this regulation is on the transcriptional level (mRNA) only
or on the post-transcriptional level (protein) is not known as COX-2 protein expression
was not measured herein. However, based on known distribution profile of COX-2
mRNA and protein, it is reasonable to hypothesize that spontaneous synaptic activity
regulates both. Under basal condition in glutamatergic neurons, COX-2 protein was
primarily detected in cell soma and dendrites compared to synapses346. In other studies,
COX-2 protein has been shown to be co-localized with postsynaptic markers but not
presynaptic markers, suggesting the presence of COX-2 protein in postsynaptic
dendritic spines74,347. Interestingly, it has been shown that mPGES-1 and mPGES-2
were co-localized with the same postsynaptic marker346, suggesting that these
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sequential biosynthetic enzymes are present in the same subcellular compartment and
together regulate PGE2 production in a tight and efficient manner. An unanswered
question is the discrepancy between COX-2 mRNA and protein subcellular distribution.
COX-2 mRNA expression levels are substantially elevated by convulsive stimuli in
hippocampus348. However, the induced COX-2 mRNA is confined to the cell bodies.
Among the same cell population, it has been shown that COX-2 protein was induced by
convulsive stimuli in the dendritic molecular layer of DG66. These results suggest that
activity-induced COX-2 protein is most likely translated in cell bodies and that dendritic
COX-2 protein may be products of selective transportation. Although this remains to be
shown, it is highly possible since dendritic COX-2 protein was detected near
endomembranes in dendritic spines346.
6.3 The role of TIA-1 in regulating epileptogenesis
As discussed above, neuronal COX-2 expression may be subjected to NMDAR
activity-dependent regulation via spontaneous release of glutamate. This regulation
could be at the transcriptional level, or on post-transcriptional level via mediating local
protein synthesis or more likely, selective transportation of COX-2 protein to dendrites.
What may be the downstream regulators of NMDAR activity-dependent COX-2 protein
expression remains a question.
RBPs are regulatory proteins that are involved in pre-mRNA processing,
transport, stability and translation (section 1.3). In fact, it has been shown that many
RBPs are direct mediators of gene expression in response to NMDAR activity (section
6.4.5), raising the hypothesis that the expression of COX-2, among other genes, are
subjected to the regulation of RBPs under the control of NMDAR. One of the RBP that
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was examined in the present study is TIA-1. Although TIA-1 does not seem to regulate
neuronal COX-2 protein expression (Chapter 3), I discovered its novel role in
epileptogenesis.
In the past, evidence has suggested that under pathological condition such as
epileptogenesis, RBPs may contribute positively or negatively towards disease
progression. Such examples include the Hu/Elavl family of RBPs. Acute change of Hu
family proteins and their targets has been found using different seizure models. Brain
HuR/Elavl1 and HuD/Elav4 levels were found increased 24 hours after pilocarpineinduced status epilepticus, most prominently in hippocampus 349. HuD mRNA levels
increased dramatically in hippocampus 24 hours after kainic acid injection, coupled with
an increased mRNA level of GAP-43, an important protein in synaptic remodeling 350.
This increased GAP-43 level was blocked in HuD knockout brain. Interestingly,
HuB/Elavl2, on the contrary showed a decreased protein level in hippocampus acutely
after kainic acid induced seizure, along with a decreased GAP-43 mRNA350. These
results suggest a regulatory role of Hu protein on GAP-43 mRNA levels after convulsive
challenge. In hippocampus, hundreds of putative ligands of HuR have been identified
with some showing differential expression acutely after PTZ-induced seizures 351.
Among transcripts that show differential expression levels in DG of mice with
spontaneous seizures induced by unilateral kainic acid injection, there was a significant
overlapping of known targets of HuR and HuD352. Interestingly, many transcripts
showed enhanced expression or altered polyadenylation profile, correlating with the role
of HuD in stabilizing mRNAs and regulating their polyadenylation. Moreover, altered
responses to convulsive stimuli has been noted in knockout animals of Hu genes.
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Conditional knockout of HuR in hippocampal neurons showed diminished kainic acidinduced seizure responses but exacerbated neurodegeneration after glutamatergic
excitation353. Lack of HuC/Elavl3 gene led to spontaneous epileptic seizure activity
represented by bilaterally synchronous sharp cortical spike discharges measured in
electroencephalographic recording 354. HuD knockout mice showed increased
susceptibility to auditory-induced seizures 355. In summary, the Hu RBP family plays an
important role in seizure generation, probably through regulating immediate early genes
or genes that control synaptic plasticity and thus seizure threshold.
Although evidence exists that RBP such as Hu/Elavl family regulates seizure
threshold, deletion of TIA-1 does not seem to alter acute seizure generation (Chapter
3). Rather, TIA-1 deletion leads to increased risk of kindling acquisition. The following
sections discuss the possible mechanisms through which deletion of TIA-1, an
important stress granule protein and essential RNA binding protein, may lead to altered
progression of epilepsy.
6.3.1 The roles of stress granule in seizure generation and epileptogenesis
TIA-1 is best known for its role under conditions of cellular stress, during which it
facilitates formation of stress granules (SGs). SGs are large complexes of proteins and
translationally silent mRNAs that reprogram translation under cellular stress conditions
254

. SGs are thought to be an adaptive response to pathological conditions where cells

may be subjected to oxidative or endoplasmic reticulum stress 356. TIA-1 plays a
prominent role in stress granule formation in mammalian cell lines 237,254. TIA-1 and
stress granule formation are associated with a number of stress conditions in neurons
as well. This includes conditions of acute oxidative and endoplasmic reticulum stress
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356,357

as well as in neurodegenerative models, where stress granule formation

progresses with the severity of the disease and contributes to neurodegeneration 94,266.
In the CNS, TIA-1 mediates the stress responses associated with brain
ischemia, tauopathies, and other neurological disease models 94,262,266,267.
It is known that oxidative stressors such as arsenite induce SGs in cultured
hippocampal neurons 358. In the meantime, oxidative stress, measured by increased
lipid peroxidation and altered activity of anti-oxidant enzymes such as superoxide
dismutase (SOD), has been found after acute seizures and in kindled brains 293-296.
Thus, it becomes an important question that whether oxidative stress and stress
granules contribute to the progression kindling. To date, the assembly of SGs in the
development of kindling has not yet been elucidated. In the present study, we failed to
detect TIA-1-positive SG in hippocampus of brains that undergone convulsive seizure
activities (Chapter 3) or of kindled brain (Chapter 4), suggesting kindling does not
induce prolonged aggregation of TIA-1 protein. However, it would be necessary to
examine SG formation using other SG markers, on a more carefully design time frame
after acute seizure, to confirm whether seizure activity is sufficient to induce SGs. It
should also be noted that neither PTZ-induced acute seizures nor kindling are
associated with a frank neuroinflammatory response or overt neurodegeneration 181. It is
possible, however, that TIA-1 and SGs contribute to other models of temporal lobe
epileptogenesis, such as that induced by status epilepticus, which do involve a
prominent neuroinflammatory response and hippocampal sclerosis.
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6.3.2 Mechanism of TIA-1 deletion-mediated enhanced mortality during kindling
In the present study, a higher mortality rate was associated with convulsions
during kindling acquisition in -/- mice relative to +/+. Whether any TIA-1 binding target
are relevant to the role of TIA-1 in suppression of lethality during kindling acquisition will
be the focus of future research. Alternatively, TIA-1 has an extensive proteome, binding
to many proteins in the normal brain 267. It is possible that protein-protein interactions
may be significant. Tau, a microtubule assembly and stabilizing factor 359, interacts with
TIA-1 and influences its binding to a subset of proteins in the TIA-1 proteome 267.
Interestingly, tau has been implicated in the hyperexcitability and lethality associated
epileptogenesis in mice lacking Kcna1 360. Thus, deletion of tau in these mice
attenuates both phenotypes. This raises the possibility that TIA-1 may function to
suppress tau function in kindling-associated lethality. Additionally, it will be important to
identify the location of action of TIA-1. If it is in the brain, in what structure (i.e.,
brainstem).
Regardless of the molecular and cellular mechanism, the role of TIA-1 in
suppression of lethality during epileptogenesis suggests a heretofore unrecognized
molecular influence in Sudden Unexpected Death in Epilepsy (SUDEP). This phenotype
resembles the Kcna1 mutation mouse model of epilepsy and SUDEP 360. Lethality in
this model begins early in the third week of life and progresses through early adulthood.
This appears to corresponded to the period of epileptogenesis, as spontaneous
seizures develop. It is relevant to mention that all lethality during kindling acquisition in
TIA-1 deficient mice occurred during tonic-clonic seizure events, suggesting that
convulsive seizures were the trigger. In wild-type animals during kindling paradigm,
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tonic hind limb extensions were also observed but are rarely followed by death,
suggesting that increased mortality may not due to an enhanced seizure activity in
knockouts, but rather due to altered downstream pathway induced by spreading seizure
activity. Cardiac abnormalities including tachycardia and bradycardia are often induced
in seizures. Meanwhile, intrinsic heart abnormalities such as QT prolongation and heart
rate variability, in turn, were proposed to contribute to SUDEP361. Tia1-/- animals are
initially reported with a high macrophagocytic TNFα expression and a higher lethality
rate upon LPS-induced endotoxin shock 241. Since both LPS and TNFα have been
shown to induce cardiodepression 362, it is possible that lack of TIA-1 in heart leads to
cardiac dysfunctions which contribute to lethality in both endotoxin shock and our
kindling model. Indeed, TIA-1 deletion in heart has been associated with altered
contractile performance of cardiomyocytes 301, although in this particular case TIA-1
deletion resulted in better recovery from ischemia.
6.3.3 Possible downstream effectors of TIA-1 deletion-mediated phenotypes in
kindling
To identify possible downstream regulators of TIA-1 deletion-mediated
phenotypes in kindling progression, kindling-induced transcriptome alterations in -/- and
+/+ hippocampi were examined by RNA sequencing analysis. Results confirmed that
exon 4 of TIA-1 coding sequences is missing in the knockout transcriptome. However,
full length TIA-1 mRNA was detected in knockout, with an increase in TIA-1 mRNA
levels. The existence of TIA-1 mRNAs in knockout transcriptome suggests they are not
subjected to surveillance mechanisms such as nonsense-mediated decay (NMD,
described later in section 6.4.5.4). NMD gets rid of aberrant mRNAs that have acquired
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premature translation termination codons (PTCs) 363. PTCs are likely generated by
faulty or alternative splicing. However, preliminary results using quantitative
visualization of RNA sequencing read alignments (data not shown) showed that despite
the lacking of exon 4, TIA-1 mRNAs in knockout remain their normal splicing patterns,
suggesting that they may not harbor PTCs and thus are not subjected to NMD. In
addition, it is known that not all PTCs trigger NMD 363. Nevertheless, the mechanism
through which mutant TIA-1 mRNAs escape surveillance mechanisms is not fully
understood. On the other hand, increased TIA-1 mRNA levels in knockout transcriptome
could be explained by genetic compensation in response to gene knockout.
Upregulation of related genes following a gene knockout may be a direct consequence
of the loss of protein function. In fact, evidence exist that TIA-1 and TIAR are able to
utilize feedback regulation to adjust the expression levels or their own. It has been
shown that overexpression of TIA-1 and TIAR induces splicing of TIA-1 mRNA using
novel alternative splicing sites, possibly resulting in frame shift or nonsense-mediated
decay of TIA-1 mRNA 238. In addition, TIAR depletion results in increased ratio of TIA1b/a, while TIA-1b is believed to encode the active form of TIA-1 that has enhanced
splicing stimulatory activity 240. Whether these up-regulated TIA-1 mRNAs have
biological consequences remains elusive. Studies on other genes reveals that mutated
mRNAs that evade surveillance can possess biological functions. In the case of β-globin
gene, nonsense mutations occurred within its last exon do not activate NMD and yield a
stable mRNA that directs the synthesis of C-terminally truncated polypeptides. These
aberrant translation products act in a dominant negative fashion, resulting in a rare form
of symptomatic heterozygous β-thalassemia (a blood disorder that reduces the

173

production of hemoglobin)364. To date, however, it is not known that whether TIA-1
mRNA, rather than protein, is participating in any biological event.
In addition to altered expression levels of TIA-1 mRNA itself in knockout
transcriptome, a global reduction of mRNA levels was seen in knockouts. Specifically,
among all differentially expressed transcripts between knockout and wild-type groups,
the majority of these transcripts are found to be reduced in knockout transcriptome. This
phenomenon is likely due to the role of TIA-1 and SG in stabilizing associated mRNA
targets. During cellular stress, protein synthesis is severely reduced and bulk mRNA is
recruited to SGs. Depletion of proteins that are stably associated with SGs during its
assembly enhances the degradation of target mRNAs365. This finding indicates that the
stabilization of mRNAs during cellular stress is facilitated by the formation of stable
mRNPs, which may be impaired in TIA-1 knockout brain. If this is true, however, the
involvement of SG in acute seizure generation and epileptogenesis needs to be
thoroughly investigated to identify when and where SGs are formed and how they may
contribute to mRNA stability under these pathological conditions.
Notably, a vast majority of altered transcripts in knockout hippocampus are
identified by the comparison between knockout group and wild-type group only. This
finding suggests that knockout animals possess alterations in gene expression levels
that are already occurred under basal condition. Many of these genes have been found
in brains and are important regulators of physiological and pathological brain functions.
For example, AP2 Associated Kinase 1 (Aak1) gene encodes a member of the Prk/Ark
family of serine/threonine kinases, which plays an essential role during receptormediated endocytosis. The formation of coated vesicles is an essential step for
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receptor-mediated endocytosis. Two oligomeric protein complexes, clathrin and the
adaptor protein 2 (AP2) complex, constitute the major coat proteins of these endocytic
vesicles. AP2 complexes are recruited to plasma membrane and interact directly with
motifs on the cytoplasmic domains of receptors366. Further assembly of clathrin into this
complex then initiates the invagination of plasma membrane and facilitates vesicle
formation 367. In non-neuronal cells, AAK1 has been shown to directly bind to clathrin
and AP2 complex and specifically phosphorylates the μ subunit of the AP2 complex in
vitro368. The phosphorylation results in suppressed internalization membrane proteins. It
is intriguing that in hippocampal neurons, AAK1 was found to be enriched at presynaptic
terminals368, suggesting that AAK1 may play a regulatory role in recycling of synaptic
vesicles after neurotransmission. In addition, AAK1 contributes to dendrite growth
regulation in hippocampal neurons by limiting the branching and length of dendrites369.
In the present study, a decrease in AAK1 mRNA (~1.2 fold) was seen in TIA-1 knockout
hippocampus compared to wild-type. In the meantime, other regulators of synaptic
neurotransmission were also identified in the transcriptome analysis including Vamp2
and Napb (both are slightly but significantly increased in knockout brains), implying a
dysfunction in neurotransmitter recycling and releasing.
6.4 Limitations and future directions
6.4.1 To investigate how neuronal activity regulates cPLA2α mRNA levels
Throughout the course of examining neuronal activity-mediated regulation of
COX-2 expression, it is intriguing to identify a correlation between decreased neuronal
activity and increased mRNA levels of cPLA2α. Specifically, antagonism of NMDAR
activity resulted in increased mRNA levels of cPLA2α in PNCs (Chapter 2), whereas
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cPLA2α mRNA expression levels decreased significantly in hippocampus 3 hours after
convulsive stimuli (Chapter 3). Phospholipase A2 enzymes encompass a superfamily
that hydrolyze the sn-2 fatty acyl bonds of phospholipids to yield fatty acids and
lysophospholipids. The Ca2+-dependent and cytosolic isoform cPLA2α has been shown
to regulate NMDAR-mediated AA release71. Either blocking cPLA2α or NMDAR activity,
or removing extracellular Ca2+ diminishes NMDA-induced prostaglandin production. Not
only the activity of cPLA2α is coupled to NMDAR, its expression levels has also been
shown to be correlated with increased neuronal activity. Protein expression levels of
cPLA2α are found to elevate in hippocampal neurons in models of epileptogenesis196.
mRNA expression levels of cPLA2α has also been found to increase after repeat
electroconvulsive stimuli in hippocampus370. Notably in both cases, expression levels
are positively correlated with neuronal activity, in contrary to the negative correlation
found in my results. This discrepancy is likely explained by the difference in treatment
paradigm. It is hypothesized that neuronal expression levels of cPLA2α are enhanced by
prolonged elevation of neuronal activity, whereas acute increase of neuronal activity
activates the enzyme, but in the meantime, down-regulates its expression as a
feedback regulation in response to increased production of AA. A previous study
measured cPLA2α expression in hippocampal tissue within 24 hours after a single
administration of kainic acid did not see significant change in either protein or mRNA
expression levels of cPLA2α165, further support the notion that repeat convulsive stimuli
is required to up-regulate cPLA2α expression. In future studies, it is necessary to
determine the precise window of acute alteration in both protein and mRNA expression
levels of cPLA2α, and whether this acute alteration is dependent on NMDAR activity.
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6.4.2 To identify COX-2 binding proteins using a novel approach
An ARE located within the proximal region of COX-2 3’UTR has been identified
as a key RBP recognition site and a number of mRNA RBPs are known to bind to and
regulate COX-2 mRNA stability or translation 89. In the present study, an attempt was
made to identify neuronal specific RBPs that are able to bind COX-2 3’UTR and
regulate its stability or translation via an NMDAR activity-dependent mechanism.
Unfortunately, the specificity and abundancy of proteins that were pulled down by an
RNA probe of the proximal region of COX-2 3’UTR were not sufficient for downstream
high throughput analysis. Although the same approach has been used to successfully
extract COX-2 mRNA binding proteins in macrophages previously84, it was not efficient
in extracting RBPs in neurons herein possibly due to an altered or missing secondary
structures in the short RNA probe compared to the native neuronal-specific COX-2
mRNA, as intrinsic RNA secondary structure has been suggested to affect the binding
of RBP to their target, such as in the case of HuR371. Therefore, an alternative future
approach is proposed herein. This approach is similar to that used by others372 and was
based on mRNA tagging technique using the MS2 bacteriophage system373. In this
method, the bacteriophage MS2 coat protein (MCP) binds to a unique RNA hairpin
sequence (MS2-binding site) which can be cloned into the mRNA of choice. These
mRNAs, when transcribed in cells, can then be pulled-down with MCP proteins,
preferably fused with tags such as fluorescence or enzymes. Briefly, MS2-MBP
(Maltose binding protein) fusion protein in plasmid will be expressed in Escherichia coli
(E. coli) and purified on an amylose column. A construct containing full length COX-2
3’UTR will be cloned into the 3’ end of the luciferase gene in a luciferase vector. Six
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tandem MS2 stem loops will be cloned out from a MS2-containing plasmid by PCR and
inserted between the 3’ end of the luciferase coding sequence and the beginning of
COX-2 3’UTR fragment. Cultured primary cortical neurons will be transfected with the
COX-2 3’UTR construct. Mock transfected cells will serve as the negative control. Cells
will then be lysed and supernatant lysate will be collected and quantitated. MS2-MBP
fusion protein will be added to pre-washed amylose beads and allowed to bind.
Immobilized MS2-MBP beads will then be added to cell lysate, incubated and washed
extensively before sending for liquid chromatography–tandem mass spectrometry
(LC/MS/MS) analysis. By using this approach, RBPs that bind to endogenous full-length
COX-2 3’UTR may be identified with a better specificity.
6.4.3 To investigate TIA-1 function in astrocytes
Results in chapter 4 showed that TIA-1 deletion leads to enhanced kindling
acquisition (Fig. 4.1) and increased mortality in kindling model (Fig. 4.3). In addition, no
trace of TIA-1 containing SG was found in neurons in kindled brain (Fig. 4.4 and 4.5),
suggesting the negative phenotypes in Tia1-/- may not result from neuronal deletion of
TIA-1. In fact, TIA-1 was found in cultured cortical astrocytes and in astrocytes within
hippocampus (Fig. 3.1 and 3.5), suggesting a functional role of TIA-1 in astrocytes.
Morphological changes marked by increased GFAP and vimentin immunereactivity in
astrocytes was observed in epileptic patients and animal models for epileptogenesis
including kindling 19. The effect of reactive astrocytes on seizure activity is still under
debate. Ablation of reactive astrocytes in a model of traumatic brain injury resulted in
markedly worsened neural damage and increased leukocyte infiltration 374, suggesting
protective role of reactive gliosis. On the other hand, activated glia may exacerbate
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seizure activity through increased production of cytokines, through reduced glutamine
synthase which in turn leads to accumulated extracellular glutamate, and through
impaired water redistribution 375. In future studies, it will be necessary to determine if
astrocytic TIA-1 plays a role in epileptogenesis progression. It would also be necessary
to investigate the genome wide alteration after TIA-1 deletion in neurons and astrocytes
as two separate populations.
6.4.4 Limitations of transcriptome analysis in TIA-1 deleted brains
In the present study, it was found that three knockout animals that received PTZ
exhibit extremely high level of ChP genes. Although it is possible that the unexpected
abundance of the ChP-specific genes is an artifact introduced by tissue preparation, the
other possibility that it indeed has a biological basis associated with TIA-1 deletion
cannot be ruled out. ChP epithelial cells are known to have a primary role in the
secretion of CSF376, as well as mediating the isolation between CSF and blood albeit
allowing the transportation of small molecules. Transport across the ChP epithelium
extends beyond ions to proteins, nutrients and metabolic precursors. Importantly, ChP
epithelial cells are known to mediate uptake of prostaglandins. Locally produced PGE2
are taken by ChP epithelial cells via organic anion transporter 3 (OAT3), acting as a
cerebral clearance pathway377. Myo-inositol is another molecule that is actively
transported across ChP epithelium and serves as the precursor for many signaling
molecules. Knockout of potassium channel subunits Kcne2, which regulates the myoinositol transportation, leads to low levels of myo-inositol in the CSF and increased
susceptibility to stress and seizures 378. Although numerous case reports 379 suggest
that choroidal fissure cyst, a cyst at the level of the choroidal fissure (where ChP is
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attached to) is associated with seizure activities, very few study investigate the function
of ChP in seizure generation and epileptogenesis or seizure-induced gene regulation in
ChP. Indeed, chronic stress was able to induce alteration of many ChP genes380 and
although CPECs normally have a slow turnover rate, they were able to proliferate in
response to external stimuli such as injury and/or growth factors381. In future, it will be
necessary to confirm whether morphological alteration or gene expression profile
change were induced by kindling in TIA-1 knockout ChP.
TIA-1 has been shown as a multi-functional RBP that regulates alternative
splicing, mRNA stability as well as translation. In the future, it would be necessary to
revisit the transcriptome data to investigate the differential expression of alternative
spliced transcripts that are potentially targets of TIA-1 regulation. On the other hand,
proteome analysis will be performed to determine the role of TIA-1 in global translation
of mRNA in the brain during epileptogenesis.
6.4.5 Regulation of neuronal gene expression via NMDAR activity-responsive
RNA binding proteins
Although TIA-1 does not appear to regulate COX-2 protein expression in
neurons, other RBPs have been implicated in the control of activity-dependent local
translational changes mediated by activation of NMDAR, thus become potential targets
in the future. The following sections will focus on the mRNA granules containing
cytoplasmic polyadenylation element binding proteins (CPEB), zipcode binding protein 1
(ZBP1), Smaug1 or XRN1. These four proteins, among several other RBPs are
responsive to NMDAR activity and can regulate mRNA silencing, transportation and/or
translation.
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6.4.5.1 Cytoplasmic polyadenylation element binding proteins (CPEB)
Cytoplasmic polyadenylation is one of many cellular mechanisms that modulate
mRNA poly(A) tail length and thus translation. Cytoplasmic polyadenylation is regulated
by the cytoplasmic polyadenylation element (CPE) binding proteins, or CPEBs, which
recognize the consensus CPE sequence (UUUUUAU) in mRNA 3’- untranslated regions
(UTRs). The CPEB RBP family has four members in vertebrates (CPEB1–4). All CPEB
proteins have two RRMs and two zinc fingers, with CPEB1 (will be referred to as CPEB
herein) showing less structural similarity to CPEB2-4. It is the only CPEB member that
presents a high affinity to CPE.382 This biochemical discrepancy suggests nonredundant function of CPEBs, which was confirmed by studies using knockout mouse
lines383-385.
In Xenopus oocytes, elongation of poly(A) tails of masked mRNAs promotes their
translation. This happens when cells re-enter meiotic division from an arrested stage, a
process where the key machinery of cytoplasmic polyadenylation is identified (reviewed
elsewhere386,387). Briefly, in the nucleus, target pre-mRNAs contain a CPE, which is
within close proximity upstream of the AAUAAA poly(A) sites. CPEB and cleavage and
polyadenylation specificity factor (CPSF) bind to CPE and AAUAAA respectively and
escort mRNA during nucleus exportation. In cytoplasm, the complex recruits poly(A)
polymerase germline development 2 (Gld2) and the deadenylating enzyme, poly(A)
ribonuclease (PARN), where PARN activity dominates over Gld2 leading to shortening
of the poly(A) tail. CPEB also binds Maskin, which prevents the assembly of the
translation initiation complex. Following hormone stimulation, the kinase Aurora A is
activated and phosphorylates CPEB, leading to expulsion of PARN and elongation of
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poly(A) tail by Gld2. ePAB, a variant of poly(A) binding protein then replaces Maskin
and promotes translation initiation. This CPEB-mediated polyadenylation and translation
has been found for many CPE-containing mRNAs during oocyte maturation.388,389
CPEB, along with most of the Xenopus cytoplasmic polyadenylation machinery
components were later found in neurons.390-392 Maskin was not found in neurons, but its
function was largely duplicated by neuroguidin (Ngd),393 a CPEB binding protein that
also inhibits translation initiation.
In non-neuronal cells, CPEB has been found in both SGs and P-bodies,
potentially acting as a link between the dynamic transitions of the two RNA granules394.
CPEB mRNA was also found in the normal rodent brain, where it is conspicuously
enriched in neurons of the hippocampal formation and cortical layers 2/3, 5 and 6, and
mitral and Purkinje cells of the olfactory bulb and cerebellum, respectively.395 In
glutamatergic excitatory neurons, CPEB-containing RNP granules were found in
dendrites and are enriched in PSDs.390,391,396
In neurons, CPEB activity is tightly regulated by NMDAR activity. The association
between NMDAR activity and CPEB function was first described in CaMKIIα
(Ca2+/calmodulin-dependent protein kinase IIα) mRNA polyadenylation in synaptosome
preparations from cultured rat hippocampal neurons.391 Glutamate stimulated
phosphorylation of CPEB in synaptosomes, which was blocked by inhibition of NMDAR,
but not by other glutamate receptors. This is linked to NMDAR activation since direct
activation of NMDAR resulted in CPEB phosphorylation and CaMKIIα mRNA
polyadenylation. CPEB-dependent dendritic transportation of CaMKIIα mRNA has been
found to occur before its polyadenylation,397 with the presence of CPE in mRNA being
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both necessary and sufficient for this process. Moreover, CPEB-containing particles
contained dynein and kinesin and were transported in a microtubule-dependent manner
at an average velocity of 4–8 μm/minute. These results suggest that CPEB escorts
dormant mRNAs to dendrites where they are later released for translation by NMDAR
activation. The mechanism of NMDAR/CPEB-dependent regulation of polyadenylation
was well characterized in hippocampal neurons.393 NMDAR activation induced CPEB
phosphorylation, dissociation of PARN, and dendritic mRNA polyadenylation. It also
induced Gld2-dependent polyadenylation and translation. Interestingly, CPEB interacted
with the mRNA of NMDAR subunit GluN2A through a 3’ CPE in its 3’UTR and regulated
its dendritic localization398. These findings imply the association between CPEBdependent polyadenylation and synaptic plasticity through regulation of NMDAR subunit
composition. This hypothesis was further confirmed in cultured rat hippocampal
neurons,398 where glycine increased the surface expression of GluN2A-containing
NMDAR via a protein synthesis-dependent mechanism.
The NMDAR activity-dependent regulation of important synaptic mRNAs
including CaMKII and NMDAR subunit provides the molecular basis for earlier findings
of altered neural plasticity in CPEB knockout animals.399-402 In neuroscience, a wellestablished measurement for synaptic plasticity is the persistent strengthening (longterm potentiation, LTP) or weakening (long-term depression, LTD) of synapses induced
by high (LTP) or low (LTD) frequency trains of stimuli on pre-synaptic compartment.
LTP or LTD induced within the Schaffer collateral-commissural pathway (SCCP) of the
hippocampus is NMDAR-dependent. Mice lacking CPEB had deficiencies in LTP but
LTD in SCCP399 appeared facilitated. Although maintenance of LTP/LTD generally
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requires protein synthesis, some forms of LTP/LTD induced by distinct stimulation
patterns do not. Interestingly, CPEB gene deletion only altered selected forms of protein
synthesis-dependent LTP/LTD, suggesting the critical role of CPEB-mediated
translation is stimulus-dependent.399 Besides SCCP, altered synaptic plasticity has also
been found in other neuronal pathways, as CPEB in Purkinje neurons was required for
cerebellar LTD and motor coordination.401 Finally, altered synaptic plasticity may
eventually contribute to altered behaviors, such as reduced extinction of hippocampal
memories in CPEB knockouts.402
In addition to CPEB, CPEB3 has also been linked with synaptic plasticity.
NMDAR activation facilitated nuclear translocation of CPEB3 in cultured neurons.403
CPEB3 binds GluA1 and A2 (AMPAR subunits) mRNAs and repressed their
translation.382,404 Knockout of CPEB3 resulted in translational elevation of plasticityrelated proteins including PSD95, NMDAR and AMPARs and CaMKIIα,383 which may
contribute to defects in a specific form of NMDAR-dependent synaptic de-potentiation405
and an enhanced hippocampus-dependent memory.383 The mechanism through which
CPEB3 functions is still not fully understood. Yet, it is at least independent of
polyadenylation of mRNA targets, due to the inability of CPEB3 to bind CPE.382
6.4.5.2 Zipcode binding protein 1 (ZBP1)
ZBP1 (zipcode binding protein 1) is an RBP that belongs to a family of
evolutionarily related proteins found in many species from Drosophila to humans.406
Expression levels are highest during development and much lower in adult tissues
indicative of its importance during development. ZBP1 is widely expressed in
developing tissues, including heart, lung, liver, intestine, epidermis and reproductive
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organs, suggesting a broad role in development.407-409 In Drosophila, ZBP1 is expressed
in the developing CNS, including brain and ventral nerve cord,410 and in fetal mice, it is
highly expressed in neurons of the CNS.
ZBP1 protein has two RRMs and four hnRNP K homology (KH) domains. The KH
domains 2 and 4 of RBP1 possess nuclear localization signals (NLS) that allow it to
enter the nucleus, where it binds to its mRNA cargo.411-413 This association masks these
signals allowing the complex to exit the nucleus. KH domains 3 and 4 bind mRNA
transcripts that possess 54 nucleotide-long sequence, named zipcode cis element, in
the 3’UTR proximal to the stop codon of target mRNAs.414-417 In fact, ZBP1 is identified
and cloned using this element.414 An analysis of embryonic brain tissue from humans
and mice identified this element in 114 conserved mRNAs.411 Among these is β-actin
mRNA. β-actin is a cytoskeletal protein that is critical for the proper growth, arborization,
and guidance of axons and/or dendrites during development.418 It is found in RNPs in
both axon growth cones and dendrite filipodia, the leading edge of the growing neurites.
The interaction of ZBP1 with β-actin mRNA is well characterized. ZBP1containing RNPs carry the translationally repressed mRNA along microtubules to axon
growth cones and dendrite filopodia, where it can be translated into protein.418-420 This
transport is mediated by the molecular motors myosin Va and kinesins.412,421,422 Thus,
ZBP1 functioned in the localization of specific subsets of mRNA to the growing edge of
the neurites and their local translation.412,423-425 The importance of RBP1 function is
supported by evidence from several studies. For example, depletion of ZBP1 or
blocking its interaction with β-actin mRNA in cultured hippocampal neuron decreased
local β-actin mRNA levels and impaired guidance of axonal growth cones and
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aborization of dendrites.418,420 Similarly, expression of an engineered mRNA containing
the β-actin 3’UTR bound ZBP1 and reduced endogenous mRNA dendritic
localization.426 Translation is not allowed until the ZBP1-mRNA complex reaches its
destination, where ZBP1 is phosphorylated at Tyr396 by Src.412,420 Phosphorylation
reduces its affinity for the zipcode elements thereby releasing the mRNA for translation.
The sequential binding and releasing of ZBP1 enable spatial and temporal control over
beta-actin mRNA translation, which is an essential mechanism to regulate neurite
growth.
In mature neurons, the actin-rich dendritic spines serve as the postsynaptic loci
for excitatory transmission and synaptic plasticity. In cultured rat hippocampal neurons,
ZBP1 granules were observed in dendritic shafts and spines that have synaptic
connections.425 KCl-induced depolarization of the neurons caused an increase in the
dendritic localization of ZBP1 granules and β-actin mRNA. An inhibitor of NMDAR
attenuated these changes indicating that they resulted from KCl-induced excitatory
neuronal activity. Interestingly, only a fraction of β-actin mRNA co-localized with ZBP1
granules and vice versa. Also, the NMDAR inhibitor did not block the increase
completely. Together, these results suggest that other RBPs may be involved in
activity-induced β-actin transport.
The zipcode element is recognized by other RBPs as well, such as HuD. For
example, both ZBP1 and HuD bind to the zipcode element in the 3’UTR of rat β-actin
mRNA. ZBP1 binds the core ACACCC motif and exhibits a unique specificity for the
secondary structure of the sequence, whereas HuD binds the U-rich sequence following
the core motif.427 This competition is restricted to mammals, as rat HuD did not bind to
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chicken β-actin mRNA, which lacks the U-rich sequence.427 The biological implication of
this competition remains unknown. Interestingly, HuD/ZBP1 interaction has been
reported in other cases where the two work in synergy. HuD and ZBP1 both bind to
GAP-43 mRNA, which has no clear zipcode element, and guide its axonal
localization.428 Interaction between HuD and ZBP1 is also identified in differentiated P19
neuronal cells where both were shown to bind Tau mRNA and regulated its trafficking to
distal axons.429
In total, although ZBP1 function has been explored extensively in growing
neurites, much remains unknown about the signal transduction mechanism that links
ZBP1 to NMDAR-dependent transport and local translation. It is also necessary to
identify novel targets of ZBP1 other than β-actin and to unravel protein/protein
interaction between ZBP1 and other RBPs. Finally, ZBP1 is not restricted to RNPs as it
was found in dendritic P-bodies and SGs,430-433 suggesting non-overlapping roles in
these functionally distinct RNA granules.
6.4.5.3 Smaug1
Smaug is an RBP that is identified as a key determinant of gene expression
during Drosophila development.434,435 Smaug protein harbors one sterile alpha motif
(SAM) domain, which recognizes binding elements in target mRNAs, named Smaugrecognition element (SRE). This element possesses a stem-loop structure containing
the conserved motif, CUGGC, within the loop.435,436 During oogenesis and early
embryogenesis, gene transcription is silenced and development is dependent on gene
products derived from the maternal transcriptome. Expression during these
developmental periods is controlled by post-transcriptional mechanisms. However later
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during maternal-to-zygotic transition, translation of zygotic mRNAs is initiated,
accompanied by silencing or destruction of maternal mRNA, which is mediated by
Smaug.437 On one hand, Smaug blocks translation initiation of SRE-containing mRNAs
by recruiting Cup, an eIF4E binding protein that prevents the association of eIF4E with
eIF4G.438 On the other hand, Smaug mediates mRNA destruction by recruiting the
CCR4-NOT complex to induce de-adenylation as the first step in mRNA decay.439,440
Two Smaug homologs (Smaug1 and 2) are contained in the mammalian
genome.436,441 In mice, Smaug1 is expressed in the brain, where it is a key component
of a specific neuronal RNP, termed S-foci.442 S-foci has been shown to be present in the
PSD-enriched fraction of glutamatergic synaptoneurosomes and co-localized with
PSD95 in dendritic spines of hippocampal neurons, suggesting that they are involved in
regulating translation in spines. S-foci in neurons are distinct from other RNPs found in
dendrites. Thus, S-foci in neurons lacked the SG components, eIF3η translation
initiation and TIA-1 translational silencer.95 This contrasts with heterologous expression
in non-neuronal cells. Further co-localization studies indicated that S-foci are distinct
from granules that contain FMRP, SMN, and Staufen 1. Neuronal S-foci also do not
contain DCP1a (a decapping enzyme and an obligatory component of P-body), a Pbody marker, and were shown to be functionally distinct from P-bodies. Additionally,
they differ from SX-bodies because they lack XRN1 5’-3- exoribonuclease, a key
component of these RNPs.443 However, like SX-bodies, S-foci are dynamic structures
that are strongly coupled with excitatory activity.95 Depolarization of cultured rat
hippocampal neurons by KCl significantly reduced the number of synapses containing
S-foci.95 Inhibition of NMDA but not AMPARs completely blocks this reduction,
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indicating that it is linked to excitatory neuronal activity, potentially by blocking Ca2+dependent signal transduction via Phosphoinositide 3-kinase (PI3K). Assembly of S-foci
seems to be dependent on availability of transcripts, but not synthesis of new Smaug1
molecules. Thus, NMDAR activation induces polysome assembly, whereas inhibition
redirects these mRNAs to S-foci. Upon NMDAR activation, association between S-foci
and CaMKIIα mRNA is reduced, suggesting that activity-dependent disassembly of Sfoci may have physiological impact on synaptic plasticity. Interestingly, while NMDAR
activation releases certain transcripts from S-foci (e.g., CaMKIIα), it induces general
translational silencing in dendrites. Finally, knockdown of Smaug1 affects synapse
formation by altering dendritic spine morphology and synaptic responses to repeated
depolarizing stimuli.
Besides Smaug1, at least two other Smaug-related proteins are found in
neurons.444,445 Smaug1 ∆EIII is a Smaug1 variant that lacks the third exon, which codes
for 10 amino acids in its SAM. Yet Smaug1 ∆EIII is still capable of RNA-binding and
shows repressor activity comparable to Smaug1.444 Smaug2, a homologous gene to
Smaug1 in mammals, plays an important role in cortical neurogenesis, being both
sufficient and necessary for cortical stem cell renewal.445 Although all three major
Smaug isoforms are capable of forming aggregations,444 their functional redundancy in
synaptic S-foci is currently unknown.
6.4.5.4 XRN1
In addition to regulation of mRNA translation, expression from many genes is
controlled at the level of mRNA stability. In fact, the two posttransciptional control
mechanisms are often coordinated.446 One prominent pathway of mRNA degradation
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involves the XRN family of 5’ → 3’ exoribonucleases.447 Two paralogs of XRNs, XRN1
and XRN2, are present in eukaryotic cells. Both require an exposed 5’ monophosphate
group on RNA substrates that is dictated by structural features of a highly conserved
catalytic domain.448 However, the two XRNs differ in their subcellular location, function,
and protein structure. Whereas XRN2 is a nuclear protein that serves critical roles in
RNA polymerase II transcription and precursor mRNA processing, XRN1 is a cytosolic
protein that is a major contributor to post-transcriptional mRNA processing. Substrate
transcripts can be generated by three distinct pathways: 1) decapped mRNAs
generated in deadenylation-dependent decay pathway, 2) endonucleolytic cleavagemediated mRNA decay, and 3) mRNA nonsense-mediated decay. However, XRN1
deletion affects specific subsets of transcripts, consistent with its substrate specificity.449
In this regard, evidence suggests that XRN1 can bind to select mRNAs that possess
stable stacked planar structures, called G-quartets, which are formed by hydrogen
bonds between four guanine ribonucleotides.450,451 Such cis-acting elements can be
found throughout the transcripts but are most frequently located within the 5’ or 3’
UTRs, which are key points of mRNA function and regulation.452 Among the known
functions of G-quartets are sorting/trafficking and translation of mRNAs. With respect to
trafficking, G-quartets play an important role in dendritic targeting of mRNAs including
PSD95 and CaMKIIα to postsynaptic sites.452 Finally, in addition to differences in
subcellular distribution and function, XRN1 protein also possess an extended carboxyl
terminus that is not found in XRN2. This domain likely contributes to distinct functional
characteristics of XRN1.453 In addition to influencing RNA binding or selfaggregation,208,454,455 it harbors several short regions enriched in lysine and/or glutamic
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acid that may provide a platform for recruiting various different protein binding
partners.456
XRN1 is generally considered to be a co-activator of P-body assembly together
with DCP1a. In addition to DCP1a, XRN1 interacts with other P-body-specific enzymes,
including the helicase DDX6 and the deadenylase CCR4-CAF1-NOT complex447 in the
degradation of sequestered mRNAs. In cultured hippocampal neurons, XRN1 formed
synaptic granules that are different from the canonical P-bodies.443 In these neurons,
XRN1 localized in the post-synaptic compartment and exhibited minimal overlap with
DCP1a, which was found in the dendritic shafts. The XRN1 containing granules, termed
SX-bodies, show little or no co-localization with other important dendritic RBPs including
FMRP, Smaug1, and SMN, suggesting that they are unique RNA granules that may
have distinct regulatory roles in synaptic mRNA regulation. XRN1 was also found in
SGs.212 Thus, bulk mRNA decay may not be the only activity of this enzyme.
SX-bodies at the synapse are thought to be temporary RNA storage sites that respond
to synaptic stimulation.443,455 SX-bodies contain mRNAs that are translationally
repressed, resistant to 5’ → 3’ decay, and can resume translation upon dissolution of
the granules443. The formation of SX-bodies negatively correlates with local protein
synthesis. Dendritic translation in cultured neurons was blocked by NMDAR
activation95,342 but was stimulated by metabotropic glutamate receptors (mGluR)
activation.457,458 The size and number of SX-bodies increase when local protein
synthesis is repressed by NMDAR stimulation, whereas stimulation of mGluR leads to
an opposite effect on SX-bodies formation. Furthermore, knock down of XRN1 blocks
NMDA-induced translational repression, suggesting SX-bodies are necessary for
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activity-induced local translation inhibition. Interestingly, this non-canonical regulatory
role of XRN1 was also observed in yeast where under glucose exhaustion, XRN1
accumulated in a plasma membrane-associated compartment that is segregated from
the rest of the mRNA-decay machinery.459 This XRN1-mediated redistribution of
mRNAs may function as a regulatory mechanism in metabolism reprogramming. Based
on the evidence showing substrate specificity of XRN1 discussed above, future studies
will be necessary to identify the complement of mRNAs that are repressed in these noncanonical XRN1-containing granules, which will lead to a better understanding of the
physiological role of SX-bodies in synaptic plasticity.
6.4.5.5 Survival of motor neuron (SMN) protein
Among its multiple functions, SMN is necessary for axonal growth cone and
dendritic filipodia maturation during development of spinal motor neurons. Two nearly
identical copies of the SMN gene, SMN1 and SMN2, are present in the human genome.
Mutations in the SMN1 gene together with deficiencies in SMN2 protein led to spinal
muscular atrophy (SMA), an autosomal recessive neuromuscular disease that
selectively disrupts spinal motor neuron development, maturation,460,461 and survival.
Variable numbers of SMN2 gene copies are possible in the human genome and SMA
disease severity correlates inversely with SMN2 copy number, suggesting that this SMN
paralog can compensate for loss of SMN1. In contrast to human, the mouse genome
has only one SMN gene.462 Inactivation of SMN gene in mice was embryonic lethal,
whereas mutant mice with a human SMN2 transgene survived but died postnatally via
an SMA-like phenotype.463,464 Like SMA in humans, severity correlated inversely with
hSMN2 copy number further suggesting the apparent redundancy.
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SMN is an essential component of RNPs that control pre-RNA splicing in the
nucleus and mRNA transport to axons and dendrites during spinal neuron
development.465-467 β-actin mRNA is one such transcript, which may at least partly
explain the role of SMN in neurite development.468 SMN is also a silencer of mRNA
translation.469 Although it may have some capacity for RNA binding itself, it lacks known
RNA binding domains and thus, mainly functions through interaction with other RBPs,
such as ZBP1 (above) and HuD (below).466 SMN function is influenced by excitatory
neuronal activity via the NMDAR. In cultured cerebellar granule cells, for example, the
presence of SMN-positive nuclear granules coincided with NMDAR development.470
Additionally, NMDAR activation increases SMN-positive granules in the nucleus and
enhances transcription of SMN,470,471 which is mediated through the PI3K-AKT pathway
downstream of Ca2+ influx.472 Moreover, NMDAR induced transcription from the human
SMN2 transgene in mice lacking SMN and this suppressed the SMA phenotype.472 On
the other hand, impairment of NMDAR activity in these mice blocked exercise-induced
motor unit maturation and neuroprotection.473 Thus, in contrast to other RBPs discussed
herein, NMDAR activity can effect mRNA processing, transport, and translation via
enhanced transcription of SMN. In addition to spinal motor neurons and cultures of
cerebellar granule cells, various neuron populations of the adult human and mouse
CNS also express SMN474. However, its function in the adult remains to be elucidated.
6.4.5.6 Heterogeneous nuclear ribonucleoproteins (hnRNP) A1
A large fraction of SMN2 mRNA (>75%) innately lacks exon 7 as a result of exon
skipping, leading to the translation of an unstable protein,475 which is thought to be the
basis of SMA.476 Evidence indicates that lack of exon 7 disrupted the ability of SMN2 to
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translocate from the nucleus to the cytoplasm,477 where it assembled into tRNPs that
transport mRNAs, including β-actin, to axons and dendrites. SMN2 exon 7 skipping or
inclusion is a complex process, involving a number of RBPs.478 Among these is
heterogeneous nuclear ribonucleoproteins A1 (hnRNP A1), which suppresses exon 7
splicing.479 hnRNP A1 binds to specific motifs found in many pre-mRNAs in addition to
SMN2 and regulates their splicing to mature mRNAs.480 Relevant to the focus of this
discussion, KCl-induced depolarization of cultured cortical neurons increased binding of
hnRNP A1 to the pre-mRNA of GluN1, an obligate subunit NMDAR. GluN1 pre-mRNA
has 22 exons and 8 different splice variants.481 hnRNPA1 splices exon 21482 (C1
cassette), which codes for 37 amino acids in the carboxy terminal intracellular tail of
GluN1. Interestingly, splicing of exon 21 by hnRNPA1 was linked to NMDAR-dependent
Ca2+ signaling, and since the presence or absence of exon 21 appears to affect
subcellular distribution or cell surface expression483-485, activity-dependent induction of
hnRNPA1 splicing may serve to regulate excitatory neurotransmission. While much is
unknown about the influence of hnRNPA1 on CNS function, it is worth noting that
environmental stimuli, such as lead poisoning and perhaps drug addiction, are known to
affect splicing of the carboxy terminal exons of GluN1, raising the possibility that
NMDAR-dependent hnRNPA1 exon splicing is indeed as an adaptive response486,487.
6.4.5.7 TAR DNA-binding protein 43 (TDP-43)
In contrast to hnRNPA1, TDP-43, a multi-functional RBP, promotes exon 7
inclusion in the SMN2 transcript. TDP-43 is a member of the hnRNP family that binds
specifically to UG-rich sequence488. It functions as a pre-RNA splicer and has been
linked with alternative splicing of multiple disease-related genes, including SMN489. This
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RBP also functions in the entire life cycle of mRNA and in non-coding RNA
processing490. In neurons, it was found in the nucleus, cytoplasm and dendrites491 and
has been implicated in SG formation490. In dendrites of cultured hippocampal neurons,
NMDA stimulation led to decreased co-localization of TDP-43 with RNA, whereas KCl
greatly enhanced this association491. KCl also enhanced the co-localization of TDP-43
with Staufen1 and FMRP. These results suggest TDP-43 responds differently to distinct
neuronal activities, and may cooperate with other activity-dependent RBPs in mRNA
transportation and local translation. The level of TDP-43 in the nucleus is also coupled
with NMDAR activity. In cortical neurons, extracellular glutamate accumulation induced
elevated nuclear TDP-43 protein levels through activation of NMDAR containing
GluN2A subunit492. This increased nuclear TDP-43 was required for neuronal survival
against glutamate accumulation, suggesting distinct activity-dependent roles of TDP-43
in the nucleus versus dendrites.
6.4.5.8 ARE/poly(U)-binding/degradation factor 1 (AUF1)
AUF1, also known as hnRNP D, is an RBP primarily targeting
adenylate/uridylate-rich elements (AU-rich elements or AREs) located within mRNA
3’UTR. AUF1 binding may lead to mRNA decay through a yet to be fully characterized
mechanism493. In brain, AUF1 expression is primarily found in the nucleus92,494 and
negatively correlates with NMDAR activity92. In cultured cerebellar granule cells, NMDA
induced a decrease in the level of nuclear AUF1 through nitric oxide (NO) production.
This led to mRNA stabilization of one specific AUF1 target, α2 subunit of NO-sensitive
guanylyl cyclase, and subsequent production of cGMP92. It is unclear whether the
decreased AUF1 level releases bound mRNA and leads to competitive binding of
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stabilizing RBPs such as HuR. The extent to which AUF1 regulates stability of other
mRNAs in neurons remains to be determined.
6.4.5.9 HuD/embryonic lethal abnormal vision-like 4 (elavl4)
Hu (Elavl) proteins belong to a family RBPs comprised of HuR (HuA/Elavl1), HuB
(Elavl2), HuC (Elavl3), HuD (Elavl4).495,496 These RBPs bind to AU-rich elements (ARE)
of target mRNAs and regulate pre-RNA processing, mRNA stability, and translation.
Whereas HuR is expressed ubiquitously, expression of HuB, HuC, and HuD is restricted
to neurons under normal conditions. HuD has been found in dendrites of neurons,
where it associates with neuronal mRNAs including neuritin, Homer1a, GAP-43,
Neuroligins, Verge and CAMKIIα.497 Dendritic HuD expression was increased upon
neuronal depolarization, accompanied by increased association of HuD mRNA binding
and their translation, and an NMDAR antagonist blocked this activity-induced increase.
Consistently, knockout of GluN1 subunit of NMDAR led to decreased HuD expression in
brain. Polysome profiling experiments showed an increase in association between HuD
and poly-A-binding protein (PABP) in polysomes following neuronal stimulation. These
results suggest that HuD mediates NMDAR activity-dependent re-distribution of bound
mRNAs to dendrites and regulates their translation by bringing these mRNAs into active
polysomes. In the developing brain, the transport of HuD and its mRNA cargo is
dependent on SMN, at least in spinal motor neurons, and this is likely due to a
necessary role of SMN for the integration of HuD into tRNPs498,499.
6.4.5.10 CArG Box binding factor A (CBF-A)
CBF-A belongs to the hnRNP A/B family of RNPs, which included hnRNP A1
(see above).500 These RBPs recognize cis-element located in the 3’UTR of target
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mRNAs termed A2RE (hnRNP A2 response element) This RBP has been identified in
various cell types, including neurons of rodent brain.500,501 In neurons, CBF-A protein is
found in the nucleus and in mRNA granules in axons and dendrites100 or more generally
bound to the RTS (RNA trafficking sequence), located within the 3’UTR of a number of
neuronal transcripts.100,501 CBF-A positive granules contain important dendritic mRNAs
including Arc, BDNF and CaMKIIα, which were bound by CBF-A directly at their RTS.
Interestingly, NMDAR stimulation led to accumulation of CBF-A granules and bound
mRNAs in dendrites,100 suggesting that the interplay between CBF-A and RTS elements
is correlated with the function of excitatory synapses. Accordingly, CBF-A silencing
impaired the dendritic localization of CaMKIIα mRNA. The involvement of CBF-A in
development of excitatory synapses and neuronal plasticity is yet to be determined.
6.4.5.11 Staufen1
The Staufen (Stau) family of double-stranded RNA-binding proteins (dsRBPs)
bind specifically to a collection of double-stranded RNA secondary structures termed
Stau-recognized structures (SRS).502 Staufen1 is found in neurons and is involved in
mRNA stability, dendritic transportation, and translation. Growing evidence suggests
that Staufen1 plays an important role in dendrite development and synaptic plasticity. In
the latter case, in NMDAR-dependent long-term memory formation in Drosophila,
Staufen1 transcription was induced in a CREB (cAMP response element binding
protein)-dependent manner.503 This induction was not observed in flies expressing a
defective NMDAR and this was presumed to be due to the loss of NMDAR-dependent
suppression of basal expression of a CREB repressor.504 In hippocampal organotypic
cultures, Staufen1 knockdown led to altered dendritic spine length and shape of CA1
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neurons, whereas NMDAR blockage prevented these changes.505 These results
suggest Staufen1 contributes to NMDAR-dependent plasticity via alteration in dendritic
spine morphology.
6.4.5.12 Fragile X mental retardation protein (FMRP)
FMRP is an RBP encoded by FMR1 gene located on the X chromosome. It binds
to a variety of cis-elements in mRNAs,506 including a G-quadruplex (a structure motif
composed of spaced GG dinucleotides).507 Mutations causing extensive expansion of a
CGG trinucleotide-repeat sequence located in the 5’UTR of FMR1, lead to epigenetic
silencing of the gene. This loss of function of FMR1 is known to be the cause of fragile
X mental retardation syndrome, a heritable cognitive disorder similar to autism spectrum
disorder.508 FMRP can shuttle between the nuclear and cytoplasmic compartments in
neurons,509 but is found at post-synaptic sites of excitatory synapses as well.
Depolarization of glutamatergic neurons, which stimulates synaptic release of
glutamate, transiently increases trafficking of FMRP and its mRNA transcript to
dendrites and post-synaptic sites. This effect is likely due to activation of mGluR5, a Gprotein-coupled mGluR.510 It is posited that these effects may be relevant to the wellestablished role of FMRP in mGluR-dependent synaptic plasticity.508 Additional
evidence from studies in the sensory cortex suggests that FMRP expression level is
coupled to NMDAR activity as well. In this regard, FMRP protein expression has been
found to be induced in the barrel cortex of the rat by unilateral whisker stimulation, a
model of experience-dependent plasticity.511 This increase is blocked by inhibition of
either mGluR or NMDAR. Similarly, in mice that were reared in the dark, FMRP levels
increased post-transcriptionally in the cell bodies and dendrites of visual cortical
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neurons following a short-term light exposure.512 This increase was also blocked by
NMDAR inhibition. These data suggests that FMRP may act through NMDAR in
experience-dependent synaptic plasticity.
6.4.6 Hypothetical model of NMDAR-responsive RBP-mediated regulation of
neuronal gene expression
As discussed above, evidence suggests the presence of RBPs that are
responsive to altered NMDAR activity. A conceptual view of the possible relationships
between NMDAR activity and dendritic translation is shown in Figure 6.1. This
schematic divides the relationship into two classes. Class A NMDAR activity-responsive
(Nar) RBPs are constitutively transported to dendritic sites, where they store
translationally silent mRNAs in tRNPs. NMDAR activation during excitatory transmission
stimulates disassembly of the granules releasing the mRNAs, thus initiating their
translation into protein (A1, e.g., Smaug1). Alternatively, mRNAs may acquire increased
stability due to exosome dissociation (A2, e.g., AUF1), thus allowing them to be
transported. Class B Nar RBPs do not bind mRNA (or bind at minimal level)
constitutively but are induced to bind their targets by increased NMDAR activity (i.e.,
excitatory neurotransmission). Upon binding, target mRNAs can be transported to
dendrites (B1, e.g., CBF-A, ZBP1), translationally silenced (B2, e.g., XRN1), or become
translationally active (B3, e.g. CPEB, HuD). Modification such as phosphorylation may
contribute to these changes (e.g., CPEB, ZBP1). Finally, NMDAR activity may induce
changes in mRNA splicing leading to alternatively spliced transcripts (B4, e.g., hnRNPA1).

199

Fig. 6.1 NMDAR-responsive RNA binding proteins

In summary, the above sections present a hypothetical model in which gene
expression levels are regulated via RBPs under the control of activated NMDAR (by
spontaneous/evoked glutamate release). Whether COX-2 gene expression is regulated
through these Nar RBPs and if so, through which RBP(s) and during which steps of the
RNA life cycle it is regulated remain interesting questions to ask in the future.
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6.5 Overall significance
The present study investigated how COX-2 mRNA levels are regulated by
excitatory neuronal activity in cultured cortical neurons. It also examined how COX-2
protein levels are regulated by convulsive stimuli in the brain. Specifically, the present
study found that TIA-1, an RBP that has been shown to regulate COX-2 expression in
non-neuronal cell, does not appear to regulate COX-2 protein expression in neurons,
arguing that COX-2 expression is regulated differently in brain. Since enhancing
neuronal COX-2 expression can raise the innate seizure threshold of the brain, a better
understanding of COX-2 regulation in the brain may facilitate development of novel
antiepileptic approaches based on augmenting neuronal COX-2 expression and/or
activity. The present study is also the first to show that disrupting TIA-1 function can
enhance the risk of epileptogenesis, possibly due to an alter transcriptome in
hippocampus. Since various RBPs have been shown to react to altered neuronal
activity and are hypothesized to contribute to the progression of epilepsy, the discovery
of TIA-1 as a regulator of epileptogenesis supports this theory and provides novel
targets for anti-epileptic strategies.
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APPENDIX TABLE 1. Effect of COX-2 inhibition on seizure and epileptogenesis
Pharmacologi
cal or genetic
modification
of COX-2

Dose and
route of
COX-2
inhibitor

Dosing
paradigm

Convulsant

Seizure or
epileptogen
esis models

Species, strain
and gender of
mice

Major effects

Adult male
NMRI mice

All NSAID decreased LD50 of
PTZ;
Diclofenac, Indomethacin and
Flurbiprofen shortened onset
time of acute seizure

Aggravated
seizure
69
activities

Adult Gerbil of
either sex

Increased severity and
nd
incidence of 2 seizure 15min
st
after 1 seizure

Aggravate
seizure
67
activities

Ibuprofen;
Diclofenac;
Indomethacin;
Flurbiprofen;

10mg/kg, i.m.*

2h prior to PTZ

PTZ (100mg/kg,
#
i.p. )

Acute seizure

Indomethacin

5mg/kg, i.p.

2h prior to
grabbing

Moderate
environmental
stress (Grab)

Acute seizure

10mg/kg, i.p.

30min prior to
Tacrine

LiCl (12mEq/kg,
i.p.) 24h prior
Tacrine (5mg/kg
i.p.)

Acute seizure

Adult male
Wistar Rat

Abolished seizure and
hippocampal damage

Indomethacin;
Celecoxib;
NS-398;
Aspirin;

10mg/kg, i.p.

30min prior to
kainic acid

kainic acid
(50mg/kg, i.p.)

Status
epilepticus

Adult male
Mice (spicies
not specified)

All aggravated seizure activity
and mortality;
Indomethacin and NS-398
aggravated neuronal death

Indomethacin;
Nimesulide;
Ketoprofen;
Celecoxib;

10mg/kg, i.p.
(Indomethacin
, Nimesulide,
Ketoprofen);
10mg/kg, p.o.
(Celecoxib)

1h prior to or
15min after
kainic acid

kainic acid
(10mg/kg, i.p.)

Acute seizure

Adult male ICR
mice

All aggravated kainic acidinduced seizure activity;
Indomethacin aggravated
neuronal death

Indomethacin

#

Summary

Anticonvulsa
$
nt effect

$

Neuronal
protective
513
effect
Aggravated
seizure
activities
Aggravated
neuronal
174
injury
Aggravated
seizure
activities
Aggravated
neuronal
168
injury

*, i.m., intramuscular. , i.p., intraperitoneal. , The term anticonvulsant is used here to describe the effects of COX-2 inhibition in studies involving
an acute seizure model (non-epileptic) whereas antiepileptic is used for studies involving an epileptogenesis model where the animals were
analyzed for spontaneous recurrent seizures or kindling acquisition.
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Pharmacologi
cal or genetic
modification
of COX-2

Dose and route of
COX-2 inhibitor

SC560;
Indomethacin;

5 mg/kg, i.p.
(SC560);
10mg/kg, i.p.
(Indomethacin)

Celecoxib;
NS398;

Celecoxib (7,20,
30mg/kg, i.p.);
NS398 (10, 30,
90mg/kg, i.p.)

Convulsant

Seizure or
epileptog
enesis
models

30min prior to
stimulation

Daily electrical
stimuli to
unilateral
amygdala up to
13 days

Kindling

Prior to
stimulation

Daily electrical
stimuli to
unilateral
amygdala

Dosing
paradigm

Species,
strain
and
gender of
mice
Male
C57BL/6J
mice (age
not
specified)

CAY10404 +
rIL-1ra

Indomethacin

140 µg/day

Single dose
prior to
pilocarpine +
once daily for
10 days after
status
epilepticus
4-week
continuous
administration

Summary

Reduced after-discharge duration
and attenuated kindling progress

Antiepileptic
514
effect

Kindling

Male
NMRI
mice

No effects on generation, spread
and termination of seizure activity
(After-discharge threshold and
duration, seizure severity and
duration)

No effect

LiCl (3mg/kg,
i.p.) 16-18h prior
Pilocarpine
#
(60mg/kg s.c. )

Status
epilepticus

P21
Wistar rat
(gender
not
specified)

Single dose pretreatment did not
have any antiepileptic effect; 10day treatment resulted in reduced
frequency of spontaneous recurrent
seizures and attenuated mossy
fiber sprouting

Antiepileptic
194
effect

Weekly Tossing

Kindling*

Adult
male EL
mice

No change in seizure threshold;
Better seizure recover and
attenuated seizure duration

Antiepileptic
178
effect

Single dose
immediate prior
to pilocarpine;
CAY10404
(10mg/kg, i.p.) +
rIL-1ra (100mg/kg,
i.p.)

Major effects
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Rofecoxib (1All drugs dose-dependently
$
4mg/kg,p.o. );
reduced mortality, increased
Rofecoxib;
Nimesulide (1Male
seizure onset time, decreased
Nimesulide;
5mg/kg, p.o.);
45min prior to
PTZ (80 mg/kg,
Acute
Albino
Anticonvulsa
seizure duration. Some drugs
191
Naproxen;
Naproxen (7 and
PTZ
i.p.)
seizure
(Laka)
nt effect
potentiated protective effects of
Aspirin;
14mg/kg, p.o.);
mice
subprotective dose of muscimol
Aspirin (10 and
and diazepam
20mg/kg, p.o.);
*, EL is an inbred albino strain that has multiple genetic loci that contributing to its recurrent seizure phenotype. Recurrent seizure can be induced
by rhythmic stimulation in young EL mice, which is a process similar to kindling.
#
$
, sc., subcutaneous. , po., per os.
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Pharmacologi
cal or genetic
modification
of COX-2

Rofecoxib

Rofecoxib

nimesulide;
rofecoxib;

Nimesulide

Nimesulide

Dose and route of
COX-2 inhibitor

1-5mg/kg, i.p.

Dosing
paradigm

45 min prior to
PTZ

Convulsant

PTZ (80 mg/kg,
i.p.)

45min prior
to PTZ
daily

PTZ, (40
mg/kg, i.p.
daily)

45min prior
to
convulsant
stimulus

Bicuculline
(4 mg/kg;
ip),
picrotoxin (8
mg/kg; ip)
electroshoc
k (60 mA for
0.2 sec);

2.5 or 5mg/kg, p.o.

45min prior
to PTZ
daily

PTZ, (40
mg/kg, i.p.
daily)

10mg/kg, i.p. twice
daily

From 1 day
prior to
kindling
until 1day
after
kindling

Multiple
subconvulsi
ve electric
shock daily
for 4 days

2 or 5 mg/kg, p.o.

nimesulide (2.5
mg/kg; ip);
rofecoxib (2
mg/kg, ip);

Seizure or
epileptoge
nesis
models

Species,
strain
and
gender of
mice

Acute
seizure

Male
Albino
(Laka)
mice

Kindling

Male
Albino
(Laka)
mice

Major effects
Increased the mean onset time of
clonus;
Reduced seizure duration;
Accelerated recovery to normal
behavior and activity after PTZ
seizures;
Rofecoxib at a dose of 0.5mg/kg
potentiated subprotective dose of
tiagabine
Significant decrease in PTZinduced kindling score (since
st
1 day);
Reduced oxidative stress

Summary

Anticonvulsa
179
nt effect

Antiepileptic
197
effect

Acute
seizure

Male
Albino
(Laka)
mice

Prolonged mean onset time of
convulsions, decreased duration of
clonus and decreased mortality rate
against bicuculline and picrotoxininduced convulsions; Ineffective
towards maximal electroshockinduced convulsions;

Kindling

Male
Albino
(Laka)
mice

Significant decrease in PTZinduced kindling score;
Reduced oxidative stress

Antiepileptic
198
effect

Kindling

Adult
male
Wistar
Rat

Attenuated kindling development

Antiepileptic
196
effect
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Anticonvulsa
192
nt effect

Pharmacologi
cal or genetic
modification
of COX-2

Conditional
genetic
deletion of the
PTGS2 gene
limited to
principal
forebrain
neurons
(synapsin 1
promoter)

Celecoxib

Dose and
route of
COX-2
inhibitor

N/A

Dosing
paradigm

N/A

Convulsant

Methylscopolamine and
terbutaline (2.5-3mg/kg,
i.p.)15-30min prior
Pilocarpine (364±33
mg/kg i.p. for control,
and 357±89 mg/kg for
cKO), terminate 1h later
by Pentobarbital
(30mg/kg, i.p.)

Seizure or
epileptoge
nesis
models

Status
epilepticus

Species,
strain
and
gender of
mice

Mice on
C57BL/6
backgrou
nd

6 mg/kg,
i.p., once
daily for 5
days or a
single
injection

kainic acid (12 or 6
mg/kg, i.p.)
2 h after
kainic acid
injection

Unchanged latency, mortality,
severity or EEG pattern; Early
(1day after status epilepticus)
aggravation but delayed (4days
after status epilepticus)
protective effects on CA1
neuronal injury. Protective
effects on somatostatin positive
interneurons;
Reduced delayed mortality
during 7 days after status
epilepticus was found in cKO
animals along with a modest
improvement in Barnes maze
test;

Same as above except
for the concentration of
Pilocarpine is 275-310
mg/kg

Prior to
kainic acid
injection

Major effects

Acute
responses
to kainic
acid
injection
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Male
Wistar rat

No improvement in object
exploration deficit or hyperactivity in
open field;
No effect on neuronal loss in
hippocampus;
All determined 8 to 11 days post
kainic acid injection.
Attenuation of the learning and
object exploration deficits in MWM
task and hyperactivity in open field;
No effect on neuronal loss in
hippocampus.
All determined 8 to 11 days post
kainic acid injection.

Summary

No effect on
acute seizure
activities
Delayed
neuronal
protective
183
effects
Reduced
mortality;
Improved
retrograde
516
memory

No effect on
behavior
consequence
of seizures

Neuronal
protective
201
effect

Pharmacologi
cal or genetic
modification
of COX-2

Celecoxib

Dose and
route of
COX-2
inhibitor

20 mg/kg,
p.o., once
daily until
the day of
sacrifice

Dosing
paradigm

Beginning
24 h after
Status
epilepticus

Convulsant

Lithium (127 mg/kg, i.p.)
24 h prior to pilocarpine
(30 mg/kg, i.p.),
terminated 1h later by
10mg/kg diazepam, i.p.

Seizure or
epileptoge
nesis
models

Status
epilepticus

Species,
strain
and
gender of
mice

Major effects

Male
SpragueDawley
rat

Reduction in the likelihood of
developing spontaneous recurrent
seizures and microglia activation.
Inhibition of hippocampal cell
proliferation, hilar neurogenesis and
CA1 gliogenesis.
Prevented neuronal loss and
microglia activation in
hippocampus.

2 mg/kg,
p.o., once
1 h before
PTZ
injection

Celecoxib

PTZ (60 mg/kg, i.p.)

Acute
seizure

Male
Wistar rat

0.2 or 20
mg/kg, p.o.,
once

Rofecoxib

Nimesulide

10 mg/kg,
i.p.

10 mg/kg,
i.p.

Increased latency for the first clonic
and generalized seizure induced by
PTZ. Decreased duration of
generalized seizure.

No effect on Seizure latency
induced by PTZ.
6 or 8 h
after kainic
acid
injection,
and twice
daily for 2
days
Alone with
kainic acid
injection

Summary

Antiepileptic
effect
Neuronal
protective
199
effect

Anticonvusiv
e effect

No effect
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kainic acid (10
mg/kg, i.p.)

Acute
responses
to kainic
acid
injection

Male
SpragueDawley
rat

Neuroprotection in hippocampus,
but not in thalamus, amygdala and
piriform cortex

Neuronal
protective
176
effect

kainic acid (10
mg/kg, i.p.)

Acute
responses
to kainic
acid
injection

Male
SpragueDawley
rat

Augmented the toxic effects of
kainic acid with more severe and
longer lasting seizure symptoms.
Significantly increased kainic acidinduced mortality. Less cell loss.

Aggravates
193
seizures
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Pharmacologi
cal or genetic
modification
of COX-2

Dose and
route of
COX-2
inhibitor

Dosing
paradigm

Rofecoxib

4 mg/kg,
i.p., once

45 min
before PTZ
injection

Parecoxib
(valdecoxib)

PTZ (i.v.*)

10 mg/kg,
i.p., twice
daily for 17
days

1.5 h after
Status
epilepticus
onset

Lithium (127 mg/kg,
i.p.) 12-17 h prior to
pilocarpine (20-50
mg/kg, i.p.),
terminated 90min
after by diazepam
10mg/kg, i.p.

3 mg/kg,
p.o., once

1 h before
kainic acid
injection

kainic acid (10
mg/kg, s.c.)

3 mg/kg,
p.o., 3 times

1 h before,
24 and 48
h after the
kainic acid
injection

kainic acid (0.6 µg,
#
i.c.v. injection)

10 mg/kg,
i.p., twice
daily for 3
days

5 h after
kainic acid
injection

SC58125

NS398

Convulsant

Seizure or
epileptoge
nesis
models

kainic acid (1 µg, intrahippocampal injection)

30 min
5 mg/kg,
before
i.p., once
kainic acid
injection
#
*, i.v., intravenous injection. , i.c.v., Intracerebroventricular injection.

Acute

Status
epilepticus

Acute
responses
to kainic
acid
injection

Acute /Not
terminated
for seizure
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Species,
strain
and
gender of
mice
Male
Albino
mice

Female
SpragueDawley
rat

Major effects
Increased seizure threshold and
thus decreased of the incidence of
PTZ-induced convulsions
Reduction of PGE2 levels in
hippocampus, frontal cortex,
amygdala and piriform cortex.
Reduction of the severity, but not
the frequency and duration of
spontaneous recurrent seizures.
Neuroprotection in the
hippocampus and piriform cortex.
Moderate reduction of learning
impairment and prevention of
locomotor hyperactivity in the
Morris water maze.

Summary

Anticonvulsa
180
nt effect

Antiepileptic
effect
Neuronal
protective
200
effect

Male
SpragueDawley
rat

Attenuation of kainic acid-induce
rise in PGE2 level in the
hippocampus.

Not
determined
for acute
seizures

Male
SpragueDawley
rat

Increased survival of hippocampal
CA3 neurons one week after kainic
acid exposure.

Neuronal
protective
164
effect

Attenuation of kainic acid-induce
rise in PGE2 level. Increase in the
number of surviving CA3
hippocampal neurons.

Neuronal
protective
effect

Transient attenuation of kainic acidinduce rise in PGE2 level and no
neuroprotection in the CA3

Not
determined
for acute
202
seizures

Male
Wistar rat

Pharmacologi
cal or genetic
modification
of COX-2

Species,
strain
and
gender of
mice

Major effects

Summary

C57BL/6J
mice

Attenuation of kindling-induced rise
in PGE2 level. Decrease in the total
after discharge duration.
Attenuation of recurrence of
electrographic and behavioral
seizures.

Antiepileptic
195
effect

Status
epilepticus

Male
SpragueDawley
rat

No effect on status epilepticusduration, latency to first seizure in
epileptogenic phase, average
number of seizures, microglial
associated neuroinflammation, hilar
cell loss or mossy fiber sprouting.
Attenuation of seizure induce rise in
PGE2 level in hippocampus

No antiepileptic
517
effect

No effect on SE-duration, SE
severity, hippocampal cell survival,
microglial associated
neuroinflammation or mossy fiber
sprouting. Increased mortality.

Increase
518
mortality

Increased seizure severity

Aggravate
519
seizure

Seizure or
epileptoge
nesis
models

Dose and route of
COX-2 inhibitor

Dosing
paradigm

Convulsant

10 mg/kg, p.o.,
once

30 min
before
Status
epilepticus
-induction

Electrical
stimulation
of
hippocampu
s

SC58236

10 mg/kg, p.o.,
once daily for 7
days

Start 4 h
after Status
epilepticus

Electrical
stimulation
of
hippocampu
s, status
epilepticus
terminated
4h later by
isoflurane

SC58236

10 mg/kg, p.o.,
once daily for 3
days or for 14 days

Start 1 day
before
Status
epilepticus
-induction

Electrical
stimulation
of
hippocampu
s

Status
epilepticus

Adult
Male
SpragueDawley
rat

Valeryl
salicylate

20 or 40mg/kg, s.c.

30min
before PTZ

PTZ
(60mg/kg,
i.p.)

Acute
seizure

Adult
Male
BALB/c

Celecoxib

6000ppm in diet
water

6 month
before
kainic acid

Nimesulide

COX-2
knockout

N/A

kainic acid
(10mg/kg,
i.p,)

Rapid
kindling

Status
epilepticus

N/A
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C57Bl/6129/Ola
backgrou
nd

Aggravate
seizure
Aggravated seizure intensity and
neuronal injury

Aggravate
neuronal
520
injury

Pharmacologi
cal or genetic
modification
of COX-2

Dosing
paradigm

Convulsant

Seizure or
epileptoge
nesis
models

Dose and route of
COX-2 inhibitor

Celecoxib

10 or 20 mg/kg,
p.o.

1h before

Flurothyl
(inhalant,
0.1mL,
10min)

Acute
neonatal
seizure

Rofecoxib

30mg/kg, p.o.

3h before
PTZ

PTZ
(32mg/kg,
i.p.)

Acute
seizure

5days
before PTZ

PTZ (40 or
55mg/kg,
i.p.)
PTZ
(40mg/kg,
i.p., daily)

Rofecoxib

30mg/kg, diet water

Acute
seizure
Kindling

209

Species,
strain
and
gender of
mice
7 to 10
days old
SpragueDawley
rat
Adult
male mice
on
C57BL/6
backgrou
nd

Major effects

Summary

Increased onset time of seizure

Anticonvulsa
521
nt effect

Increased acute seizure intensity
and incidence

Aggravate
68
seizure

Unchanged seizure severity
Male CD1 mice

No effect
Unchanged progress of kindling
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APPENDIX TABLE 2. NMDAR-responsive RNA binding proteins
RNA
binding
protein
CPEB
AUF1

CBF-A

Smaug1
HuD
SMN
Staufen
hnRNP-A1
ZBP-1
XRN1
TDP-43
FMRP

Neuronal cellular
distribution
Cell body, Synapse,
enriched in postsynaptic
390,391,396
density
Primarily in the
494
nucleus
Nucleus,
cytoplasm,
dendrites, pre- and
post-synaptic
100
sites
Cytoplasm and
95,442
dendrites
Cell body and
349,497
dendrites
Cell body and
466
dendrites
Cytoplasm and
524,525
dendrites
Primarily in the
480
nucleus
Cell body, dendrites
425
and axons
Cell body, dendrites
and post-synaptic
443
sites
Nucleus, cytoplasm
491
and dendrites
Nucleus and
509
cytoplasm ,
dendrites and
510
synapses

Neuronal RNA
granule
presented

Cis-acting sequence on
mRNAs

NMDAR activationdependent change

tRNP, SG,
390,396,394
PB

Cytoplasmic polyadenylation
382
element (CPE)

Phosphorylation

SG

522

AU rich element

hnRNP A2 response
element/RNA trafficking
sequence elements (RTS)

+

CBF-A RNP
100,523
granule
S-foci

100,501

Smaug recognition element
436
(SRE)

95

+

HuD RNP
497
granule
tRNP, SG
tRNP
SG

493

AU rich element

466

496

Unknown
Various Stau-recognised
502
structures (SRS)
AU rich element; UAGA(G)
480
motif

524

526

tRNP, SG,
430-433
PB

Zipcode element

SG, PB, SX212,443,447
body

G-quartets

SG

490

, PB

510

tRNP
431
PB

491

, SG

527

450,451

UG-repeats
,

416

488

G-quadruplex
506
motifs

507

and other

Activity-dependent
functional in RNA
processing
Polyadenylation-induced
391,393,398
translation

391,393

Down-regulation of protein
92
level

mRNA stabilization

Accumulation in
100
dendrites

mRNA transportation

Disassembly of S-foci

95

mRNA translation

95

mRNA translation

497

349

Increased expression ;
497
Dendritic redistribution
Increased
470,472
transcription

92

100

Unknown
505

Not directly studied

Dendritic Morphology

Increased binding to target
482
pre-mRNA
Increased dendritic
425
expression

Alternative pre-mRNA
482
splicing

Increased size and number
443
of SX bodies

mRNA storage and
443
silencing

Decreased binding to RNA
491
in dendrites

Unknown

Increased protein
511,512
expression

Unknown

+

mRNA transportation

+

425

tRNP, transport ribonucleoprotein; SG, stress granule; PB, processing body; S-foci, Smaug1 mRNA silencing granules; SX-body, XRN1 synaptic
granules.
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APPENDIX TABLE 3. Raw read characteristics

Total
Avg.
Avg.
Mouse
#
IDs
Genotype Treatment Reads read length read quality

%N

*

% GC

TA1_S11

KO

Saline

67524832

74.46

33.21

0.01

49.03

TA2_S12

KO

PTZ

73285558

74.45

34.04

0.01

49.16

TA5_S1

WT

Saline

72046940

74.46

34.04

0.01

48.81

TB2_S2

WT

Saline

82177350

74.48

33.96

0.01

48.71

TB3_S13

KO

PTZ

71923278

74.45

33.97

0.01

48.95

TB5_S3

WT

Saline

66195524

74.47

33.81

0.01

49.07

TC1_S4

WT

PTZ

70995380

74.48

34.06

0.01

48.93

TC2_S5

WT

PTZ

43061028

74.48

34.03

0.01

48.91

TC3_S14

KO

PTZ

70713034

74.45

34.01

0.01

48.94

TD3_S9

KO

Saline

53928752

74.44

33.66

0.01

47.85

TD4_S10

KO

Saline

80880876

74.45

34.00

0.01

48.98

TE2_S15

KO

PTZ

79422620

74.45

33.93

0.01

48.93

TE3_S16

KO

PTZ

77200872

74.47

33.95

0.01

48.55

TE5_S6

WT

PTZ

70666828

74.48

33.85

0.01

48.94

TF1_S7

WT

PTZ

82127172

74.47

34.01

0.01

48.91

TF4_S8

WT

PTZ

78702894

74.48

34.00

0.01

48.86

*, %N stands for the percentage of unidentified base call
#, Total reads here represent all reads from the paired end sequencing (2 x 75bp)
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APPENDIX TABLE 4. Raw read characteristics after trimming

Mouse IDs Genotype Treatment

Total
#
reads

Avg.

Avg.

read length

read quality

%N

% GC

TA1_S11

KO

Saline

33762483

74.37

33.22

0.01

49.04

TA2_S12

KO

PTZ

36642882

74.35

34.05

0.01

49.18

TA5_S1

WT

Saline

36023531

74.36

34.04

0.01

48.82

TB2_S2

WT

Saline

41088773

74.38

33.96

0.01

48.72

TB3_S13

KO

PTZ

35961719

74.34

33.97

0.01

48.96

TB5_S3

WT

Saline

33097874

74.37

33.81

0.01

49.08

TC1_S4

WT

PTZ

35497771

74.38

34.06

0.01

48.95

TC2_S5

WT

PTZ

21530550

74.38

34.04

0.01

48.93

TC3_S14

KO

PTZ

35356598

74.35

34.01

0.01

48.95

TD3_S9

KO

Saline

26964468

74.34

33.66

0.01

47.87

TD4_S10

KO

Saline

40440580

74.35

34.00

0.01

48.99

TE2_S15

KO

PTZ

39711471

74.35

33.93

0.01

48.94

TE3_S16

KO

PTZ

38600625

74.36

33.95

0.01

48.57

TE5_S6

WT

PTZ

35333489

74.38

33.85

0.01

48.96

TF1_S7

WT

PTZ

41063689

74.37

34.01

0.01

48.92

TF4_S8

WT

PTZ

39351573

74.38

34.01

0.01

48.87

*, %N stands for the percentage of unidentified base call
#, Total reads here represent unpaired reads after trimming (1 x 75bp), note the number reduced to ~1/2
of paired total reads in Appendix Table 3
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APPENDIX TABLE 5. Raw Gene Counts after quantification.

Sample name

Genotype

Treatment

Min Max

Mean

Median

Q1

Q3

TA1_S11

KO

Saline

0

107876

933.01

74.00

0.00

767.00

TA2_S12

KO

PTZ

0

174552

1063.83

93.00

0.00

882.00

TA5_S1

WT

Saline

0

114010

1032.56

88.00

0.00

870.50

TB2_S2

WT

Saline

0

144024

1176.99

87.00

0.00

957.98

TB3_S13

KO

PTZ

0

287954

1025.22

102.00

0.00

875.00

TB5_S3

WT

Saline

0

165676

937.43

75.00

0.00

771.00

TC1_S4

WT

PTZ

0

122641

1025.23

80.00

0.00

840.43

TC2_S5

WT

PTZ

0

73725.3

617.67

48.00

0.00

507.00

TC3_S14

KO

PTZ

0

257812

1030.20

95.00

0.00

872.00

TD3_S9

KO

Saline

0

79873.4

716.80

51.02

0.00

588.50

TD4_S10

KO

Saline

0

119148

1167.10

109.00

0.00

993.00

TE2_S15

KO

PTZ

0

130780

1131.08

87.00

0.00

923.38

TE3_S16

KO

PTZ

0

128124

1100.12

91.00

0.00

908.00

TE5_S6

WT

PTZ

0

108485

999.70

88.00

0.00

842.00

TF1_S7

WT

PTZ

0

141710

1168.38

92.00

0.00

959.50

TF4_S8

WT

PTZ

0

141663

1124.50

87.00

0.00

920.50

0

287954

1015.61

82.00

0.00

832.53

All samples
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